Вестник РГМУ Дополнение к специальному выпуску №1 2011 год

!"#$%&' ()*+, 2011, ,-.-/%"%&" ' 0."1&2/3%-45 67.5#'5 No1

!

04. !"#$%& «'"()#*& +%,-,.%&» Pediatric Surgery /,"0)"0*("12 )"#$%%: 0.3.4., 5,67"))6, 8.9. :",*)2#%4 !

04-1 !"#$%& '(&()*#'%!+ ,#$!'")$()-,&.)) / !0,#1#2#$)) .3$%")) 0!*#% 3 1#(#+ ' 04, !."#$%&'( )*+,*$ -.)'/'(0+'1 (2#+ 3.4.56*$*0,*6 7*8&*&$2)0+'9 :*0#)2$0,6.((%9 ;.)'/'(0+'9 <('6.$0',.,, 7*8&*&$2), =*00'> ?.8@: */.(',@ ABB.+,'6(*0,@ 0,2,'C.0+*9 $.(*0/'(,'&$2B'' DMSA +2+ -.,*)2 *D$.).8.('> 0,$#+,#$(* B#(+/'*(28@(*&* 0*0,*>('> D*C.+ # ).,.9 0 D#E%$(*--*C.,*C('+*6%- $.B8F+0*- (G;=). ;2,.$'28% ' -.,*)%: H8> *D$.).8.('> *IJ.-2 «B#(+/'*('$#FK.9»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

D*E6*8>F, E2+8FC',@, C,* 0 #6.8'C.('.- 0,.D.(' $.B8F+02 (2I8F)2.,0> #-.(@P.('. *IJ.-2 B#(+/'*('$#FK.9 D2$.(1'-%, 0*D$*6*O)2FK..0> 0('O.('.- E2162,2 $2)'*B2$-D$.D2$2,2. G$' A,*- D$' *)(*0,*$*((.- D*$2O.('' 0#--2$(2> (2+*D',.8@(2> B#(+/'> D*C.+ -*O., (. 'E-.(>,@0>, +*-D.(0'$#>0@ E2 0C., B#(+/'*(28@(*&* $.E.$62 E)*$*6*&* *$&2(2. 7%6*)%: D$*6.).((%.

'008.)*62('> D*E6*8>F, E2+8FC',@, C,* 0,2,'C.0+2> $.(*0/'(,'&$2B'> DMSA >68>.,0> 6%0*+*'(B*$-2,'6(%- 0D*0*I**/.(+' 0,$#+,#$(*-B#(+/'*(28@(*&* 0*0,*>('> D*C.+ # ).,.9 0 D#E%$(*--*C.,*C('+*6%$.B8F+0*-. ;.,*) >68>.,0> -28*'(62E'6(%-, C,* D*E6*8>., $.+*-.()*62,@ .&* P'$*+*.

D$'-.(.('. )8> )'(2-'C.0+*&* (2I8F).('> E2 B#(+/'*(28@(%0*0,*>('.- D*C.+ # ).,.9 0 D#E%$(*--*C.,*C('+*6%- $.B8F+0*- 6 +2,2-(.E..

EVALUATION OF STATIC RENOSCINTIGRAPHY IN DETERMINING RENAL FUNCTION IN CHILDREN WITH VUR S.Sgurygin MD I.Khvorostov Volgograd State Medical University, Volgograd, Russian Federation Objective: To evaluate the effectiveness of static renoscintigraphy DMSA as a method for determining the structure of renal function in children with vesicoureteral reflux (MTCT). Materials and methods: To determine the amount of "functioning" kidney tissue using static renoscintigraphy with radiopharmaceutical Technetium-99m-tehnemek (dimercaptosuccinic acid, DMSA) 80-600 megabekkerel activity (MBq), defined by dose isotope calibrator. 76 children aged 1 to 16 years were examined. A total of 17 children with TMR I-II degree, with the PMR-III degree - 40 patients, PMR IV-V degree - in 19 children. Determined: the total index of the integrated capture, the index of the integral capture the right and left kidney, the index of the integral capture a healthy and a damaged kidney, the glomerular filtration rate, the rate of the index return of creatinine.

Results: When the DMSA-scan was performed, kidney damage of varying severity was found in all patients. Also, pollibly, increasing degree of reflux leads to a decrease in the volume of functioning parenchyma, accompanied by a decrease in the capture of the radiopharmaceutical. At the same time hemilesioncan make no effect on cummulative renal function due to compensation by the healthy ren. Conclusions: We suggest that static renoscintigraphy DMSA is a highly informative way to assess the structural and functional state of kidneys in children with vesicoureteral reflux. The method is minimally invasive, which allows to recommend its widespread use for dynamic monitoring of renal function in children with vesicoureteral reflux in catamnesis

2&5#,$&6 (#,&0)6 / %!402#%'$!4 2#*#$)) &1#$!)1)(!/.

0.1.2789:;<9 =>?@ABB?>, C?DE?> FAC7G7HBD78 H9ID -.2.J9KLB7HBD9L ,?BB7MBD7M N?BIC9>BE<AHHOM FAC7G7HBD7M IH7<A>B7EAE 7F. $. ).

07>?N?<9, 4?BD<9, ,?BB7L 4'E+*A(.$&.,'C.0+2> 82E.$(2> ,.$2D'> (4QL) –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

G$*6*)',0> ,.$2D.6,'C.0+'-' 2DD2$2,2-' «<E*$», «<E*$ 3R!», «;#0,2(&», «;2,$'+0», «;'8,2». 4QL D$*6*)',0> 2-4 +#$02-' 0 '(,.$628*- 1-6 -.0>/.6. S20,*,2 0.2(0*6 – .O.)(.6(* '8' C.$.E ).(@, 60.&* 7-10 (2 +#$0, D*08.)#FK'. 0.2(0% -*&#, 6+8FC2,@ 5-7 D$*/.)#$.

M%8* *I08.)*62(* 18 D2/'.(,*6 6 6*E$20,. *, 9 -.0>/.6 )* 14 8.,.

R8'('C.0+'9 ABB.+, I%8 )*0,'&(#, # 60.1 I*8@(%1. G*I*C(%1 $.2+/'9 (. *,-.C28*0@. 7* 60.1 08#C2>1 *,-.C2820@ D*8*O',.8@(2> )'(2-'+2 E2I*8.62('>:4 I*8@(%- #)28*0@ 'EI.O2,@ *D.$2,'6(*&* #)28.('> 2).(*')*6. < 6 I*8@(%1 – #-.(@P'8*0@ +*8'C.0,6* $.0D'$2,*$(%1 E2I*8.62('9, +#$0% 4QL D$*6*)>,0> $2E 6 6 -.0>/.6, # 8 I*8@(%1 – D*8(2> $.-'00'>. 4.*I1*)'-* *,-.,',@ 2I0*8F,(#F I.EI*8.E(.((*0,@ -.,*)2.

G$*0,*,2 6%D*8(.('>, 6%0*+2> ABB.+,'6(*0,@, *,0#,0,6'. *08*O(.('9 ' D*I*C(%1 ABB.+,*6, I.EI*8.E(.((*0,@ -.,*)2 ).82., 6*E-*O(%2-I#82,*$(*.

D$*6.).('. 4QL ' I*8.. P'$*+*. 6(.)$.('. .. 6 +8'('C.0+#F D$2+,'+#.

LASER THERAPY IN COMPLEX TREATMENT OF ADENOIDITIS P.Lichacheva MD, PhD G.Balyasinskaya Russian State Medical University by N.I.Pirogov, Moscow, Russian Federation Low-energy laser therapy (LeLT) – method of treatment, using therapeutic lasers, based on its effects: anti-inflamatory activity, microcirculation normalization, analgesic activity, blood rheology improvement, immunologic activity normalization, desensitization activity, nerve conduction improvement, reparative process stimulation. Lasertherapy has significant results both as an independent method and in combination with traditional methods, as a part of complex therapy. The purpose of this work is research of the effectiveness portability of laser therapy by children of all age groups.

Research is held with light of low-energy lasers in red (630-650 nm) and short-range infrared light (850-890 nm). It is held on “Uzor”, ”Uzor 3KS”, ”Mustang”, ”Matrix”, ”Milta”. LeLT is held on 2 – 4 courses with 1 – 6 months interval. Procedures frequency – every day or alternate-day, 7-10 per course, next procedures may include 5 – 7 procedures.

An examination of 18 patients aged from 9 months to 14 years old was performed.Clinical effect was reached with all patients. Side effects were not noted. Disease positive dynamic was noted in all cases: 4 patients managed to avoid operative adenoidectomy. 6 patients mentioned the decreasing of quantity of respiratory diseases, LeLT courses hold once per 6 months, 8 patients mentioned full remission. Absolute indolence of method is an important point to be made. Simplicity of carrying out, high efficiency, absence of complications and side effects, indolence ofthe method makes LeLT possible in ambulatory usage and it’s wide introduction in clinical practice.

04-5

"! !

0"'1&8 «,"$#'28 9&:5:;&8»

!

04-10 BAHA - )402&$(),3#4P+ '23Q!/!+ &00&,&( %!'($!+ 0,!/!1)4!'() /.4.'9C>AEC7H?< =>?@ABB?>, C.F.H. -.2.J9KLB7HBD9L ,?BB7MBD7M N?BIC9>BE<AHHOM FAC7G7HBD7M IH7<A>B7EAE 7F. $. ).

07>?N?<9, 4?BD<9, ,?BB7L 7 (20,*>K.. 6$.-> D$*I8.-2 ,#&*#1*0,' D$'*I$.,2., 60. I*8@P..

E(2C.('.. 7 =*00' (20C',%62.,0> I*8.. 13 -8(. 082I*08%P2K'1, 0$.)' ('1 (2 ).,.9 D$'1*)',0> I*8.. 1 -8(. !8#1*6%. 2DD2$2,% 6*E)#P(*&* E6#+*D$*6.).('> ABB.+,'6(%(* (. D$' 60.1 B*$-21 (6')21) ,#&*#1*0,'. T8@,.$(2,'6(%- $.P.('.- E2 $#I.O*- 0,28* D$'-.(.('.

'-D82(,'$#.-*&* 08#1*6*&* 2DD2$2,2 +*0,(*&* E6#+*D$*6.).('> Baha, +*,*$%9 2+,'6(* '0D*8@E#.,0> 6$2C2-'-*,*$'(*82$'(&*8*&2-' )8> #8#CP.('> 08#12 # D2/'.(,*6 0 1$*('C.0+'- *,',*- ' 0 0'()$*-2-', 0*D$*6*O)2FK'-'0> 2,$.E'.9 (2$#O(*&* 08#1*6*&* D$*1*)2. 7 =U .&* 0,28' '0D*8@E*62,@ ,*8@+* *+*8* 3-4 8., (2E2), '-D82(,2/'F D$*'E6.8' D$'I8'E',.8@(* 20 D2/'.(,2- $2E(%1 6*E$20,(%1 &$#DD. 7 ,* 6$.->, +2+ 6 T(&8'',)2((#F *D.$2/'F ).82F, 1600-1800 ).,>- 6 &*), 'E ('1 *+*8* 20% (#O)2F,0> 6 $.-'-D82(,2/'' D* D$'C'(. *,,*$O.('> +*0,@F ,',2(*6*&* '-D82(,2, ,$26-2,'C.0+*- D*6$.O).('' +*(0,$#+/'' ' ,*8@+* # 2% *D.$2/'> D$*1*)', 0 D*6$.O).('.- ,6.$)*9 -*E&*6*9 *I*8*C+'. R2B.)$2 *,*$'(*82$'(&*8*&'' D.)'2,$'C.0+*&* B2+#8@,.,2 =:;< )*8&'. &*)% E2('-2.,0> D$*I8.-*9 6$*O).((%1 D*$*+*6 $2E6','> #P(*9 $2+*6'(%, 2,$.E'' (2$#O(*&* 08#1*6*&* D$*1*)2, 1$*('C.0+'-' *,',2-'. 42 D$*,>O.('' )*8&'1 8., D$*B. V.$I2,*6 3.3., D$*B.00*$ M28>0'(0+2> :.Q. E2('-28'0@ 6*D$*02-' $.2I'8',2/'' 08#12 # ).,.9 0 D*$*+2-' $2E6','> #P(*9 $2+*6'(%, 2 ,2+O. 2,$.E'.9 (2$#O(*&* 08#1*6*&* D$*1*)2. R2B.)$28@(%-' 0*,$#)('+2-' (M*&*-'8@0+'9 ;.=., ;'(20>( 7.!) $2E$2I*,2( $>) 08#1*0*1$2(>FK'1 *D.$2/'9 # ).,.9 0 1$*('C.0+'-' 0$.)('-' *,',2-'.

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aha-E6#+*6%- D$*/.00*$*-, )* '-D82(,2/''. ND.$2/'' D* '-D82(,2/'' E2('-2., *+*8* 40 -'(, ()8> 0,2$P'1 D2/'.(,*6 6*E-*O(2 -.0,(2> 2(.0,.E'>). !8#1*6*9 2DD2$2, 0*E)2., 1*$*P'9 A0,.,'C.0+'9 ABB.+,, -*).8@(%9 $>) *C.(@ $2E(**I$2E.(, + +2O)*-# 2DD2$2,# Baha 06*9 (2I*$ 6%0*+*,.1(*8*&'C(%1 2+0.00#2$*6.

BAHA – BONE ANCHORED HEARING AID V.Sadretdinov MD, PhD G.Balyasinskaya Russian State Medical University by N.I.Pirogov, Moscow, Russian Federation Baha – Bone Anchored Hearing AidNowadays the problem of hearing loss is becoming more important. There are more than 13 million hearingimpaired people live in Russia, among them more than 1 million are children. Air sound conduction hearing aids are effective, but not in all forms (species) of hearing loss. An alternative solution abroad was the application hearing aid Baha(Bone Anchored Hearing Aid), which is actively used by physicians- otolaryngologists to improve the hearing at patients with chronic otitis and syndromes that are accompanied by atresia of outer ear. They started to use it in Russia only about 3-4 years ago, implantation was implemented about 20 patients of different age groups. While in England, this operation do to 1600-1800 children per year, from them about 20% require in re-implantation because of rejection of bone titanium implant, traumatic damage of construction and only 2% of surgery is pass with the damage of the scleromeninx. Subdepartment of Otolaryngology, RSMU Faculty of Pediatrics many years deals with the problems of congenital pinna malformations, atresia of ear canal, chronic otitis. For many years professors Sherbatov and Balyasinskaya worked on question of rehabilitation of hearing sense for children with congenital pinna malformations and also with atresia of ear canal. The employee of Otolaryngology department (Bogomilsky MR, Minasian VS) had developed a number of operations wich will help to save ability to hear for children with chronic otitis. Today Department is in active work on the scientific study of hearing function and different methods of correction or such children.Actively introduced high-tech

#! !

methods of treatment and rehabilitation of children with conductive and sensorineural hearing loss. Employees of the subdepartment on the basis of the Morozov Children's Clinical Hospital today operated on 3 children with atresia ear canal and pinna, which were implanted bone conduction device BAHA. At this point, all children are successful rehabilitation of hearing, noted the positive results of audiological tests. Indications for implantation of hearing aids are very extensive(wide), the most important of them: anomaly development of the auditory ossicles, external otitis,chronic otitis and media otitis, otosclerosis;Treacher Collins syndrome, Goldenhar syndrome, Crouzon syndrome; large bone-air interval (more than 30 Db). The operation can be done to children at the age of 3-4. For children under 3 years old can use a soft head band with a Baha-sound processor, so children can use Baha from birth. The operation lasts about 40 minutes (for older patients it’s possible to use local anesthesia). Hearing aid is creating good aesthetic effect, the range is very diverse, there are its own set of high-tech accessories for every Baha’s apparatus.

04-11 32R(,&5/3%!/&6 1)&-$!'()%& / 1#('%!+ Q),3,-)) &.&.2ID9S, &./.5TUVD? 9BB7BEAHE, D9HC7C9E FAC7G7HBD78 H9ID /.4.$7D?H?<, E>9<F9E?K?N-?>E?=AC '.J.5K?W7H !FBD9L -?BIC9>BE<AHH9L 4AC7G7HBD9L &D9CAF7L, !FBD, ,?BB7L ?.8@: 'E#C',@ #8@,$2E6#+*6#F +2$,'(# D.$.8*-*6 )8'((%1 ,$#IC2,%1 +*0,.9 # ).,.9 $2E8'C(*&* 6*E$20,2, 2I)*-'(28@(*9 ,$26-%, 0 D*6$.O).('.- 6(#,$.(('1 *$&2(*6 ' +$*6*,.C.('.-, ' (.9$*,$26-% # ).,.9 $2((.&* 6*E$20,2. ;2,.$'28% ' -.,*)%. 42-' *I08.)*62(* 19 ).,.9 0 ,$26-*9 )8'((%1 ,$#IC2,%1 +*0,.9 (6*E$20, *, 1 &*)2 )* 14 8.,), 9 ).,.9 0 2I)*-'(28@(*9 ,$26-*9 (6*E$20, *, 3 )* 12 8.,) ' 65 ).,.9 0 (.9$*,$26-*9 (6*E$20, *, 1 -.0>/2 )* 1 &*)2). G$' D.$.8*-21 +*(.C(*0,.9 '008.)*62('> D$*'E6*)'8' 6 D$'.-(*- D*+*.

D*$,2,'6(%- 2DD2$2,*- <W3 TLOKA-500. <WH D$*6*)'8' +2+ -'('-#- 6 )6#1 D$*.+/'>1, D$' (.*I1*)'-*0,' 6%D*8(>> D*8'D*E'/'*((*. '008.)*62('.. G$*6*)'820@ $.D*E'/'> *,8*-+*6 D*) +*(,$*8.- <W3, D$' #)*68.,6*$',.8@(*- 0,*>('' *,8*-+*6 – '--*I'8'E2/'> ' -*(',*$'(& 0$2K.('> D.$.8*-2 <W3 (2 5-7; 14-17; 25-30 0#,+'.

H.,>- 0 2I)*-'(28@(*9 ,$26-*9 6 #08*6'>1 $.2('-2/'*((*&* *,).8.('> '8' *D.$2/'*((*9 I%8* D$*6.).(* <W3 (2 D$.)-., D*6$.O).('> 6(#,$.(('1 *$&2(*6. G$' 6%>68.('' D*6$.O).('> 0.8.E.(+' 0 6(#,$'I$FP'((%- +$*6*,.C.('.- D$*6*)'820@ 82D2$*0+*D'C.0+2> *D.$2/'> '8' 82D2$*,*-'>. G$' 0*C.,2((*D*6$.O).('' 0 8.6*9 D*C+*9 ' (.6*E-*O(*0,' 0*1$2(',@ *$&2(, D$*6*)'820@ *$&2(*#(*0>K2> *D.$2/'>. 70. ).,' 6%D'02(% 0 6%E)*$*68.('.-.

H.,>- 0 (.9$*,$26-*9 D$*6*)'8' '008.)*62('> 2DD2$2,*- SIEMENS G-60, C2K. 6 $.2('-2/'*((*- *,).8.('', D* (.*,8*O(%D*+2E2('>-. ND$.).8>8' -.0,* ' 12$2+,.$ D*6$.O).('>, 6.8'C'(# 0-.K.('> *,8*-+*6 ' $2E-.$ 6(#,$'C.$.D(*9 &.-2,*-% (0#I)#$28@(*9 ' AD')#$28@(*9). G$*6*)'8*0@ K2)>K.. 8.C.('. – D#(+/'>, ,$.B'(2/'> '8' )$.('$*62('. -'+$*'$$'&2,*$2-'. G$' (28'C'' &.-2,*-% )* 8-10 -- ' *,0#,0,6'' 6%$2O.((*&* )'08*+2/'*((*&* 0'()$*-2 D$*6*)'8*0@ +*(0.$62,'6(*. 8.C.('. ' <W3 6 )'(2-'+.. <)2628*0@ *D$.).8',@ 0,2)'', 12$2+,.$(%. )8> *$&2('E#FK.90> &.-2,*-%.

G*8#C.((%. $.E#8@,2,% '008.)*62('9, D*E6*8>F, 0).82,@ 6%6*) * ,*-, C,* D$'-.(.('. <WH 6 (.*,8*O(*9 ,$26-2,*8*&'' ' ).,0+*9 1'$#$&'' D* '(B*$-2,'6(*0,' (. ,*8@+* (. #0,#D2.,, (* '(*&)2 ' D$.6*01*)', 6*E-*O(*0,' $.(,&.(*8*&'C.0+*&* -.,*)2 '008.)*62('>.

ULTRASONIC DIAGNOSIS IN PEDIATRIC SURGERY A.A.Lukash, A.V.Zuzko candidate of medical sciences, the assistant V.M.Nikonov, traumatic and orthopaedic surgeon S.B.Zlobin Omsk State Medical Academy, Omsk, Russian Federation As a noninvasive, available and informative method, ultrasonography is unexpendable in pediatric surgery.

The Purpose is to research ultrasonic presentation of pipe bones fractures among children of different age, abdominal trauma, with internal injures and bleeding, and neurotraumas among small children.

Materials and methods. We have examined 19 children with pipe bones fractures (1-14 years old), 9 children with abdominal trauma (3-12 years old) and 65 children with neurotrauma (1-12 months). In case of limb fractures the examination was made with a portable ultrasonic device TLOKA-500 in the reception ward. Ultrasonic examination was performed in two views at least; if needed the multiple view scanning was made.

Under the ultrasonic examination control the bone reposition was made, under the satisfactory condition of fragments immobilization and monitoring of fracture coalescence with the ultrasonic examination at 5-7; 14-17; 25-30 days.

!"#$%&' ()*+, 2011, ,-.-/%"%&" ' 0."1&2/3%-45 67.5#'5 No1

!

At conditions of resuscitation department or operating suite, the children with abdominal trauma were examined with the ultrasonic examination concerning internal injuries. If any lien injuries with intraperitoneal bleeding were found out, laparoscopic operation or laparotomy were made.

In case of multisystem injury of the left kidney and impossibility to save the organ the resection operation was performed. All children were discharged as recovered.

With regard to acute indications, children with neurotrauma were examined with the device SIEMENS G-60 in resuscitation departments mostly. They defined the spot and nature of injures, size of fragments dislocation and intracranial subdural and epidural hematomas. Sparing treatment was organized, it included puncture, trepanation or drainage with microirrigators. In case of hematoma up to 8-10 mm and no apparent dislocation syndrome, conservative management and ultrasonic examination were carried out in progression. We succeeded in defining phases being typical for the organizing hematoma.

The received researches results proved that ultrasonic examination in acute traumatology and pediatric surgery are as good as roentgenologic diagnostic techniques.

04-14 0!%&5&$)6 % Q),3,-)*#'%!43 2#*#$)X 1#.#%(& 4#YY#231!*%!/!+ 0#,#-!,!1%) '#,1"& 3 1#(#+ 42&1Z#-! /!5,&'(& #.&..AC?>AHD? =>?@@AB?> ).X.%?N9H?< '9F9>BD7M -?BIC9>BE<AHHOM 4AC7G7HBD7M 3H7<A>B7EAE, '9F9>9, ,?BB7L T+,#28@(*0,@ ,.-%. H.B.+, -.OO.8#)*C+*6*9 D.$.&*$*)+' (H;XG)*)'( 'E (2'I*8.. C20,%1 6$*O).((%1 D*$*+*6 0.$)/2. 7 'E*8'$*62((*- 6'). 60,$.C2.,0> D$'I8'E',.8@(* # 30 % 60.1 I*8@(%1 0 6$*O).((%-' D*$*+2-' 0.$)/2. ?.8@ '008.)*62('>. G$*6.0,' 2(28'E ' *D$.).8',@ *D,'-28@(%.

D*+2E2('> )8> 1'$#$&'C.0+*&* 8.C.('> H;XG # ).,.9 -82)P.&* 6*E$20,2.

H.B.+, -.OO.8#)*C+*6*9 D.$.&*$*)+' (H;XG) – A,* *,6.$0,'.

-.O)# 8.6%- ' D$26%- O.8#)*C+2-'. H.B.+,% -*&#, $20D*82&2,@0> 6 $2E8'C(%1 -.0,21 -.OO.8#)*C+*6*9 D.$.&*$*)+'. 42'I*8.. C20,* *(' 8*+28'E#F,0> 6 -.-I$2(*E(*9 C20,'. R2$)'*1'$#$&2-' (2 I2E. !2-2$0+*&* *I820,(*&* +8'('C.0+*&* +2$)'*8*&'C.0+*&* )'0D2(0.$2 6%D*8(>8'0@ *D.$2/'' D* '0D$268.('F ).B.+,2. H'2&(*E H;XG 0,26'80> (2 *0(*62('' *IK.+8'('C.0+*&* *I08.)*62('>, $.(,&.(*&$2B'' &$#)(*9 +8.,+' ' A8.+,$*+2$)'*&$2B''. L2+ O. 60.).,>)* ' D*08. *D.$2/'' -(*&*+$2,(* D$*6*)'820@ A1*+2$)'*&$2B'>. ND$.).8>8'0@ $2E-.$ ' 8*+28'E2/'> ).B.+,2 -.OO.8#)*C+*6*9 D.$.&*$*)+', 0'0,*8'C.0+'9 ' )'20,*8'C.0+'9 $2E-.$ 8.6*&* O.8#)*C+2, )'2-.,$ 8.6*&* D$.)0.$)'>, 2*$,%, D$26*&* O.8#)*C+2 ' 8.&*C(*9 2$,.$''. T(28'E )*DD8.$-A1*+2$)'*&$2B'' 6+8FC28 6%C'08.('. &$2)'.(,2 )268.('> -.O)# O.8#)*C+2-' D* D*,*+# C.$.E H;XG. !*&820(* (2P'- '008.)*62('>-, 0D*(,2((*.

E2+$%,'. (. 60,$.C2.,0> # -82).(/.6 0 I*8@P'- H;XG, D*A,*-# E2+$%,'. ).B.+,2 $.+*-.()#.,0> 60+*$. D*08. .&* *I(2$#O.('>, (.E26'0'-* *, 6*E$20,2 ' 6.02. G*+2E2('9 + *D.$2/'' 08.)#FK'.: ).B'/', -200% ,.82, 0.$).C(2> (.)*0,2,*C(*0,@, 8.&*C(2> &'D.$,.(E'> ' )'82,2/'> 8.6%1 *,).8*6 0.$)/2. 5'$#$&'C.0+2> ,.1('+2 I%82 0,2()2$,(*9 ' E2+8FC2820@ 6 (28*O.('' E2D82,% ' #P','' ).BB.+,2. N)(*6$.-.((* 0 E2+$%,'.- H;XG D$*'E6*)'820@ +*$$.+/'> 0*D#,0,6#FK'1 6$*O).((%1 D*$*+*6 0.$)/2.

G.$6'C(*. 1'$#$&'C.0+*. E2+$%,'. H;XG 6 ,.C.('. D.$6*&* &*)2 O'E(' >68>.,0> -28*$'0+*62((%- ' ABB.+,'6(%- 6%I*$*- -.,*)2 8.C.('> )8> I*8@P'(0,62 0'-D,*-2,'C(%1 -82).(/.6. G*08. #0D.P(*&* E2+$%,'> H;XG # I*8@P'(0,62 -82).(/.6 (2I8F)2.,0> I%0,$*. 0('O.('. 8.&*C(*-2$,.$'28@(*&* )268.('> ' *I8.&C.('.

0'-D,*-2,'+'. =2((..

E2+$%,'.

H;XG 6 -82).(C.0,6.

D$.)#D$.O)2., $2E6','. (.*I$2,'-*9 8.&*C(*-0*0#)'0,*9 *I0,$#+,'6(*9 D2,*8*&''.

INDICATIONS FOR SURGICAL TREATMENT OF VENTRICULAR SEPTAL DEFECT OF THE HEART IN YOUNG CHILDREN E.A.Fedorenko proffesor I.U.Koganov Samara State Medical University, Samara, Russian Federation Relevance of the topic. Ventricular septal defect (VSD) - one of the most common congenital heart defects. In the isolated form occurs in approximately 30% of all patients with congenital heart disease. The aim of the study. Analyze and determine the best indications for surgical treatment of ventricular septal defect in young children. Surgeons on the basis of the Samara regional clinical cardiology clinic performed surgery to correct the defect. The diagnosis of VSD was based on the general clinical examination, chest radiography, and electrocardiography. Determine the

size and location of the defect of interventricular septum, systolic and diastolic left ventricular size, the diameter of the left atrium, aorta, right ventricle and pulmonary artery. Analysis of Doppler echocardiography includes the calculation of the pressure gradient between the ventricles on the flow through the VSD. According to our study, spontaneous closure does not occur in infants with large ventricular septal defect, and therefore recommended the closure of the defect soon after its discovery, regardless of age and weight. Indications for surgery are as follows: underweight, heart failure, pulmonary hypertension and dilatation of the left heart.

Surgical technique was standardized and consisted in the imposition of a patch, and sutured deffekta. Simultaneously with the closure of VSD was performed concomitant correction of congenital heart disease. Primary surgical closure of VSD in the first year of life is low-risk and effective choice of treatment for most symptomatic infants. Following the successful closure of VSD in most infants, a rapid decrease in pulmonary arterial pressure and relief of symptoms. Early closure of ventricular septal defect in infancy prevents the development of irreversible pulmonary vascular obstructive disease.

04-20 0,)4#$#$)# 4&2!)$/&5)/$!+ 4#(!1)%) / Q),3,-)*#'%!4 2#*#$)) !'(,!-! $&,3Z#$)6 4!5-!/!-! %,!/!!J,&[#$)6 3 1#(#+ %.&.J9>CAA<9,&.&.49>EOHAHD?,/./. 47SD7H 59<ACIT\7M D9@AC>?M CAEBD?M 87>I>N77, C.F.H., =>?@ABB?> &./.07BDK9D?< !FBD9L N?BIC9>BE<AHH9L FAC7G7HBD9L 9D9CAF7L, !FBD, ,?BB7L T+,#28@(*0,@ 'E#C.('> *0,$%1 (2$#P.('9 -*E&*6*&* +$*6**I$2K.('> (N4;R) # ).,.9 *D$.).8>.,0> 6%0*+*9 '(628')'E2/'.9 ' 0-.$,(*0,@F D*08. D.$.(.0.((*&* E2I*8.62('>.

NIK2> 0-.$,(*0,@ *, '(0#8@,*6 0*0,268>., 0,6 (2 100000 ).,0+*&* (20.8.('>. ?.8@: <8#CP.('. +2C.0,62 1'$#$&'C.0+*&* 8.C.('> # ).,.9 0 N4;R 6 *0,$*D.$'*)., D#,.D$'-.(.('> #0*6.$P.(0,6*62((*&* -'+$*'(62E'6(*&* -.,*)2 )$.('$*62('> &.-2,*-. ;2,.$'28% ' -.,*)%: 6 *,).8.('' (.9$*1'$#$&'' :HRM Y3 &.N-0+2 E2 D.$'*) 1993-2010&&. (21*)'8*0@ (2 8.C.('' 43 $.I.(+2 0 N4;R D* &.-*$$2&'C.0+*-# ,'D#, 6 6*E$20,. *, 1 -.0>/2 )* 16 8.,; 'E ('1 -28@C'+*6 – 25, ).6*C.+ – 18. NI08.)*62('. 6+8FC28* (.6$*8*&'C.0+'9 *0-*,$, '008.)*62('. 8'+6*$2, ;=L &*8*6(*&* -*E&2, A1*A(/.B28*0+*D'F. ND.$2,'6(*. 6-.P2,.8@0,6* 6%D*8(>8' 6 *IJ.-. *,+$%,*&* #)28.('> &.-2,*-%, D#(+/'*((*9 20D'$2/'' ' (2$#O(*&* )$.('$*62('> I*+*6%1 O.8#)*C+*6. ! 2009 &*)2 6 +8'('+. ).,0+*9 1'$#$&'' N-:;T D$'-.(>.,0> 0D*0*I )8',.8@(*&* E2+$%,*&* (2$#O(*&* )$.('$*62('> 0#I)#$28@(%1 0+*D8.('9 # ).,.9 (D$'*$',.,(2> 0D$26+2 U:< U3G! Y 2010111820), D* )2((*9 -.,*)'+. *+2E2(2 1'$#$&'C.0+2> D*-*K@ 9 ).,>- 0 N4;R D* &.-*$$2&'C.0+*-# ,'D#. R *0*I.((*0,>- -.,*)2 *,(*0',0> 66.).('. )6#1 +2,.,.$*6 6 D*8*0,@ &.-2,*-% C.$.E *)(* B$.E.6*. *,6.$0,6'., 6 D$*,'6*D*8*O(%1 (2D$268.('>1 D*) *0,$%#&8*- D* (2D$268.('F D2$288.8@(* +*(6.+0',28@(*9 D*6.$1(*0,' -*E&2. G$.)82&2.-%9 0D*0*I )8',.8@(*&* E2+$%,*&* (2$#O(*&* )$.('$*62('> -28*'(62E'6.(, -*O., D$'-.(>,@0> # (.)*(*P.((%1 ' *082I8.((%1 ).,.9, 2 ,2+O. D*E6*8>., $2)'+28@(* *D*$*O(>,@ &.-2,*-# ' -*O., '0D*8@E*62,@0> +2+ D$'8'6(*-*,8'6(2> 0'0,.-2.

7%6*): $.E#8@,2, D$'-.(.('> 0D*0*I2 – D*6%P.('. ABB.+,'6(*0,' 1'$#$&'C.0+*&* 8.C.('> D$' N4;R D* &.-*$$2&'C.0+*-# ,'D# # ).,.9 E2 0CZ, #-.(@P.('> 6$.-.(' *D.$2/'', )8',.8@(*0,' (2$+*E2, 6*E-*O(*&* *IJZ-2 +$*6*D*,.$', $./')'62.

MINIMALLY INVASIVE SURGERY TECHNIQUE EXPLOITING FOR ACUTE CEREBROVASCULAR EVENT IN CHILDREN K.A. Bardeeva, A.A. Martynenko, V.VMishkin MD, PhD, Professor, Head of the Department A.V.Pisklakov Omsk State Medical Academy, Omsk, Russian Federation Importance for study the acute cerebrovascular events (ACVE) in children is defined by high rate of morbidity and mortality after ACVE. Mortality rate from the strokes is 0.6 per 100 000 children.

Objective: To improve the quality of surgical treatment in children with ACVE in the acute period by applying an elaborated microinvasive approach for haematoma drainage.

Materials and methods: 43 children with ACVE, a hemorrhagic type, aged from 1 month to 16 years old including 25 boys and 18 girls have been treated in the Neurosurgery Department of the Omsk Municipal Children Hospital Y 3 for the period from 1993 to 2010. The general examination included a neurological examination, liquor test, MRI, and echoencephalography. Surgery was performed and included an open haematoma removal, needle aspiration and external drainage of the lateral ventricles.

Prolonged external closed drainage of the subdural accumulations in

$! !

0"'1&8 «,"$#'28 9&:5:;&8»

! children has been performed at the Omsk Pediatric Hospital #3 since 2009 (Certificate of Acceptance Y 2010111820 FGU FIPS). Nine children with hemorrhagic ACVE underwent surgery using this approach. Peculiarities of the approach is two catheters insertion into the haematoma cavity through a single drilled hole in opposite directions at an acute angle in the direction parallel to the convexital brain surface. The prolonged external closed drainage surgical approach is minimally invasive and can be used in premature and weakened children. It allows haematoma emptying and can be used as a tidal system.

Conclusion: Result for such surgical approach applying is increasing of surgical treatment efficacy for ACVE in children by reducing the surgery time, duration of anesthesia, blood loss, and recurrence.

04-26 !0P( 0,)4#$#$)6 J!(32)$)*#'%!-! (!%')$& ()0& & / 1#('%!+ 3,!2!-)) 4.$.29U7S<7K7 C.F.H., =>?@ABB?> 2.J.4AH?<\7D?<9 ,?BB7MBD7M N?BIC9>BE<AHHOM FAC7G7HBD7M IH7<A>B7EAE 7F. $. ).

07>?N?<9 7 8.C.('' $200,$*90,6 -*C.'0D#0+2('> # ).,.9 6.)#K.9 >68>.,0> B2$-2+*,.$2D'>. 4* *(2 (. 60.&)2 *,6.C2., +$',.$'>- ABB.+,'6(*0,' ' D.$.(*0'-*0,' 8.+2$0,6.((%1 D$.D2$2,*6, 2 # ).,.9 '-.., 6*E$20,(%. *&$2('C.('>. [,* *I#08268'62., D*'0+ +2+ (*6%1 B*$-#8 D$.D2$2,*6 0 0.8.+,'6(%- ).90,6'.-, ,2+ ' (*6%1 0D*0*I*6 '1 66.).('>. <0D.P(%- D$'-.$*- ,2+*&* D*'0+2 >68>F,0> D$.D2$2,% I*,#8'('C.0+*&* ,*+0'(2 ,'D2 T (MLLT).

7 *,.C.0,6.((*9 +8'('C.0+*9 D$2+,'+. )8> D$'-.(.('> 6 #$*8*&'' $2E$.P.( D$.D2$2, MLLT – Q2(,*+0 (R4H=).

G* $2E$.P.('F 8*+28@(*&* A,'C.0+*&* +*-',.,2 =:;< 0 B.6$28> 2010&. (2 +2B.)$. ).,0+*9 1'$#$&'' -.,*)'+2 8.C.('> $2E8'C(%1 62$'2(,*6 A62+#2,*$(%1 ' $.E.$6#2$(%1 )'0B#(+/'9 -*C.6*&* D#E%$> (;G) 0 D*-*K@F Q2(,*+02 D$'-.(>820@ # 19 ).,.9 6 6*E$20,. *, 3 )* 15 8.,. G*08. #,*C(.('> )'2&(*E2 60. ).,' D*8#C28' D*A,2D(*.

8.C.('., )8',.8@(*0,@ .&* 0*0,268>82 *, 1 &*)2 )* 13 8.,.

G* 12$2+,.$# *0(*6(%1 (2$#P.('9 $.E.$6#2$(*9 ' A62+#2,*$(*9 B#(+/'' ('O('1 -*C.6%1 D#,.9 I*8@(%. I%8' $2E).8.(% (2 3 &$#DD% (!-. ,2I8'/# 1).

M*8@(%- I ' III &$#DD 0 /.8@F #6.8'C.('> ABB.+,'6(*9 .-+*0,' ;G '0D*8@E*62820@ 6(#,$').,$#E*$(2> -.,*)'+2 66.).('> Q2(,*+02 D*) D*0,*>((%- A()*0+*D'C.0+'- +*(,$*8.-. H.,>- II &$#DD% '(J.+/'' Q2(,*+02 D$*6*)'8'0@ ,$2(0#$.,$28@(* 6 (2$#O(%9 0B'(+,.$ #$.,$%.

G$' 0$26(.('' D$.)- ' D*0,D$*/.)#$(%1 $.E#8@,2,*6 *I08.)*62('> # ).,.9 I &$#DD% *,-.C.(* 6* 60.1 08#C2>1 '0C.E(*6.('. #$&.(,(*0,' ' #$&.(,(*&* (.).$O2('> -*C', #6.8'C.('> *IJ.-2 ;G, #-.(@P.('.

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

G$.)62$',.8@(%. )2((%. (2P'1 '008.)*62('9 D*+2E28', C,* Q2(,*+0 -*O., I%,@ '0D*8@E*62( )8> 8.C.('> ,.$2D.6,'C.0+' $.E'0,.(,(%1 08#C2.6 )'0B#(+/'' ('O('1 -*C.6%1 D#,.9 # ).,.9.

By the nature of the main violations of reservoir and evacuation function of the lower urinary tract were divided into 3 groups (See Table 1).

Patient groups I and III to increase the effective capacity of the MP used the technique of introduction vnutridetruzornaya Lantoksa under permanent endoscopic control. Children of Group II were injected Lantoksa transurethral external sphincter in the urethra.

When comparing pre-and postprotsedurnyh survey of children in group I was noted in all cases, the disappearance of urgency and Urge incontinence, increased IP, decrease intravesical pressure.

The children of Group II noted an increase in urinary flow rate, reducing the amount of residual urine by 70% or more, complete emptying of the MP failed to achieve in any case.

Children from group III the effective volume of MP increased, on average, in 2,5 times. Maximum detrusor pressure decreased, the frequency of the periodic catheterization decreased to 4-6 times a day, which undoubtedly was the indicator of quality of life. In patients with severe myelodysplasia introduction Lantoksa was an alternative to augmentation MP. Side effects and complications when using this technique were noted.

Preliminary data from our studies showed that Lantoks can be used for the treatment of treatment-resistant cases of lower urinary tract dysfunction in children.

04-29 % !"#$%# ,#532R(&(!/ Q),3,-)#'%!+ %!,,#%"))-)0!'0&1)) 3 1#(#+ !1$!4!4#$(P4 '0!'!J!4 «ONLAY FLAP» Y.Q.)W>9N7F?<, 1.,.49F9E9K7A<, Z.Z.Z?THIB?<, Z.!.(?SW?A< 59<.D9@AC>?M, C.F.H. &.&.-9@I>?< &HC7]9HBD7M N?BIC9>BE<AHHOM FAC7G7HBD7M 7HBE7EIE, &HC7]9H, 3UWAD7BE9H 7 (20,*K.. 6$.-> D$' 1'$#$&'C.0+*9 +*$$.+/'' &'D*0D2)'' # ).,.9 (2'I*8@P.. $20D$*0,$2(.('. D*8#C'8' -.,*)'+', '0D*8@E#FK'. D$' B*$-'$*62('' #$.,$% -.0,(%. ,+2(' ' -*I'8@(%. +*O(%. 8*0+#,% (2 D',2FK.9 (*O+.. ?.8@F $2I*,% >6'820@ */.(+2 $.E#8@,2,*6 *D.$2/'9 D$' $2E8'C(%1 B*$-21 &'D*0D2)'' # ).,.9.

NI08.)*62(% 31 -28@C'+' 0 $2E8'C(%-' B*$-2-' &'D*0D2)''. N(' $20D$.).8'8'0@ D* 6*E$20,#: *, 1 &*)2 )* 3 8., - 5 (16,1%), 4 - 6 8. - 10 (32,2%), 7 - 10 8. - 8 (25,8) ' 0,2$P. 10 8. - 8 (25,8%) ' D* B*$-.: &*8*6C2,2> - 6 (19,3%), 6.(.C(*9 I*$*E)% - 7 (22,6%), 0,6*8*62> - 16 (51,6%), D.(*-0+$*,28@(2> - 1 (3,22%), «&'D*0D2)'> I.E &'D*0D2)''» 1 (3,22%). 70. ).,' *I08.)*62(% (2 (28'C'. 0*C.,2((%1 2(*-28'9, D$*6.).(% *IK.+8'('C.0+'. '008.)*62('>.

70. ).,' *D.$'$*62(% *)(*-*-.(,(%- 0D*0*I*- onlay flap (#+$%62FK'9 8*0+#,). 7 .Z *0(*6. 8.O', 0*1$2(.('. #$.,$28@(*9 )*$*O+', (2 +*,*$#F (2+82)%62.,0> 6%+$*.((%9 'E -.0,(%1 ,+2(.9 8*0+#, (2 D',2FK.9 (*O+.. G$' ,>O.8%1 B*$-21 &'D*0D2)'' D$'I.&28' + 0*E)2('F 2$,'B'/'28@(*9 #$.,$% D* Duplay. 7 +2C.0,6. “#+$%62FK.&* 8*0+#,2” '0D*8@E*628' +*O(*-08'E'0,%. ,+2(' (2 (*O+. 'E 6.(,$28@(*9 D*6.$1(*0,' D*8*6*&* C8.(2. 7 +2C.0,6.

P*6(*&* -2,.$'282 '0D*8@E*628' Marilon, +*,*$%. >68>.,0> 2$.2+,'6(%-' ' (. 6%E%62F, 6*0D28',.8@(%. $.2+/''. < 60.1 ).,.9 $.E#8@,2,% D$'E(2(% 1*$*P'-' +$*-. 3 I*8@(%1. < ('1 0B*$-'$*628'0@ #$.,$28@(%. 06'K'. G$'C'(*9 A,*&* (2 (2P 6E&8>) >68>.,0> 6%$2O.((*. $#I/.62('. ' (.)*0,2,*+ +*O'.

L2+'- *I$2E*-, *)(*-*-.(,(%9 0D*0*I 1'$#$&'C.0+*9 +*$$.+/'' &'D*0D2)'' -.,*)*- onlay flap 0 '0D*8@E*62('.- 0*1$2(.((*9 #$.,$28@(*9 )*$*O+' )8> 0*E)2('> 2$,'B'/'28@(*9 #$.,$% 0D*0*I0,6#., #8#CP.('F ,$*B'+', I82&*)2$> C.-# #)2.,0> 0*1$2(',@ 2).+62,(*. D',2('. +*O', *I.0D.C'62FK.. 1*$*P.. D$'O'68.('.

8*0+#,2, 2 ,2+O. D*E6*8>., 'EI.O2,@ +*8@/.6%1 2(20,*-*E*6.

EXPERIENCE OF USING BOTULINUM TOXIN TYPE A IN PEDIATRIC UROLOGY M.N.Lazishvili MD, PhD L.B. Menovschikova State Educational Institution of Higher Professional Education, Moscow, Russian Federation

THE RESULTS OF SURGICAL CORRECTION OF HYPOSPADIAS TO ESTIMATE IN CHILDREN WITH ONE-STAGE METHOD “ONLAY FLAY” J.H.Ibragimov, D.R.Mamataliev, Sh.Sh.Shoyunusov, Sh.O.Toshboev Head of Department A.A.Gafurov Andizhan State Medical Institute, Andijon, uzbekistan

In the treatment of urination disorders in children is a leading drug treatment. But it does not always meet criteria for efficacy and tolerability of drugs, and the children have age restrictions. This causes the search as new formulations of drugs with selective action, and new ways of introducing them. A successful example of such a search is botulinum toxin type A (BTTA).

In domestic clinical practice for use in urology allowed drug BTTA Lantoks.

To resolve the local ethics committee SMU since February 2010. the department of pediatric surgery technique for treatment of various evacuation options and tank bladder dysfunction (MP) using Lantoksa was used in 19 children aged 3 to 15 years. After the diagnosis all children receive a phased treatment, its duration ranged from 1 year to 13 years.

Nowadays, during surgical correction of hypospadias in children, the most widespread techniques used in the formation of urethra local fabrics and mobile skin flaps in the feeding pedicle.

The aim of the job was to assess the results of operations in various forms of hypospadias in children.

The study included 31 boys with various forms of hypospadias. They were categorized by ages: from 1 year to 3 years - 5 (16, 1%), 4 - 6 liters. - 10 (32, 2%), 7 - 10 liters. - 8 (25.8) and over 10 liters. - 8 (25, 8%) and in form of: capitate - 6 (19, 3%), coronary sulcus - 7 (22,6%), stem - 16 (51,6%), Peno-scrotal - 1 (3 22%), “hypospadia without hypospadias"- 1 (3,22%).

All children were examined for the presence of combined anomalies which were held by general clinical research.

The results of the research give the followings: all children were operated

%! !

!"#$%&' ()*+, 2011, ,-.-/%"%&" ' 0."1&2/3%-45 67.5#'5 No1

! on one-stage method onlay flap. It is based on preservation of the urethral track, which imposed a cut of the local tissue flap on the feeding pedicle.

The hypospadias have resorted to creation of proximal part of the artificial urethra in difficult situation, formed by Duplay method. In order to stop the bleeding, the beads were used and soaked in a solution of \-ACC and adrenaline. the skin-mucosal tissue was used as the "onlay flap" on the stem of the ventral surface of the penis. The Marilon were used as a suture material, which are areactive, inert and do not cause inflammatory reactions. The wound irrigation was performed with an antibiotic solution with dicaine, instillation of the bladder antiseptics in the postoperative period. Catheters were removed for 7 days after surgery.

The results of all children were good, except for 3 patients who had formed a urethral fistula. In our opinion, the reason for this is the numerous unsuccessful operations, marked scarring and lack of skin. There was a spontaneous removal of the catheter in one of them and hit of urine to the newly formed urethra and paraurethral tissue.

Thus, one-stage method of surgical correction of hypospadias using an onlay flap with preserved urethral track, for the artificial urethra helps to improve trophisms, thus able to maintain adequate nutrition skin, providing a good engraftment of the flap, but also avoids the circular anastomosis.

04-30 ')-4!)1&2R$P+ %!2R0!0!^5 ' 2&0&,!'%!0)*#'%!+ &'')'(#$")#+ (./.%IUHAG?<9 =>?@ABB?>, C?DE?> FAC7G7HBD78 H9ID, U9<ACIT\7M D9@AC>?M CAEBD?M 87>I>N77 4-4'3 )./.0?CCIWHOM 4?BD?<BD7M N?BIC9>BE<AHHOM FAC7D?-BE?F9E?K?N7:ABD7M IH7<A>B7EAE, 4?BD<9, ,?BB7L TD82E'> 682&28'K2 – 6$*O).((%9 D*$*+ $2E6','> O.(0+'1 D*8*6%1 *$&2(*6, 8.C.('. +*,*$*&* >68>.,0> *)(*9 'E 2+,#28@(%1 D$*I8.).,0+*9 &'(.+*8*&'C.0+*9 1'$#$&'' ' '-.., )8> D2/'.(,*6 6%0*+*.

0*/'28@(*-D0'1*8*&'C.0+*. E(2C.('..

3E6.0,(* -(*O.0,6* -.,*)'+ B*$-'$*62('> '0+#00,6.((*&* 682&28'K2 0 '0D*8@E*62('.- 6 +2C.0,6. -2,.$'282 )8> +*8@D*D*AE2 +*O(%1 8*0+#,*6, D8*)(%1 *I*8*C.+, I$FP'(%, $.E./'$*62((%1 C20,.9 ,*(+*9, 0'&-*6')(*9 '8' D$>-*9 +'P+', 288*D820,'C.0+'1 -2,.$'28*6. N)(2+*, )2((%. *D.$2/'' >68>F,0> 8'I* *C.(@ ,$26-2,'C(%-', 8'I* (. )2F, #)*68.,6*$',.8@(%1 $.E#8@,2,*6.

7 (2P.9 +8'('+. #0D.P(* $2E$2I2,%62F,0> ' 6%D*8(>F,0> -.,*)'+' 82D2$*0+*D'C.0+*&* +*8@D*D*AE2, D*E6*8>FK'. )*I',@0> (2'I*8..

ABB.+,'6(%1 $.E#8@,2,*6 ' E(2C',.8@(* 0('E',@ $'0+ $2E6','> *08*O(.('9.

7 D.$'*) 0 2004 D* 2010 &*) 0'&-*')28@(%9 +*8@D*D*AE 0 82D2$*0+*D'C.0+*9 200'0,.(/'.9 I%8 D$*6.).( # 36 D2/'.(,*6 (25 0 0'()$*-*- ;29.$2-=*+',2(0+*&*-RF0,.$2-52#E.$2 ' 11 0 0'()$*-*,.0,'+#8>$(*9 B.-'('E2/'') 6 6*E$20,. *, 13 )* 17 8.,. 7 1*). *D.$2/'' I%8* '0D*8@E*62(* ,$' ,$*2+2$2, $.E./'$*62( #C20,*+ 0'&-*6')(*9 +'P+' )8'(*9 15 0- 0 )6#-> D',2FK'-' 0*0#)2-', *)'( +*(./ +*,*$*&* *D#K.( + D$*-.O(*0,' 0 B*$-'$*62('.*,6.$0,'> (.*62&'(%, 6*00,2(*68.(2 /.8*0,(*0,@ +'P+'.

G$*)*8O',.8@(*0,@ *D.$2/'' 0*0,268>82 *+*8* 110 -'(#, (*, 80 )* 240 -'(#,).

7 $.E#8@,2,. *D.$2/'> 62&'(*D820,'+' 0 '0D*8@E*62('.0'&-*6')(*9 +'P+' )282 6.8'+*8.D(%. B#(+/'*(28@(%. ' +*0-.,'C.0+'. $.E#8@,2,% 0 ('E+*9 C20,*,*9 D*08.*D.$2/'*((%1 *08*O(.('9. H2((2> -.,*)'+2 +*8@D*D*AE2 -*O., $200-2,$'62,@0> +2+ «E*8*,*9 0,2()2$,» )8> 8.C.('> 2D82E'' 682&28'K2 # D2/'.(,*6 0 0'()$*-*- ;29.$2-=*+',2(0+*&*-RF0,.$2-52#E.$2 ' 0'()$*-*,.0,'+#8>$(*9 B.-'('E2/''.

LAPAROSCOPIC SIGMOID VAGINAL REPLACEMENT T.V. Kuznetsova MD, PhD, Professor, Head of the Department I.V.Poddoubnyi Moscow State University of Medicine and Dentistry, Moscow, Russian Federation Vaginal aplasia is congenital defect of female genital organs; it;s treatment is one of actual problems of children's gynecologic surgery and has high socially-psychological value for patients.

It is known dozen methods of formation of a neovagina with use as a material for colpopoiesis skin flaps, a pelvic peritoneum, resected parts of small intestine, sigmoid or a rectum, alloplastic materials. However, these operations are either very traumatic, or don't give satisfactory results.

In our clinic methods of laparoscopic colpopoiesis are successfully developed and carried out, allowing to get the most effective results and considerably decrease a risk of development of complications.

36 patients (aged from 13 to 17 years) underwent laparoscopic neovaginoplasties during the period from 2004 to 2010 for MayerRokitansky-Kuster-Hauser syndrome (MRKHS) – in 25 girls (XX genotype) and for testicular feminization syndrome (TFS) – in 11 XY patients. Three trocars (12 mm umbilical+ two 5 mm) were used in all

cases. A 15 cm segment of sigmoid colon with two preserved feeding vessels was isolated. One end of the segment was pulled down to the perineum and sutured in the hymenal region to form the neovaginal orifice, the integration of intestine was restored. The mean operating time was about 110 minutes (from 80 to 240 min.).

In consequence, laparoscopic sigmoid vaginal replacement provides excellent functional and cosmetic results with low frequency of postoperative complications. Intracorporeal sigmoid vaginoplasty may be employed as an “gold standard” procedure in the patients with MRKHS and TFS.

04-42 %2)$)%!-4!,.!2!-)*#'%)# 0&,&22#2) 0,) (,&/4&()*#'%!+ (,&%")!$$!+ 4)#2!0&()) 3 1#(#+. &./.3BAHD?, ,./.JAK?<9 C?GAHE D9@AC>O CAEBD?M 87>I>N77 B DI>B?F I>?K?N77 7 9HC>?K?N77,C?DE?> FAC7G7HBD78 H9ID 29>VD7H )N?>V )<9H?<7: !FBD9L -?BIC9>BE<AHH9L 4AC7G7HBD9L &D9CAF7L, !FBD, ,?BB7L R8'('+*--*$B*8*&'C.0+'.

D2$288.8' D$' ,$26-2,'C.0+*9 ,$2+/'*((*9 -'.8*D2,'' # ).,.9.

G$*I8.-2 )'2&(*0,'+' ' 8.C.('> D*6$.O).('9 0D'((*&* -*E&2 # ).,.9 0*1$2(>., 2+,#28@(*0,@ )* (20,*>K.&* 6$.-.('. < ).,.9 D$.*I82)2F, 'E*8'$*62((%.

D*6$.O).('> 0D'((*&* -*E&2 (,$2+/'*((2> -'.8*D2,'>, 0'()$*- SCIWORA spinal cord injury without radiograchic abnormality). 4.E$.8*0,@ ,+2(.9, I%0,$2> )'(2-'+2 +8'('C.0+'1 0'-D,*-*6 *IJ>0(>F, 08*O(*0,@ )'2&(*0,'+'. ?.8@ $2I*,%: #8#CP.('. )'2&(*0,'+' D*0,$2)26P'1 ).,.9 0 ,$26-2,'C.0+*9 ,$2+/'*((*9 -'.8*D2,'.9 (LL;). ;2,.$'28% ' -.,*)%: 7 A+0D.$'-.(,. 6*0D$*'E6.).(2 LL; # 6 +$*8'+*6. G$*6.).(* -*$B*8*&'C.0+*. '008.)*62('. -2+$* ' -'+$*D$.D2$2,*6 D*6$.O).((*&* 0D'((*&* -*E&2.

G$*6.).( $.,$*0D.+,'6(%9 2(28'E +8'('C.0+*&* ,.C.('> LL; # 82 ).,.9 6 6*E$20,. 0 3-15 8., (21*)'6P'10> (2 8.C.('' 6 *,).8.('' ).,0+*9 (.9$*1'$#$&'' :HRM-3 0 2000 D* 2009&. N/.(+2 (.6$*8*&'C.0+*&* ).B'/',2 D$*6*)'820@ D* P+28. ASIA, D$'(>,*9 IMSOP ' P+28. Frankel. G$*6*)'8*0@ $.(,&.(*&$2B'> ' ;=L '008.)*62('.. G$' */.(+. 0,.D.(' ,>O.0,' '0D*8@E*628'0@ +$',.$'' Zwimpler. NIJ.- -'('-28@(*9 6%I*$+' $200C',2( D* (*-*&$2--.

T8@,-2(2 ' 0*0,26'8 75. 7%).8.(* )6. &$#DD%: ).,' )*P+*8@(*&* 6*E$20,2 (n=11) ' P+*8@(*&* (n=71). G>,(2)/2,' D*0,$2)26P'6%D*8(.(2 [4;:. =.E#8@,2,%. 3008.)*62('. -*$B*8*&'C.0+*&* -2,.$'282, D*8#C.((*&* 6 A+0D.$'-.(,., D*),6.$)'8* -(*&*#$*6(.6*. D*$2O.('. 0D'((*&* -*E&2 (!;) D$' LL;.

G$' 2(28'E. +8'('C.0+'1 )2((%1 #0,2(*68.(*, C,* D*6$.O).('> 0D'((*&* -*E&2 # ).,.9 )*P+*8@(*&* 6*E$20,2 ,'D2 7 D* Frankel 60,$.C28*0@ 6 1 (2I8F).('', ,'D ! 6 4 (2I8F).('9, ,'D D 6 3 (2I8F).('9, ,'D ] 6 3 (2I8F).('9. < ).,.9 0,2$P. 7 8., D*6$.O).('> ,'D2 B ' C (. 60,$.C28'0@, ,'D2 D 60,$.C28*0@ 6 23 (2I8F).('9, ,'D2 ] 6 48 (2I8F).('9. < 8 D*0,$2)26P'1 D$'0#,0,6*6282 +8'('+2 -(*&**C2&*6*&* D*6$.O).('>. < 15 D$'E(2+' -(*&*#$*6(.&* D*6$.O).('> (*0'8' 0#I+8'('C.0+'9 12$2+,.$ ' 6%>68.(% [4;:. 7 M%0,$%9 $.&$.00 +8'('C.0+'1 D$*>68.('9 D$'6*)'8 + (.6.$(*9 */.(+. 0,.D.(' ,>O.0,' 6 3 08#C2>1.

7%6*)%: 1. < ).,.9 $2((.&* 6*E$20,2 D$.*I82)2F, I*8.. ,>O.8%. D*$2O.('> !;.

2. H8> LL; # ).,.9 12$2+,.$(* -(*&*#$*6(.6*. D*6$.O).('. !;.

3. H8> *IJ.+,'6(*9 */.(+' 0,.D.(' D*6$.O).('> !; # ).,.9 (.*I1*)'-* D$*6.).('. [4;: .

CLINICAL AND MORPHOLOGICAL PARALLELS IN TRAUMATIC TRACTION MYELOPATHY IN CHILDREN. A.Usenko, R.Belova reader in Pediatric Surgery with the Course of Urology and Andrology, Doctor of Medical Science I.Larkin Omsk State Medical Academy, Omsk, Russian Federation Clinical and morphological parallels in traumatic traction myelopathy in children.

The problem of diagnosis and treatment of spinal cord injury in children is still topical issue today. Children mainly have isolated spinal cord injury (myelopathy traction syndrome SCIWORA spinal cord injury without radiographic abnormality). Immaturity of the tissues, fast dynamics of clinical symptoms is explained by the difficulty of diagnosis.

Objective: improving diagnosis of affected children with traumatic traction myelopathy (TTM).

&! !

0"'1&8 «,"$#'28 9&:5:;&8»

!

Materials and methods: In the experiment reproduced TTM in 6 rabbits. A morphological study of macro and micro parts of damaged spinal cord was made.

A retrospective analysis of clinical course of TTM in 82 children aged from 3-15 years was treated in the department of pediatric neurosurgery GDKB3 from 2000 to 2009. Evaluation of neurological deficits was carried out on the scale of ASIA, approved by IMSOP and Frankel scale. X-rays and MRI investigations were carried out. In assessing the severity of trauma, the criteria of Zwimpler were used. Minimum sample volume is calculated by the nomogram of Altman and equal to 75. Two groups were allocated: preschool children (n = 11) and school children (n = 71). Fifteen injured persons were put to ENMG. Results. Morphological study of material obtained in the experiment, confirmed the multi-level spinal cord lesion (SC) in TTM. Clinical data analysis revealed that spinal cord injury in preschool children of the type B for Frankel occurred in 1 case, the type C - in 4 cases, the type D - in 3 cases, the type E - in 3 cases. Children older than 7 years of had not the injury of the type B and C, but D type occurred in 23 cases, the type E - in 48 cases. 8 of injured children had the clinic multifocal damage.

In 15 cases, the signs of the multilevel injuries were all subclinical and identified by ENMG. Rapid regression of clinical symptoms led to an incorrect evaluation of the severity in 3 cases.

Conclusions: 1. Children are exposed to a heavy SC defeat.

2. For TTM children are characterized by multi-level SC injury.

3. To make an objective assessment of the degree of SC injury for children, it is necessary to make ENMG.

there is a necessity of application modern synthetic implants for a trachea plasticity. a perspective direction is the usage of a synthetic material from polytetrafluorethylene. The main goal of the experiment is to fix possibility of application of the given synthetic material at reconstructive-plastic operations on a trachea. Experiment was spent on 5 rabbits of breed "a gray giant", the age of all rabbits was 3 months, and the weight didn't exceed 2kl. Under the general combined anesthesia the trachea was allocated on an extent 5,00-. From a synthetic material created "muff", which shrouded a trachea on an extent 3,00-. During the trachea revision after 1 month it is revealed that implant densely grows together with a trachea, doesn't cause active inflammatory reaction, doesn’t encapsulate and doesn’t reject, and also not displaced and keeps the form of "a hollow tube» The following stage carried out a trachea resection in a zone of imposing of "muff". In the postoperative period was spending the antibacterial, symptomatic therapy directed on spree over of signs of respiratory insufficiency. Following the results of the work, has been done conclusions about possibility of use of this synthetic material at reconstructive-plastic operations on a trachea.

04-45 ^%'0#,#4#$(&2R$!# !J!'$!/&$)# /!54!Y$!'() )'0!2R5!/&$)6 ')$(#()*#'%!-! )402&$(&(& 0,) ,#%!$'(,3%()/$!-02&'()*#'%)Q !0#,&")6Q $& (,&Q##. />IWKA<BD7M &. '., 'F7>H?<9 './., -I>BD9L &. '.

D.F.H. Z9BE7H $. 0. ,?BB7MBD7M N?BIC9>BE<AHHOM FAC7G7HBD7M IH7<A>B7EAE 7F. $. ).

07>?N?<9, 4?BD<9, ,?BB7L

T).(*')(%. 6.&.,2/'' ' 2).(*')',% D$'6*)>, + $2E6','F 0*0,*>('> «C20,* I*8.FK.&* $.IZ(+2», C,* (.$.)+* E2+2(C'62.,0> 2).(*,*-'.9. ;*$B*8*&'C.0+' D$' A,*- *D$.).8>.,0> -.,2D82E'> -(*&*$>)(*&* -.$/2,.8@(*&* AD',.8'> 6 -(*&*08*9(%9 D8*0+'9. ?.8@F '008.)*62('> >6'8*0@ *D$.).8.('. -*$B*8*&'C.0+*&* 0*0,*>('> AD',.8'> &8*,*C(*9 -'()28'(% # ).,.9 $2E(%1 6*E$20,(%1 &$#DD ' 0**,(*P.('. 0,.D.(' -.,2D82E'' 0 +8'('C.0+'- )'2&(*E*-. ;.,*)*- 06.,*6*9 -'+$*0+*D'' I%8' 'E#C.(% D$.D2$2,% &8*,*C(%1 -'()28'( 46 ).,.9 6 6*E$20,. *, 2-1 )* 14-,' 8.,, #)28Z((%1 6 QN=+8'('+. !GI:G;T 0 >(62$> D* (*>I$@ 2010 &. H.,' I%8' $2E).8.(% (2 3 &$#DD%: )* 6 8., (20 ).,.9); 7-11 8., (20 ).,.9); 0,2$P. 12 8., (7 ).,.9). =20D$*0,$2(Z((*0,@ -.,2D82E'' AD',.8'> -'()28'(% */.('62820@ D* 0,.D.(>-: I - 082I* 6%$2O.((2> – D8*0+'9 AD',.8'9 $20D*82&2.,0> -.(.. C.- (2 D*8*6'(. D*6.$1(*0,' 0$.E2; II – #-.$.((2> – D8*0+'9 AD',.8'9 *162,%62., (. -.(.. 2/3 D*6.$1(*0,' 0$.E2; III - $.)+'. #C20,+' -.$/2,.8@(*&* AD',.8'> '8' .&* *,0#,0,6'.

(2 0$.E.. < ).,.9 1-9 &$#DD% -.,2D82E'> I 0,.D.(' 60,$.C2820@ 6 40% 08#C2.6, II 0,.D.(' 6 40% ' III 0,.D.(' 6 20% (2I8F).('9. 7* 2-9 &$#DD. I 0,.D.(@ 60,$.C2820@ 6 50%, II - 6 30%, III – 6 20% D$.D2$2,*6. 7 3-9 &$#DD. -.,2D82E'> I 0,.D.(' (2I8F)2820@ 6 83%, II - (. 60,$.C2820@, III – 6 17% 08#C2.6.

G$' 0*D*0,268.('' 0,.D.(' -.,2D82E'' ' +8'('C.0+*&* )'2&(*E2 6%>0('8*0@, C,* D$' &'D.$,$*B'' *D$.).8>.,0> D$.'-#K.0,6.((* I 0,.D.(@ -.,2D82E'' (82% 08#C2.6), D$' 2).(*')',. – *IP'$(%. #C20,+' D8*0+*&* AD',.8'> (III 0,.D.(@ 6 79% 08#C2.6).

7%6*)%: 1. 42'I*8@P2> 0,.D.(@ -.,2D82E'' AD',.8'> 6%>68.(2 6 &$#DD. ).,.9 )* 6-,' 8.,.

2. G$' &'D.$,$*B'' &8*,*C(*9 -'()28'(% *D$.).8>.,0> (.I*8@P2> 0,.D.(@ -.,2D82E'', D$' 2).(*')',. – *IP'$(%. #C20,+' D8*0+*&* AD',.8'>.

3. ND$.).8.('. 0,.D.(' -.,2D82E'' AD',.8'> 2).(*')*6 D*08.

D2$/'28@(*9 2).(*,*-'' D*E6*8', *D$.).8',@ B#(+/'*(28@(*.

0*0,*>('. 0*1$2(Z((*9 ,+2(' ' D$*&(*E'$*62,@ D2,*8*&'F )$#&'1 -'()28'(.

!,.(*E% ,$21.' +2+ # ).,.9, ,2+ ' 6E$*08%1 >68>F,0> *)(*9 'E (2'I*8.. 2+,#28@(%1 D$*I8.- 6 1'$#$&''. G$'C'(%, D$'6*)>K'. + 0,.(*E'$*62('F ,$21.' $2E(**I$2E(%. H8> *D$.).8.('> ,2+,'+' 1'$#$&'C.0+*&* 8.C.('> 62O(%- >68>.,0> (. ,*8@+* D$'C'(2 0,.(*E2, (* ' .&* D$*,>O.((*0,@. G$'-.(.('. 6(#,$'D$*06.,(%1 A()*0+*D'C.0+'1 -.,*)'+ 8.C.('> *&$2('C.(*, ', +2+ D$26'8*, (.

D$'6*)', + 0,*9+*-# D*8*O',.8@(*-# $.E#8@,2,#. =2)'+28@(*.

8.C.('. 6*E-*O(* D$' (.D$*,>O.((%1 0,.(*E21, 6 06>E' 0 ).B'/',*0*I0,6.((*&* D820,'C.0+*&* -2,.$'282.

L.*., 6*E('+2., (.*I1*)'-*0,@ D$'-.(.('> $2E8'C(%1 '-D82(,2,*6 )8> D820,'+' ,$21.'. G.$0D.+,'6(%- (2D$268.('.- >68>.,0> '0D*8@E*62('.

0'(,.,'C.0+*&* -2,.$'282 (2 *0(*6. D*8',.,$2B,*$A,'8.(2. ?.8@ A+0D.$'-.(,2: #0,2(*6',@ 6*E-*O(*0,@ D$'-.(.('> )2((*&* 0'(,.,'C.0+*&* -2,.$'282 D$' $.+*(0,$#+,'6(*-D820,'C.0+'1 *D.$2/'>1 (2 ,$21... [+0D.$'-.(, D$*6*)'80> (2 5 +$*8'+21 D*$*)% "0.$%9 6.8'+2(", 6*E$20, 60.1 +$*8'+*6 0*0,268>8 3 -.0>/2, 2 6.0 (.

D$.6%P28 2+&. G*) *IK.9 +*-I'('$*62((*9 2(.0,.E'.9 ,$21.> 6%).8>820@ (2 D$*,>O.('' 5,00-. 3E 0'(,.,'C.0+*&* -2,.$'282 0*E)262820@ "-#B,2", +*,*$2> *+#,%6282 ,$21.F (2 D$*,>O.('' 3,00-.

G$' $.6'E'' ,$21.' C.$.E 1 -.0>/ 6%>68.(*, C,* '-D82(,2, D8*,(* 0$20,2.,0> 0 ,$21..9, (. 6%E%62., 2+,'6(*9 6*0D28',.8@(*9 $.2+/'', (. '(+2D0#8'$#.,0>, (. *,,*$&2.,0>, 2 ,2+O. (. 0-.K2.,0> ' 0*1$2(>., B*$-# "D*8*9 ,$#I+'". !8.)#FK'- A,2D*- 6%D*8(>820@ $.E.+/'> ,$21.' 6 E*(. (28*O.('> "-#B,%". 7 D*08.*D.$2/'*((*- D.$'*).

D$*6*)'820@ 2(,'I2+,.$'28@(2> ' 0'-D,*-2,'C.0+2> ,.$2D'>, (2D$268.((2> (2 +#D'$*62('.

D$'E(2+*6 )%12,.8@(*9 (.)*0,2,*C(*0,'. G* ',*&2- D$*).82((*9 $2I*,% I%8 0).82( 6%6*) * 6*E-*O(*0,' '0D*8@E*62('> )2((*&* 0'(,.,'C.0+*&* -2,.$'282 D$' $.+*(0,$#+,'6(*-D820,'C.0+'1 *D.$2/'>1 (2 ,$21...

EXPEREMENTAL STUDY OF POSSIBILITY OF USING THE SYNTHETIC IMPLANT AT RECONSTRUCTIVE-PLASTIC OPERATIONS ON THE TRACHEA A.S.Vrublevskiy, S.B.Smirnova, A.S.Gurskaya candidate of medical sciences N.P.Shastin Russian State Medical University by N.I.Pirogov, Moscow, Russian Federation Trachea stenoses in adults and in children is one of the most challenging problems in surgery. The reasons leading to the creation of the stenoses of trachea are various. It’s very important not only the cause of the stenoses but an extension too for choosing an appropriate tactics of the surgery treatment The usage endoscopic treatment techniques is limited, and, eventually, don't lead to proof positive result. Radical treatment is possible at not extended stenoses, because of the lack of own plastic material. Thus,

'! !

04-55 '!'(!6$)# 2).!^0)(#2)&2R$!-! ')4J)!5& 3 1#(#+ ' &1#$!)1$P4) /#-#(&")64) ) &1#$!)1)(&4) (.4.J9<N9SA<, -.Z.(I@9EIK7H &BB7BEAHE (.&.)IC7H9 '9HDE-0AEA>WI>NBD9L -?BIC9>BE<AHH9L 0AC79E>7:ABD9L 4AC7G7HBD9L &D9CAF7L, '9HDE-0AEA>WI>N, ,?BB7L

STATE OF THE LYMPHOEPITHELIAL SYMBIOSIS IN CHILDREN WITH ADENOID VEGETATIONS AND ADENIODITIS T.M.Bavgashev, G.Sh.Tufatulin Assistant T.A.Iudina Saint-Petersburg state pediatric medical academy, Saint-Petersburg, Russian Federation Adenoid vegetations and adenoidites lead to condition development «often ill child» that quite often comes to an end with an adenotomy. Hystology the metaplasia of ciliary epithelium in the multilayered flat is thus defined.

Research objective was definition of a morphological condition of an epithelium of a pharyngeal tonsilla at children of different age groups and a parity of degree of a metaplasia with the clinical diagnosis.

The method of light microscopy had been studied preparations of pharyngeal tonsillas of 46 children at the age from 2 till 14th years removed in SPbSPMA from january till november, 2010 Children have been parted on 3 groups: till 6 years (20 children); 7-11 years (20 children);

!"#$%&' ()*+, 2011, ,-.-/%"%&" ' 0."1&2/3%-45 67.5#'5 No1

! is more senior 12 years (7 children). Prevalence of a metaplasia of an epithelium of an almond was estimated on degrees: I - weakly expressed – the flat epithelium settles down less than on half of surface of a section; II – moderated – the flat epithelium covers not less than 2/3 surfaces of a section; III - rare sites of a ciliary epithelium or its absence on a section.

At children of 1st group the metaplasia of I degree met in 40 % of cases, II degrees in 40 % and III degrees in 20 % of observations. In 2nd group I degree met in 50 %, II - in 30 %, III – in 20 % of preparations. In 3rd group the metaplasia of I degree was observed in 83 %, II - didn't meet, III – in 17 % of cases.

By comparison of degree of a metaplasia and the clinical diagnosis it was found out that at a hypertrophy I degree of a metaplasia (82 % of cases) is defined mainly, at an adenoiditis – extensive sites of a flat epithelium (III degree in 79 % of cases).

Conclusions: 1. The greatest degree of a metaplasia of an epithelium is taped in group of children till 6th years.

2. At a hypertrophy of a pharyngeal tonsilla small degree of a metaplasia is defined, at an adenoiditis – extensive sites of a flat epithelium.

3. Definition of degree of a metaplasia of an epithelium of adenoides after a partial adenotomy will allow to define a functional condition of the kept tissue and to prognosticate a pathology of other tonsillas.

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– 16 D2/'.(,2- P#(,'$*62('. (. D$*6*)'8*0@). 70.- ).,>- D$*6*)'80> +*-D8.+0 )'2&(*0,'C.0+'1 ' 8.C.I(%1 -.$*D$'>,'9. N/.(+2 2)2D,2/'' 6 +2,2-(.E. D$*6*)'820@ D* -.O)#(2$*)(%- P+282Lansky ' Karnovsky; */.(+2 +2C.0,62 O'E(' – Function status Index, Ped QL Qulity life aqute. NI. +*&*$,% I%8' $2E).8.(% (2 3 D*)&$#DD%: I – 1*$*P'9 $.E#8@,2,, II – #)*68.,6*$',.8@(%9, III – (.#)*68.,6*$',.8@(%9. G$*&(*0,'C.0+'. B2+,*$% I%8' 6%>68.(% D$' D*-*K' D*08.)*62,.8@(*&* 0,2,'0,'C.0+*&* B2+,*$2 728@)2 ' */.(+*9 '(B*$-2,'6(*0,' +*ABB'/'.(,*6. =.E#8@,2,%: 6 D.$6*9 +*&*$,. 1*$*P'9 $.E#8@,2, *,-.C.( # 42 D2/'.(,*6, #)*68.,6*$',.8@(%9 – # 27, (.#)*68.,6*$',.8@(%-' –19, 6* 6,*$*9 +*&*$,. 6* 60.1 08#C2>1 – (.#)*68.,6*$',.8@(%9, C,* )*0,*6.$(* ('O. D* 0$26(.('F 0 D.$6*9 +*&*$,*9 (t +$',.$'9 !,@F).(,2 0 D*D$26+*9 M*(B.$*(' )8> ,$.1 0$26(.('9).

4.I82&*D$'>,(%-' B2+,*$2-' $'0+2 I%8': '().+0 [62(02 I*8@P. 0,75 (p -.(@P. 0,05, DC = +5, I = 2,5), ,*8K'(2 -*E&*6*&* D82K2 -.(@P. 0,50- ( p -.(@P. 0,05, DC= +2,5, I= 1,25), (.)*(*P.((*0,@ ( p -.(@P. 0,05, DC = +7, I = 3,75), 6(#,$'O.8#)*C+*6%. +$*6*'E8'>('> 3 – 4 0, (DC = + 9, I = 4,5), ,.C.('. 6(#,$'#,$*I(*9 '(B.+/'' (DC = + 20, I = 10,0), */.(+2 D* P+28. Lansky ('O. 40% (DC = + 8, I = 4,0).

M82&*D$'>,(%-' B2+,*$2-' >68>F,0> D$*6.).('. *D.$2/'' 7G" 6 0$*+' )* 4 -.0 (DC = - 15, I= 7,5).

7%6*)%: (.I82&*D$'>,(%-' B2+,*$2-' '01*)2 # ).,.9 0 6(#,$.((.9 &')$*/.B28'.9 >68>F,0> '().+0 [62(02 I*8@P. 0,75, ,*8K'(2 -*E&*6*&* D82K2 -.(@P. 0,50-, (.)*(*P.((*0,@, 6(#,$'O.8#)*C+*6%. +$*6*'E8'>('> 3-4 0,, ,.C.('. 6(#,$'#,$*I(*9 '(B.+/''.

FACTORS DETERMINING OUTCOME IN THE REMOTE POSTOPERATIVE PERIOD AT CHILDREN WITH INTERNAL HYDROCEPHALUS E.B.Jafarova, R.V.Belova Associate Professor, MD I.I.Larkin Omsk State Russian Academy, Omsk, Russian Federation Factors determining outcome in the remote postoperative period at children with internal hydrocephalus Predicting the outcome of shunt operations in children with internal hydrocephalus - an important medical and social problem.

OBJECTIVE: Optimization of diagnosis and prediction of the outcome of internal hydrocephalus in children.

MATERIALS AND METHODS: conducted a prospective analysis of 104 clinical cases of internal hydrocephalus in children. The minimum sample

size for a study is calculated on normogramme Altman and made 104 people. The 88 children were operaten by ventriculoperitoneal shunt ( a cohort I – 16 by - passing patients did not meet). All children performed a complex of diagnosis and medical actions taking into account health, economic standart of the Russian Federation. The estimation of adaptation in a catamnesis was conducted on the international scales of Lansky and Karnovsky; an estimation of quality of life – Function status Index, Ped QL Qulity life acute. Both cohorts were divided into 3 sub-groups: 1 is a good result, 2 - satisfactory, 3 – unsatisfactory. Prognostic factors were educed with a consecutive statistical factor of Wald and by the estimation of informative of the coefficients.

RESULTS: In the first cohort a good result was noted in 42 patients, satisfactory - in 27, unsatisfactory – 19; In the second cohort in all cases unsatisfactory, which was significantly lower in comparison with the first cohort ( t criterion of Student with the amendment of Bonefrony for three comparisons).

Adverse risk factors were: Evans'index is more 0,75 (p less than 0,05, DC = +5, I = 2,5), the thickness of cerebral mantle is less 0,5 sm (p less than 0,05, DC = +2,5, I = 1,25), prematurity borness (p it is less 0,05, DC = +7, I = 3,75), intraventricular hemorrhage% 3 – 4 st (DC = + 9, I = 4,5), a current (course ) of a pre-natal infection (DC = + 20, I = 10,0), an estimation on a scale of Lansky below 40 % (DC = + 8, I = 4,0). Favorable factors are carrying out of operation ventriculoperitonealis shunt in terms to 4 months (DC = - 15, I = 7,5).

CONCLUSIONS: unfavorable factors for an outcome at children with an internal hydrocephalus are the Evans`index, the thickness of cerebral mantle, prematurity borness, intraventricular hemorrhage 3 – 4 st, a current of a pre-natal infection.

04-63 ')432R(&$($!# %!$'#,/&()/$!# 2#*#$)# /,!Y1_$$!+ %!'!2&0!'() 0! 4#(!13 0!$'#() ) /,!Y1_$$!-! /P/)Q& J#1#, 3 1#(#+ ' &,(,!-,)0!5!4 &.-.4?>?U?<9, )./.%>ABEVLS7H =>?@ABB?>, C.F.H. /.4.%>ABEVLS7H ,?BB7MBD7M N?BIC9>BE<AHHOM FAC7G7HBD7M IH7<A>B7EAE 7F. $. ).

07>?N?<9, 4?BD<9, ,?BB7L N0(*6%62>0@ (2 )2((%1 8',.$2,#$% D*08.)('1 8.,, -*O(* 0).82,@ 6%6*), C,* -.,*) 8.C.('> 6$*O)Z((*9 +*0*82D*0,' D* G*(0.,' (21*)', 60Z I*8@P. 0,*$*(('+*6 0$.)' =*00'90+'1 *$,*D.)*6.

N,).8@(*9 D$*I8.-*9 *$,*D.)'' $2((.&* ).,0+*&* 6*E$20,2 >68>.,0> 0*C.,2('. 6$*O)Z((*9 +*0*82D*0,' ' 6$*O)Z((*&* 6%6'12 IZ).$, 6 C20,(*0,' # I*8@(%1 0 2$,$*&$'D*E*-. !'-#8@,2(,(*. 8.C.('. &'D0*6%-' D*6>E+2-' $2(@P. (.

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

N)(*6$.-.((*, '-.820@ 6*E-*O(*0,@ 0*C.,2,@ &'D0*6%. 02D*O+' 0 *)(*-*-.(,(%- 8.C.('.- 6$*O)Z((*&* 6%6'12 IZ).$ 0 D*0,.D.((%#6.8'C.('.- *,6.).('> 6 ,2E*I.)$.((%1 0#0,2621, 0 ,$.I#.-%- #&8*6* B$*(,28@(*9 D8*0+*0,' C,* E(2C',.8@(* 0*+$2,'8* *IK'. 0$*+' 8.C.('> )2((*9 &$#DD% ).,.9.

N0(*6%62>0@ (2 D.$6%1 $.E#8@,2,21, -.,*) D*+2E28 06*.

D$.6*01*)0,6*,>68>.,0> '(*62/'*((%- ' ,$.I#., (2+*D8.('> )28@(.9P.&* *D%,2.

CONCOMITANT CONSERVATIVE TREATMENT OF CONGENITAL CLUBFOOT AND CONGENITAL DISLOCATION OF THE HIP BY PONSETI MANAGEMENT IN CHILDREN WITH ARTROGRIPOZOM A.Morozova MD, PhD I.Krestyashin Russian State Medical University by N.I.Pirogov, Moscow, Russian Federation Based on the literature of recent years, we can conclude that the method of treatment of congenital clubfoot by Ponseti is becoming more and more supported among the Russian orthopedists. Another problem of Orthopedics for early childhood is a combination of congenital clubfoot and congenital dislocation of the hip, particularly for patients with artrogripozom. Simultantnoe cast treatment was not possible, therefore, consistently favored one vice, according to the principles of orthopedics, which significantly prolongs treatment.

Ponseti method is applied to the Children Hospital Y 13. NF Filatov from May 2009., over time in treatment there were 60 children (85 feet), three of

(! !

0"'1&8 «,"$#'28 9&:5:;&8»

! them were patients with arthrogryposis in combination with 2-sided hip dislocation, subluxation of the knee and the 2-sided clubfoot.In all cases, after the imposition of five bandages and ahilotomii, the closest result was evaluated as good. At the same time, it was possible to combine plaster boots with one-stage treatment of congenital dislocation of the hips with a gradual increase in hip abduction, with the required angle in the frontal plane, which significantly reduced the overall duration of treatment of this group of children.

Based on initial results, the method showed its superiority, it is innovative and requires the accumulation of further experience.

04-64 ^%'0#,#4#$(&2R$!# !J!'$!/&$)# /!54!Y$!'() )40!2R5!/&$)6 ')$(#()*#'%!-! )402&$(&$(& 0,) ,#%,3'(,3%()/$!-02&'()*#'%)Q !0#,&")6Q $& 1)&.,&-4#.

C./.'F7>H?<9, &.'.-I>BD9L =>?@ABB?>, C.F.H. &.X.,9UIF?<BD7M ,?BB7MBD7M N?BIC9>BE<AHHOM FAC7G7HBD7M IH7<A>B7EAE 7F. $. ).

07>?N?<9, 4?BD<9, ,?BB7L 4.*I1*)'-*0,@ '0D*8@E*62('> 0'(,.,'C.0+'1 '-D82(,2,*6 D$' D820,'+. )'2B$2&-% 6*E('+2., D$' $2E6','' 2D82E'' +#D*82 )'2B$2&-%, D$' 8*O(%1 )'2B$2&-28@(%1 &$%O21 # (*6*$*O).((%1 ' ).,.9 $2((.&* 6*E$20,2.

42'I*8..

6%0*+*,.1(*8*&'C(%-' 0'(,.,'C.0+'-' -2,.$'282-' 0C',2F,0> )6#0,*$*(('. 0.,+' (2 *0(*6. D*8',.,$2B,*$A,'8.(2 0 (.2)&.E'6(%- D*+$%,'.-. 7 $2I*,.

'008.)*62( (*6%9 *,.C.0,6.((%9 0'(,.,'C.0+'9 -2,.$'28 (2 *0(*6.

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

EXPERIMENTAL RESEARCH OF SYNTHETIC IMPLANTS USAGE IN DIAPHRAGM RECONSTRUCTIVE PLASTIC SURGERY S.V.Smirnova, Gurscaja A.S. professor, PhD A.U.Razumovskiy Russian State Medical University by N.I.Pirogov, Moscow, Russian Federation Synthetic implants for diaphragm defects correction are used in young children and infants with diaphragm aplazia and congenital diaphragmatic hernias. The most high-tech synthetics are bilateral grids (PTFE) with nonadhesive coating. The research deals with a new Russian synthetic material (PTFE) with its thickness of 1,0 mm, 50-75 mcm and two functionally different surfaces. The research is aimed to determine the possibility of these synthetic implants usage for reconstructive plastic surgery on the diaphragm based on morphologic analysis. The experiment with rabbits of 3 months old with 3 kg weight. 10 implantations of the synthetic material were performed. All animals underwent surgery with general combined anaesthesia support, synthetic material patches were implanted to the left part of a diaphragm. Histomorphologic analysis was performed on 30, 60, 180 days after the operation. Samples of animals’ blood for biochemical parameters were analyzed before and after the implantation as well. It was proved that our synthetic material did not cause any reactions of rejection of implants. The material kept its structure without any contractures or deformations of the implantation zone with efficient airtightness of a pleural cavity. It is important to note that the experiment was conducted on growing animals. Our experiment has proved that, our material is recommended for diaphragm reconstructive plastic surgery including pediatric patients.

04-65

)! !

!0,#1#2#$)# !J`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

7%6*)%: $20C., =R3 D* )2((%- <W! D*E6*8>., *IJ.+,'6'E'$*62,@ */.(+# 0,.D.(' &')$*(.B$*E2 # ).,.9 0 '0D*8@E*62('.- D*8#C.((*&* D*+2E2,.8> )8> (2I8F).('> E2 ABB.+,'6(*0,@F D$*6.).((*9 *D.$2/'' ' $.2I'8',2/'*((*&* 8.C.('>.

DEFINING THE UNBIASED MAREKER OF HYDRONEPHROSIS IN CHILDREN W.M.Salami MD, PhD Galina Rumjantseva Tver State Medical Academy, Tver, Russian Federation Objective: To objectify the differentiation degree of hydronephrosis in children according to the calculation renocortical index (RCI) using ultrasound scanning (ICO).

Materials and methods: analysis of 176 skanogram in 88 children aged from three months to 16 years, of which 63 (71.59%) diagnosed with various degrees of hydronephrosis. The control group consisted of 25 (28.4%) children with normal age-size buds and calyx-pelvis system (CPS). Preliminary assessment of the degree of hydronephrosis was performed to visualize urogram: I degree of hydronephrosis detected in 25 (39,8%), II-21 (33,33%) and III-7 (11.11%) patients.

Results of the survey: Based on the study of linear dimensions of the kidneys and CPS according to PSM trials was calculated by the formula used in calculating the urogram (ratio of area CPS / kidney area). The results allowed to determine the objective marker, indirectly indicating the degree of anatomical and functional changes in the kidney. The mean value of RCTs with hydronephrosis degree I was .455 in the second- 0.555, third0.663. In healthy children in the control group, this figure corresponded to 0.386.

Conclusions: The calculation of the RCTs according to the PSM can objectify the assessment of the degree of hydronephrosis in children by using the figures obtained for monitoring the effectiveness of the operation and rehabilitation treatment.

04-69 %!402#%'$!# 2#*#$)# 3%3Z#$$PQ ,&$ 3 1#(#+ X.$./?K?S7H9, 2./.4?>N9KAHD?, 1.$.,?C7EAKA< C.F.H., =>?@ABB?> /.&.JO:D?< ,?BB7MBD7M 3H7<A>B7EAE 1>I]WO $9>?C?<, 4?BD<9, ,?BB7L ?.8@:3E#C.('. *0*I.((*0,.9 #+#P.((%1 $2(, '1 *08*O(.('9 # ).,.9, 6%$2I*,+2 $2/'*(28@(*&* 8.C.('>.

W2)2C':3E#C.('.

C20,*,% $2E6','> &(*9(%1 *08*O(.('9, -'+$*I'*8*&'C.0+2> 12$2+,.$'0,'+2 $2(, */.(+2 ABB.+,'6(*0,' +*-D8.+0(*&* 8.C.('>. ;.,*)%:T(28'E -.)'/'(0+*9 )*+#-.(,2/'' E2 2006-2010&, 82I*$2,*$(%1 )2((%1, 0,2,'0,'C.0+2> *I$2I*,+2 $.E#8@,2,*6. ;2,.$'28%:W2 2006-2010&. 6 ;H:RM (2 0,2/'*(2$(*- 8.C.('' D* D*6*)# #+#P.((%1 $2( (21*)'8'0@ 811 ).,.9 ($'0. 1).

70.- D2/'.(,2- D$*6*)'8*0@ +*-D8.+0(*. 8.C.('.: !D./'B'C.0+2> D$*B'82+,'+2 I.P.(0,62 ' 0,*8I(>+2.=2/'*(28@(%9 *IJZ- 1'$#$&'C.0+*9 *I$2I*,+' $2(, 0 #C.,*- 12$2+,.$2 D*6$.O).('9, 8*+28'E2/'', 6%$2O.((*0,' 6*0D28',.8@(%1 'E-.(.('9.!'0,.-(2> +*-D8.+0(2> 2(,'I2+,.$'28@(2> ,.$2D'> D$.D2$2,2-' P'$*+*&* 0D.+,$2 ).90,6'> '01*)> 'E $.E#8@,2,*6 D*0.62 'E $2(%.

!"#$%&' ()*+, 2011, ,-.-/%"%&" ' 0."1&2/3%-45 67.5#'5 No1

!

H.0.(0'I'8'E'$#FK2> ,.$2D'>, 0('O2FK2> $'0+ ' 0,.D.(@ 6%$2O.((*0,' 6*E-*O(%1 288.$&'C.0+'1 $.2+/'9 (2 62+/'(2/'F ' 2(,'I2+,.$'28@(#F ,.$2D'F. =.E#8@,2,%:42'I*8.. C20,%-' O.$,62-' #+#0*6 O'6*,(%1 >68>F,0> ).,' 6 6*E$20,. *, 7)* 15 8.,. M*8@P'(0,6* D*6$.O).('9 D$'1*)',0> (2 +*(.C(*0,', *0*I.((*, (2 6.$1('.($'0. 2). N+*8* 56% 0*0,26'8' #+#P.((%. $2(% 0 &(*9(*-6*0D28',.8@(%-' 'E-.(.('>-', I.E 6%$2O.((%1 'E-.(.('9 - *+*8* 44% N0(*6(%. 6*EI#)',.8' '(B.+/'' D*08. #+#0*6 O'6*,(%1: Passturella spp. 6 70% S. Aureus 6 60% 2(2A$*I% 6 70% ' )$.

T(,'I2+,.$'28@(2> ,.$2D'> D$*6*)'820@ 0 #C.,*-'+$*I'*8*&'C.0+*&* 2(28'E2, 2(,'I2+,.$'28@(%-' D$.D2$2,2-' D.$.+$%62FK'-' 6.0@ 0D.+,$ 6%P.#+2E2((*9 -'+$*B8*$%.

7%6*)%:N,-.C2.,0> ,.().(/'> + $*0,# +*8'C.0,62 #+#P.((%1 $2(.

N0*I*&* 6('-2('> E208#O'62F, #+#P.((%. $2(% 6.$1('1 +*(.C(*0,.9 - C2K. $2E6'62F,0> &(*9(%. *08*O(.('>. =2(% (2 8'/. ,$.I#F, *0*I*9 1'$#$&'C.0+*9 ,2+,'+', )8> '0+8FC.('> A0,.,'C.0+'1 ' B#(+/'*(28@(%1 ).B.+,*6.

R*-D8.+0(*. 8.C.('. #+#P.((%1 $2( 0('O2., $'0+ $2E6','> &(*9(%1 *08*O(.('9, #8#CP2., D$*&(*E I*8@(%1, D$'6*)', + #-.(@P.('F )(.9 D$*6.).((%1 6 0,2/'*(2$..

COMPLEX TREATMENT OF THE BITTEN WOUNDS IN CHILDREN Yulia Voloshina, Ludmila Morgalenko, Dmitrii Roditelev, Yulia MD, PhD Vladimir Bychkov Peoples’ Friendship University of Russia Studying the clinical features of bitten wounds, complications of bitten wounds in children, developing rational tactics of treatment.

Task:Studying bitten wounds, frequency development of purulent complications, the microbiological characteristic of wounds, Valuating the efficiency of complex treatment.

Methods:The analysis of the medical documentation for 2006-2010&., the laboratory data, statistical processing of received results.

Materials:During the year 2006-2010. In state hospitals, hospitalization concerning bitten wounds were- 811 children (fig. 1).

All patients carried out complex treatments:Specific preventtation of rabies and tetanus.

Surgical processing of wounds, taking into account character of damages, localization, expressiveness of inflammatory changes.System complex therapy- i.e the usuage of wide spectrun antibiotics The desensibilitative therapy which reduces the risk of possible allergic reactions to immunization, vaccination, antibacterial therapy.Results: The most frequent victims of bites form animals are children at the age from 7)* 15 years. Majority of the cases are localized on the arm and forearm . (Fig. 2). About 56 % of the bitten wounds had pyoinflammatory changes, without expressed changes - about 44 % The causative agents of an infection after animals bites: Passturella spp. 70 %, S. Aureus 60 %, 2(2A$*I%,70 %.

Complex antibacterial therapy was carried out taking into account the microbiological analysis, the antibacterial preparations blocking all spectrum of the above-stated causative agents.

Conclusions:There is a growing tendency of quantity of bitten wounds.

Bitten wounds located at the arm and forearm must be severly treated because purulent complications is more often develop. Facial wounds requires special surgical tactics, for an exception of esthetic and functional defects.

The complex approach to treating bitten wounds reduces risk of purulent complications, improves the future conditions of patients, leads to reduction of days spent in a hospital.

04-72 (#,&(!4P 3 1#(#+ ,&52)*$!+ 2!%&2)5&")): '(,3%(3,& 0&(!2!-)). ,#532R(&(P Q),3,-)*#'%!-! 2#*#$)6.

1. '.(9>9B?<9 D.F.H. 9BB. #. '.07FAH?<9 '9>9E?<BD7M -?BIC9>BE<AHHOM 4AC7G7HBD7M 3H7<A>B7EAE 7F. /.). ,9UIF?<BD?N?, '9>9E?<, ,?BB7L ?.8@: T(28'E 0,$#+,#$% D2,*8*&'' ' $.E#8@,2,*6 *D.$2,'6(*&* 8.C.('> ).,.9 0 ,.$2,*-2-' $2E8'C(*9 8*+28'E2/''. ;2,.$'28% ' -.,*)%: G$*6.).( $.,$*0D.+,'6(%9 2(28'E 8.C.('> 39 ).,.9 0 ,.$2,*-2-' $2E8'C(*9 8*+28'E2/'', (21*)'6P'10> 6 H5R !:;< 0 1995 - 2010&&.

H'2&(*0,'+2 E2I*8.62('>: 0,2()2$,(*. +8'('+*-82I*$2,*$(*.

'008.)*62('., ;=L, RL, <W3, $.(,&.(*&$2B'> +$.0,/*6* – +*DC'+*6*9 *I820,', *D$.).8.('. #$*6(> 28@B2 – B.,*D$*,.'(2. :'0,*8*&'C.0+*. '008.)*62('. *D.$2/'*((*&* -2,.$'282. =.E#8@,2,%: ! 1995 – 2010 &&. 6 H5R (21*)'8*0@ (2 8.C.('' 39 ).,.9 0 #+2E2((*9 D2,*8*&'.9. 3E ('1 +$.0,/*6* – +*DC'+*62> ,.$2,*-2 (RRL) 52%, n=20. 7*E$20, ).,.9 *, 2 0#,*+ )* 5 8.,. H* *D.$2/'*((*.

*08*O(.('. – # 1 $.IZ(+2 - $2E$%6 *I*8*C.+ RRL. ND.$2,'6(*.

8.C.('. – #)28.('. *D#1*8' 0 $.E.+/'.9 +*DC'+2, D$' (.*I1*)'-*0,' 6%D*8(>8' 0B'(+,.$*8.62,*$*D820,'+#, &8F,.*D820,'+#, 6 1 08#C2. *D.$2,'6(*. 6-.P2,.8@0,6* )*D*8(.(* $.E.+/'.9 -*C.6*&* D#E%$> ' 62&'(%. =./')'6 E2I*8.62('> *,-.C.( 6 3 08#C2>1.

L.$2,*-2 >'C('+2 - 26%, n=10. 7*E$20, ).,.9 *, 6 )* 15 8.,.

ND.$2,'6(*.

6-.P2,.8@0,6* 6%D*8(.(* *,+$%,%'8' 82D2$*0+*D'C.0+'- )*0,#D*-: #)28.('. *D#1*8' 0 0*1$2(.('.*0,2,*C(*9 ,+2(' >'C('+2 n=5, *62$'*A+,*-'> n=3, ,#I*62$'*A+,*-'> n=2. =./')'6*6 (.,.

L.$2,*-% >'C.+ - 8%, n=3. 70.- D2/'.(,2- 6%D*8(.(2 *$1'A+,*-'>. =./')'6*6 (.,. L.$2,*-% )$#&'1 8*+28'E2/'9: ,.$2,*-2 -28*&* 028@('+2 – 2.6 %, n=1 – #)28.('. *D#1*8' 6-.0,. 0 I*8@P'- ' -28%028@('+*-; D$.02+$28@(2> ,.$2,*-2 6 0*0,26. 0'()$*-2 Currarino 2.6%, n=1 – #)28.('. *D#1*8', 0 $.E.+/'.9 +$.0,/2; ,.$2,*-2 ,'-#02 – 2.6%, n=1 - #)28.('. *D#1*8'; ,.$2,*-2 P.' 2.6%, n=1 – #)28.('. ,.$2,*-%, ,.$2,*-2 0$.)*0,.('>, 6 0*C.,2('' 0 (.'-#((*9 6*)>(+*9 D8*)2 2.6%, n=1 – #)28.('. *D#1*8'.

7%6*)%: L.*, E2 D*08.)('. 15 8., 6 H5R *D.$'$*62(% 39 ).,.9 0 ,.$2,*-2-' $2E8'C(*9 8*+28'E2/'': RRL – 52%; ,.$2,*-2 &*(2) – 34%; $.)+'. B*$-% ,.$2,*- – 14%. ;*$B*8*&'C.0+2> 6.$'B'+2/'> )'2&(*E2 – 100%. =./')'6 *D#1*8' *,-.C.( # 3 I*8@(%1 0 RRL. Q.,28@(%1 '01*)*6 *,-.C.(* (. I%8*.

CHILDREN TERATOMAS OF DIFFERENT LOCALIZATION: PATHOLOGY STRUCTURE. RESULTS OF SURGICAL TREATMENT D.S.Tarasova candidate of medical sciences, the assistant E.S.Pimenova Saratov State Medical University by V.I. Razumovsky, Saratov, Russian Federation Objective: Analysis of pathology structure and the results of surgical treatment of children with teratomas of different localization.

Methods: A retrospective analysis of treatment was made among 39 children with teratomas of different localization who undergo medical treatment in The Children Surgical Clinic of SSMU (CSC) in 1995 - 2010.

Diagnostics of diseases: ordinary clinic - laboratorial research, MRT, CT, ultrasonography, X-ray study of cacro-coccygeal space, the determination of alpha-fetoprotein level, histologic study of surgical substance.

Results: In 1995-2010 there were 39 children with stated pathology in the CSC. Among them 52%, n=20 with cacro-coccygeal teratoma (CCT). Presurgical event – 1 child had a breaking of CCT membrane. Surgical treatment – surgical excision with coccyx resection, sphincter and levator ani reconstruction and gluteus reconstruction if it was needed, urinary bladder and vagina resection was done besides surgery in one case. Tumor regression was marked 3 times.

Ovarian teratoma - 26%, n=10. Surgical treatment was made openly or by means of laparoscopy: surgical excision with preservation of residual tissue n=5, ovariectomy n=3, ovariectomy and salpingectomy n=2. No regression.

Teratoma of the testicle - 8%, n=3. Orchiectomy was done to all the patients. No regression.

Teratomas of other localization: teratoma of the lesser omentum 2.6 %, n=1 – surgical excision with excision of lesser and greater omentum; presacral teratoma as a part of Currarino syndrome 2.6%, n=1 - surgical excision with sacrum resection; thymic teratoma – 2.6%, n=1 - surgical excision; cervical teratoma 2.6%, n=1 – teratoma removal; mediastinal teratoma with nonimmune hydrops, 2.6%, n=1 – surgical excision.

Conclusion: In summary, during the last 15 years 39 children with teratomas of different localization underwent surgery in the CSC: CCT– 52%; gonadal teratoma – 34%; rare forms of teratomas – 14%. Histologic diagnosis verification – 100%. Tumor regression was marked among 3 patients with CCT. The lethal upshot is noted was not.

04-73 !0,#1#2#$)# !0()4&2R$!-! 4#(!1& $&2!Y#$)6 4)%,!'!'31)'(!-! Z/& 3 ,&'(3[#-! !,-&$)54&. ).'.*7>D?<, ,.&.Q9NI>?< D.F.H. /././?KD?< ,?BB7MBD7M N?BIC9>BE<AHHOM FAC7G7HBD7M IH7<A>B7EAE 7F. $. ).

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

*! !

0"'1&8 «,"$#'28 9&:5:;&8»

! #E8*6*&* P62 (<"), (.D$.$%6(*&* P62 (4"), +*-I'(2/'' (.D$.$%6(*&* ' #E8*6*&* P6*6 (R"); */.(',@ D$*1*)'-*0,@ -'+$*2(20,*-*E*6 D*0$.)0,6*- <W3 0 /6.,(%- )*D8.$*60+'+2$,'$*62('.-; 'E#C',@ D$*/.00 $.&.(.$2/'' E*(% 2(20,*-*E2 0 D*-*K@F &'0,*8*&'C.0+*&* '008.)*62('>. ;2,.$'28% ' -.,*)%: +$%0%-02-/% 6 +*8'C.0,6. 24 P,. 8'('' Wistar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

E*(% 2(20,*-*E2; 0 D*-*K@F &'0,*8*&'C.0+*&* '008.)*62('> I%8* *I(2$#O.(*, C,* $.&.(.$2/'> A()*,.8'> 0*0#)2 ')., E2 0C., *I$2E*62('> D$'0,.(*C(*&* ,$*-I2, ,2+O. *,-.C.(2 &'D.$D82E'> &82)+*-%P.C(%1 +8.,*+ 6 E*(.

2(20,*-*E2, C,* 6 (.+*,*$%1 08#C2>1 D$'6*)'8* + *++8FE'' 2(20,*-*E2. 7%6*)%: # $20,#K.&* *$&2('E-2 /.8.0**I$2E(* '0D*8@E*62,@ D$.$%6(%. -.,*)'+' 0*0#)'0,*&* P62.

GROWING ORGANISM MICROVASCULAR SUTURE PLACEMENT: OPTIMUM METHOD STUDY. I.S.Chirkov, R.A.Hagurov Contender Medical Sciences V.V.Volkov Russian State Medical University by N.I.Pirogov, Moscow, Russian Federation There are plenty of different microvascular suture placement methods nowadays, but there is no unambiguous opinion regarding microvascular suture placement for children. (V.F. Baitinger Vessel-suture, Tomsk, 2005; A.E. Belousov, Plastic, reconstructive and aesthetic surgery. Spb.: Gipokrat, 1998). The purpose of this research is to define an optimum method of microvascular suture placement on artery and vein of different diameter for growing organism. The task was to estimate advantages and disadvantages of microvascular anastomosis placement by interrupted suture, continuous suture, combination of interrupted and continuous suture; estimate microanastomosis permeability using color Doppler mapping ultrasound; estimate anastomosis zone regeneration using histological study. Materials and methods: male rats 24 pieces, “Wistar”, 10 weeks old, weight 250 – 300 gr. were divided into 4 groups (8 pieces in each: 4 pieces arterial anastomosis, 4 pieces venous anastomosis): interrupted suture group, continuous suture group and combination of interrupted (2/3 circumference) and continuous (1/3 circumference) suture group. Anastomosises were placed on femoral artery and vein. Quality of anastomosises placed was evaluated intraoperatively (20 minutes past anastomosis placement) using color Doppler mapping ultrasound; changes in anastomosis zone were evaluated using histological study. Results: interrupted suture is easier to place but it is less leakproof; continuous suture may cause anastomosis zone crimping. It’s been found out using histological study that vessel endothelium regeneration goes at the expense of mural thrombus buildup. Also nonstriated mussel cells hyperplasia is registered in anastomosis zone which caused in some cases anastomosis occlusion. Resume: It is rationale to use interrupted suture methods for growing organism.

04-74 0!'2#!0#,&")!$$!# !J#5J!2)/&$)# //#1#$)#4 4#'($!-! &$#'(#()%& *#,#5 ,&$#/!+ !,!')(#2R$P+ %&(#(#, 0!'(!6$$!-! 1#+'(/)6 0.#.J7>TD?< 1?GAHE X./.Y7>D?<9 ,?BB7MBD7M N?BIC9>BE<AHHOM FAC7G7HBD7M IH7<A>B7EAE 7F. $. ).

07>?N?<9, 4?BD<9, ,?BB7L 3008.)*62('. ABB.+,'6(*0,' *I.EI*8'62('> 66.).('.- -.0,(*&* 2(.0,.,'+2 C.$.E $2(.6*9 *$*0',.8@(%9 +2,.,.$ D$*6.).(* # 33 )*(*P.((%1 (*6*$*O).((%1 (21*)'6P'10> 6 U:< 4?T:'G =*0-.),.1(*8*&'9 '-. R#82+*62. H.,' I%8' $2E).8.(% (2 )6. &$#DD%: 6 &$#DD. Q (n=15) D*08.*D.$2/'*((*. *I.EI*8'62('. D$*6*)'8*0@ 66.).('.- -.0,(*&* 2(.0,.,'+2 (8')*+2'() C.$.E $2(.6*9 *$*0',.8@(%9 +2,.,.$ D*0,*>((*&* ).90,6'> ' 6 &$#DD. G (n=18) D$'-.(>8' D*0,*>((#F 6(#,$'6.((#F '(B#E'F D$*-.)*82 (0,02-0,1 -&/+&/C20) 0 D*-*K@F Perfusor compact S. :$#DD% I%8' 0$26('-% -.O)# 0*I*9 D* 6*E$20,# (2 -*-.(, *D.$2/'', 1'$#$&'C.0+*9 D2,*8*&'', *IK.-# 0*0,*>('F ' 2(,$*D*-.,$'C.0+'- D*+2E2,.8>-.

H8',.8@(*0,@ 66.).('> -.0,(*&* 2(.0,.,'+2 C.$.E $2(.6*9 *$*0',.8@(%9 +2,.,.$ 0*0,26'82 66±21 C20*6 (-'('-28@(* 20 C20*6, -2+0'-28@(* 116 C20*6). 4.*I1*)'-*0,@ 6 )*D*8(',.8@(*- 66.).('' *I.EI*8'62FK'1 D$.D2$2,*6 6*E('+82 6 D.$6%. 0#,+' D*08. *D.$2/''

"+! !

# 6 (40%) (*6*$*O).((%1, (2 6,*$%. - # 4 (27%) ).,.9 ' (2 ,$.,@' – # 1 (7%) $.I.(+2. < 7 (47%) (*6*$*O).((%1 6* 6$.-> '(B#E'' -.0,(*&* 2(.0,.,'+2 6 D*08.*D.$2/'*((#F $2(# 66.).('> )*D*8(',.8@(*&* *I.EI*8'62('> (. D*,$.I*628*0@. G* #$*6(F 0*E)262.-*&* *I.EI*8'62('> 6 D*08.*D.$2/'*((*- D.$'*). (*6*$*O).((%.

0$26('628'0@ D* P+28. CRIES, +*O(*9 D$*6*)'-*0,', )'(2-'+. +2$)'*'(,.$628*&$2--% (R3:) ' &*$-*(28@(*&* 0,2,#02. T ,2+O. D* )8',.8@(*0,' (21*O).('> (*6*$*O).((%1 (2 37Q ' (28'C'F D*08.*D.$2/'*((%1 *08*O(.('9. 3E#C.('. -.,*)2 66.).('> -.0,(*&* 2(.0,.,'+2 C.$.E $2(.6*9 *$*0',.8@(%9 +2,.,.$ D*0,*>((*&* ).90,6'> )8> D*08.*D.$2/'*((*&* *I.EI*8'62('> D*+2E28* .&* ABB.+,'6(*0,@ ' I.E*D20(*0,@ # (*6*$*O).((%1.

POSTOPERATIVE ANAESTHESIA BY INFUSION OF LOCAL ANAESTHETIC THROUGH WOUND IRRIGATING CATHETER OF CONSTANT ACTION P.E.Birukov Docent Y.V.Zhirkova Russian State Medical University by N.I.Pirogov, Moscow, Russian Federation Research of efficiency of anaesthesia by infusion of local anaesthetic through wound irrigating catheter was realized at 33 carried newborns in FGU Kulakov’s SCOGaP Rosmedtehnology. Children were divided on two groups: in L group (n=15) postoperative anaesthesia was made by infusion of local anaesthetic (Lidocaine) through wound irrigating catheter of constant action and in group P (n=18) constant intravenous infusion of Promedol (0,02-0,1 mg/kg/hour) by Perfusor compact S was used. Groups were comparable among themselves on age at the moment of operation, on surgical pathology, on the general condition and on anthopometrical indicators. Catheter was established in the end of operation when operational wound was sutured. Duration of infusion of local anaesthetic through wound irrigating catheter was 66±21 hours (minimum 20 hours, 116 hours are maximum). Necessity for additional infusion of anaesthetizing drugs appeared on the first day after operation at 6 (40 %) newborns, on the second - at 4 (27 %) children and on the third – at 1 (7 %) child. 7 (47 %) newborns during infusion of local anaesthetic in a postoperative wound weren't required in extra anaesthetics. On level of created anaesthesia in the postoperative period newborns were compared on CRIES scale, skin conductivity, dynamics on cardiogramm (CIG) and the hormonal status. And also on duration of being at artificial ventilation and on existence of postoperative complications. Studying method of infusion of local anaesthetic through wound irrigating catheter of constant action for postoperative anesthesia had shown its efficiency and safety at newborns.

04-76 1)..#,#$"),!/&$$P+ 0!1Q!1 % 2#*#$)X -#4&$-)!4 3 1#(#+ ).).'A>D?<, <>9: F7D>?87>I>N !.&.0?CS7<9K?<9 0>?@ABB?>, CFH -A>9BVD7H &. /. ,?BB7MBD7M N?BIC9>BE<AHHOM FAC7G7HBD7M IH7<A>B7EAE 7F. $. ).

07>?N?<9, 4?BD<9, ,?BB7L T+,#28@(*0,@: 1. 42 0.&*)(>P('9 ).(@ *,0#,0,6#F, *I*0(*62((%. D*+2E2('> )8> *D.$2,'6(*&* 8.C.('> I*8@(%1 0 &.-2(&'*-2-'. ?.8@: =2E$2I*,2,@ D*)1*) + 8.C.('F &.-2(&'*- $2E8'C(*&* 6')2 ' 8*+28'E2/'9, *0(*6%62>0@ (2 )2((%1 0*6$.-.((%1 -.,*)*6 '008.)*62('> (<W3 0 )*D8.$*60+'- 0+2('$*62('.-, RL). ! 2005 D* 2010 &&. 6 H:RM Y13 (2I8F)28*0@ 0,2/'*(2$(* 403 $.I.(+2 (2005&. – 52C.8; 2006 – 61C.8; 2007 – 68C.8; 2008 – 75C.8; 2009 – 51C.8; 2010 – 96C.8). 3E 60.1 0,2/'*(2$(%1 D2/'.(,*6 # 73,4% - +26.$(*E(%. &.-2(&'*-%, 26,6% - +*-I'('$*62((%.; 6 ,*- C'08. # 13,6% –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

H2((%. -.,*)% '008.)*62('> D*E6*8>F, */.(',@ 62O(%. D2$2-.,$% 2(&'*-%, '01*)> 'E +*,*$%1 -*O(* 6%I$2,@ (2'I*8.. $2/'*(28@(%9 -.,*) 8.C.('>, 2 ,2+O. D$*6*)',@ +*(,$*8@ ABB.+,'6(*0,' ,.$2D''.

L2+*9 D*)1*) + 8.C.('F D$'6.8 + I*8.. *D,'-28@(%- $.E#8@,2,2- – 0*+$2K.('F )8',.8@(*0,' 8.C.('> D2/'.(,*6 (0 4 – 5 8., )* 1 &*)2). ! D*>68.('.- ,2+*&* D*)1*)2 6 I*8.. $2((.- 6*E$20,. 0,28' D$*6*)',@ $2)'+28@(*. #)28.('. 2(&'*-%0 - 1& – 45,9%, 1 - 2 & – 37,4% ' > 2 8., – 16,7%. H* 2008 &*)2 D*)1*) + ,.$2D'' &.-2(&'*-, *0(*62((%9 ,*8@+* (2 +8'('C.0+*9 +2$,'(. ' 8'C(*- *D%,. 6$2C2, D$'6*)'8 + )8',.8@(*-# D*'0+# ABB.+,'6(*&* -.,*)2 8.C.('>, ' 6 06>E' 0 A,'-,+

!"#$%&' ()*+, 2011, ,-.-/%"%&" ' 0."1&2/3%-45 67.5#'5 No1

!

I*8.. *,0$*C.((%- $2)'+28@(%- *D.$2/'>-:0 - 1 & – 44,2%, 1 - 2& – 22,1%,> 2 8., – 33,7% ' 6D8*,@ 15 8.,, C,* (.I82&*D$'>,(* *,$2O28*0@ (2 *,)28.((%1 $.E#8@,2,21.

L2+'- *I$2E*-, <W3 0 )*D8.$*60+'- 0+2('$*62('.- ' RL 0 +*(,$20,'$*62('.- ' ,$.1-.$(*9 $.+*(0,$#+/'.9, '&$2F, 62O(#F$*8@ 6 +*-D8.+0(*9 */.(+. 2(&'*-% ' 6%I*$. $2/'*(28@(*&* -.,*)2 8.C.('>.

DIFFERENTIATED METHOD OF HEMANGIOMAS TREATMENT IN CHILDREN I.I.Serkov, O.A. Podshivalova Professor Geraskin A.V. Russian State Medical University by N.I.Pirogov, Moscow, Russian Federation Topicality: 1. Today there are no reasonable statements to the operational treatment of hemangiomas.

Goal: Develop the approach to the treatment of hemangiomas of different type and localization based on information from modern methods of investigation (ultrasound with Doppler scan, CT).

From 2005 to 2010 in Children Hospital Y13 were observed stationary 403 children (2005y. – 52per; 2006 – 61per; 2007 – 68per; 2008 – 75per; 2009 – 51per; 2010 – 96per). 73,4% of all the inpatiens had cavernous hemangimas; 26,6% combined hemangiomas. 13,6% of all the inpations had hemangiomas with complicated anatomical localization. Methods of treatment of hemangiomas depend on their type and localization.

Since 2008y. in Children Hospital Y13 ultrasound with Doppler scan is used as a screening method for studying all patients with hemangiomas. If ultrasonography is not informative, CT with contrast and three-dimensional reconstruction was used to determine accurate tumor volume and it’s angioarchitectonics. These methods allow us to estimate important parameters of angiomas on the basic of which we can choose the most rational method of treatment and conduct monitoring of the effectiveness of therapy. This approach to treatment has led to better results – shortening the treatment of patients (from 4 – 5 years to 1 year). With the advent of such an approach to treatment at an early age began to carry out a radical removal of angiomas: 0-1y. – 45,9%; 1-2y – 37,4; >2y. – 16,7%.

Until 2008, the approach to the treatment of hemangioma was based only on clinical and personal experiences of doctors. This led to a prolonged search for effective methods of treatment and a more delayed radical surgery: 0-1y. – 44,2%; 1-2y – 22,1%; >2y – 33,7% and up to 15 years, which adversely affected the long-term results.

Thus, the Doppler ultrasound scan and computed tomography with contrast and three-dimensional reconstruction play an important role in the comprehensive assessment of angiomas and selecting a rational method of treatment.

04-77 )$(,!02&'()%& ' ,&51#2#$)#4 0!2!/PQ ) 4!*#/PQ 03(#+. &.&./9K7A<9 =>?@ABB?> &.%..9MUIK7H 4?BD?<BD7M N?BIC9>BE<AHHOM FAC7D?-BE?F9E?K?N7:ABD7M IH7<A>B7EAE, 4?BD<9, ,?BB7L N)(*9 'E (.$.P.((%1 D$*I8.- 6 ).,0+*9 D820,'C.0+*9 &.(',28@(*9 1'$#$&'' *0,2.,0> 6*D$*0 '(,$*',*D820,'+' # ).6*C.+ 0 6$*O).((*9 )'0B#(+/'.9 +*$% (2)D*C.C('+*6 (7HR4). 7 +8'('C.0+*9 +2$,'(.

7HR4 D$.*I82)2., 6'$'8'E2/'> &.(',28'9. G$' #0,2(*68.('' # D2/'.(,2 '0,'((*9 D*8*6*9 D$'(2)8.O(*0,', 0D./'28'0,% ' $*)',.8' D2/'.(,2 0,28+'62F,0> 0 D$*I8.-*9 D0'1*8*&'C.0+*9 2)2D,2/'' $.I.(+2. 5'$#$&'C.0+*. 8.C.('. E2+8FC2.,0> 6 $.E.+/'' &'D.$,$*B'$*62((*&* +8',*$2 ' 0*E)2('> 61*)2 6* 682&28'K.. ?.8@F (2P.9 $2I*,% >68>.,0> #8#CP.('. +*0-.,'C.0+'1 ' B#(+/'*(28@(%1 $.E#8@,2,*6 1'$#$&'C.0+*&* 8.C.('>.

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

INTROITOPLASTIC WITH THE DIVISION OF REPRODUCTIVE AND URINARY TRACT A.A.Valieva

professor A.K.Faizylin Moscow state university of general medicine dentistry, Moscow, russian Federation One of the unsolved problems in pediatric plastic surgery remains the question of genital introitoplastiki in girls with congenital adrenal hyperplasia . The clinical picture of genital virilization dominant congenital adrenal hyperplasia. In establishing the patient's true gender, professionals and parents of patients faced with the psychological adaptation of the child.

Surgical treatment consists of resection of the hypertrophied clitoris and a vaginal opening.

The aim of our work is to improve the cosmetic and functional results of surgical treatment.

In our clinic, in contrast to many other surgical institutions in the country using microsurgical method of preserving the clitoris head on the neurovascular bundle. This method allows in the future, upon reaching puberty, to maintain the sensitivity of the clitoris and the head respectively orgasm during sexual intercourse. The second step is an M-shaped introitoplastika with the division of the urinary and genital tract, allowing the urethra to withdraw artifitcial vulva and create an artificial vagina, eliminating the feminine form of hypospadias. Results and conclusions: This technique avoids chronic cystitis, which develop after sexual intercourse. Preservation of neurovascular bundle with the division head of the clitoris and genital urinary tract is the operation of choice in patients with congenital adrenal hyperplasia, which allows patients to adapt successfully in society.

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

G*) *0,$*9 ).0,$#+,'6(*9 D(.6-*('.9 08.)#., D*('-2,@ *08*O(.('.

D(.6-*('' $2E8'C(*9 A,'*8*&'' (0,2B'8*+*++*6*9, 0'(.&(*9(*9, D$*,.9(*9, 0,$.D,*+*++*6*9 ' ,. ).), D$*,.+2FK.. 0 *I$2E*62('.6(#,$'8.&*C(%1 D*8*0,.9 ' 0+8*((*. + D$'0*.)'(.('F D8.6$28@(%1 *08*O(.('9. 70.&* E2 )2((%9 D.$'*) (21*)'8*0@ (2 8.C.('' 235 ).,.9 0 )2((*9 D2,*8*&'.9. < 165 $.I.(+2 $2E6','F D.$6'C(*9 ).0,$#+/'' 8.&+'1 D$.)P.0,6*628* N=73 (*0,$2> $.0D'$2,*$(2> 6'$#0(2> '(B.+/'>). 7 +2C.0,6. -'+$*I(%1 6*EI#)',.8.9 ).0,$#+,'6(%1 D(.6-*('9 6.$'B'/'$*62(% $2E8'C(%.

-'+$**$&2('E-%, D$',*-, C,* # 49 I*8@(%1 $*0,2 B8*$% (.

(2I8F)28*0@. 1. 4.*I1*)'-* *,-.,',@ D*8'A,'*8*&'C(*0,@ $2E8'C(%1 B*$- ).0,$#+,'6(%1 D(.6-*('9.2. G$.*I82)2FK'+8'('+*-$.(,&.(*8*&'C.0+'-' B*$-2-' >68>8'0@ 2I0/.00 8.&+*&* ' D'*,*$2+0.3. 7%>68.(2 D$>-2> 6E2'-*06>E@ -.O)# 0$*+*- *, (2C282 E2I*8.62('>, 6$.-.(.- D*0,#D8.('> I*8@(*&* 6 0D./'28'E'$*62((%9 0,2/'*(2$ ' D$.)P.0,6#FK'9 2(,'-'+$*I(*9 ,.$2D'.9.4.

[BB.+,'6(%- 6*E).90,6'.- (2 *C2& D*$2O.('> D$' D'*,*$2+0. >68>.,0> $2(.. )$.('$*62('. D8.6$28@(*9 D*8*0,'.5. !('O.('.

1$*('E2/'' D$*/.00*6 6 8.&+*- ' D8.6$. 06>E2(* 0 D$*B'82+,'+*9 ' 8.C.('.- D*0,D(.6-*,'C.0+'1 +'0,, B'I$'(*,*$2+02 ' 8.&*C(*D8.6$28@(%1 0D2.+.

ACUTE SUPPURATIVE DESTRUCTIVE PNEUMONIA CHILDREN. RESULTS OF TREATMENT AND OUTCOMES E.V.Guzikov professor M.A.Barskaya Samarsky State Medical University, Samara, Russian Federation

IN

Acute purulent destructive pneumonia (OGDP) up to 10% of the total number of pneumonia in children, although in recent years in leading pediatric surgical clinics mortality among these patients is less than 2%, the share of destructive pneumonia in the overall case fatality rate of other children with purulent -septic pathology is 50%.

Under acute destructive pneumonia should be understood complication of pneumonia of various etiologies (staphylococcus, pseudomonas, proteus, streptococcus, etc.), which proceeds with the formation of intrapulmonary cavities and inclined to join the pleural complications. Total for this period was on the treatment of 235 children with this pathology. In 165 child development of primary pulmonary destruction preceded the ARI (acute respiratory viral infection). As the microbial agents of destructive pneumonia verified by various microorganisms, despite the fact that in 49 patients the growth of flora were observed. 1. It should be noted poly

""! !

0"'1&8 «,"$#'28 9&:5:;&8»

! etiology of various forms of destructive pneumonia. 2. The predominant clinical and radiological forms were lung abscess and piotoraks.3. The direct relationship between the time of onset, time of admission to a specialized hospital and prior antimicrobial therapy. 4. Effective influence on the lesion with pyothorax is earlier drainage of pleural polosti.5.

Reducing chronic processes in the lung and pleura associated with the prevention and treatment metapneumonic cysts fibrinotoraksa and pulmonary-pleural adhesions.

04-80 !0()4)()5&")6 1)&-$!'()%) ) 2#*#$)6 4&'()(!/ 3 1#(#+.

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

D*)1*)% + )'2&(*0,'+. ' 8.C.('F )2((*9 B*$-% 1'$#$&'C.0+*9 '(B.+/''. R*-D8.+0(%. *I08.)*62('> I*8@(%1 6+8FC28': <W3 -*8*C(%1 O.8.E ' *$&2(*6 -28*&* ,2E2, I2+,.$'*8*&'C.0+*.

'008.)*62('. 0*).$O'-*&* 'E *C2&2 '(B.+/'', 3UT (2 6(#,$'+8.,*C(*9 '(B.+/'', *IK'9 2(28'E +$*6' ' -*C'. 7%>68.(* ,*$D')(*. ,.C.('. E2I*8.62('> # ).6*C.+ 0,2$P.9 6*E$20,(*9 &$#DD%, *0*I.((* D$' D*E)(.- *D.$2,'6(*- 6-.P2,.8@0,6..

L2+'- *I$2E*-, 08.)#., $2E).8',@ ,2+,'C.0+'. D*)1*)% 8.C.('> *0,$%1 -20,',*6 # ).,.9 D.$'*)2 (*6*$*O).((*0,' ' 0,2$P.&* 6*E$20,2. W2D*E)28%. )'2&(*0,'+2 ' *D.$2,'6(*. 8.C.('. 2I0/.002 6 -*8*C(*9 O.8.E. # ).6*C.+ 0,2$P.&* 6*E$20,2 D$'6*)>, + E2,>O(*-# ,.C.('F E2I*8.62('>, *I$2E*62('F +'0,. R*-D8.+0(*. 8.C.('. 0 ABB.+,'6(*9 A-D'$'C.0+*9 2(,'I2+,.$'28@(*9 ,.$2D'.9, $2(('$2)'+28@(%- 6-.P2,.8@0,6*- 0 '0D*8@E*62('.- 0*6$.-.((%1 '(,.$2+,'6(%1 D*6>E*+ ' D$'-.(.('.- 6 D*08.*D.$2/'*((*- D.$'*).

6*IA(E'-2 0D*0*I0,6*628* I*8.. $2((.-# 6%E)*$*68.('F. OPTIMIZATION OF DIAGNOSIS AND TREATMENT MASTITIS IN CHILDREN. M.P.Nosulich professor M.A.Barskaya Samarsky State Medical University, Samara, Russian Federation

OF

Relevance. Mastitis childhood disorders are of great medical and social significance. It is believed that mastitis typical for the neonatal period, meanwhile, there are reports on the relevance of Mastitis in girls of pubertal age. The aim of the study. . The study of the epidemiology, etiology, pathogenesis, clinical mastitis in childhood by optimizing the diagnosis and treatment. Materials and methods. The statistical processing of records of children with the disease mastitis in period of 2008-2010. The distribution of children by sex and age revealed that the infants of the first 9 months of life mastitis occur with almost equal frequency among patients of both sexes. Further, with increasing age, there is a tendency at first (up to 3 years), and then the pattern in the growth rate of this pathology among girls.The distribution of mastitis in the form of the disease, flow, location and extent of destruction. Defined tactical approaches to diagnosis and treatment of this form of surgical infection. Comprehensive examination of the patients included: Ultrasound of the breast and pelvic organs, bacteriological examination of the contents of the source of infection, ELISA for intracellular infection, blood tests and urine tests. Found torpid course of the disease in girls older age group, especially with late surgical intervention. Thus, the next section tactical approaches the treatment of acute mastitis in children the neonatal period and older. Belated diagnosis and surgical treatment of an abscess in the mammary gland of older girls lead to a prolonged course of disease, formation of cysts. Complex treatment with an effective empiric antimicrobial therapy, early radical

"#! !

intervention with the use of modern interactive dressings and use of postoperative Wobenzym promoted earlier recovery.

04-87 !0P( ^$1!Q),3,-)*#'%!-! 2#*#$)6 /P'!%)Q .!,4 &(,#5)) 0,64!+ %)Z%) 3 1#(#+ !.'.19H7KAHD?, #././9B7KVA<9, %.&.'E>ILHBD7M =>?@ABB?> &.$.'F7>H?< ,?BB7MBD7M N?BIC9>BE<AHHOM FAC7G7HBD7M IH7<A>B7EAE 7F. $. ).

07>?N?<9, 4?BD<9, ,?BB7L 7 +8'('+. ).,0+*9 1'$#$&'' =:;< H:RM Y13 '-. 4.U, U'82,*62 0 2005 &*)2 D* 2010 &*) 6%D*8(.(* 32 A()*1'$#$&'C.0+'1 6-.P2,.8@0,62, ).,>- 6 6*E$20,. *, 1-&* -.0>/2 )* 3-1 8.,, D* D*6*)# 6%0*+'1 B*$- 2,$.E'' D$>-*9 +'P+'. G* 6*E$20,# ).,' $20D$.).8'8'0@ 08.)#FK'- *I$2E*-: 1-.0-6-.0 – 7 I*8@(%1; 6-.01&*) – 18 I*8@(%1; 1-3 &*)2 – 7 I*8@(%1. 7 *)(*- 08#C2. +*$$.+/'> D*$*+2 6%D*8(>820@ # ).6*C+' 1 -.0>/2 0 I.E06'K.6*9 B*$-*9 D*$*+2. < -28@C'+*6 0**,(*P.('. D* 6')# D*$*+2 I%8* 08.)#FK'-: 2(*$.+,28@(2> 2&.(.E'>–1; I.E06'K.62> B*$-2-4; $.+,*#$.,$28@(%9 06'K–15; $.+,*6.E'+28@(%9 06'K–12. 70.- D2/'.(,2- I%8* 6%D*8(.(* *I08.)*62('., +*,*$*. 6+8FC28*: <W3 *$&2(*6 I$FP(*9 D*8*0,'; $.(,&.(*+*(,$20,(*. '008.)*62('.; [;: (2$#O(*&* 2(28@(*&* 0B'(+,.$2. ND.$2,'6(*. 8.C.('. )2((*9 &$#DD% D2/'.(,*6 D$*6*)'8*0@ 6 3 A,2D2: 1 A,2D: 60.- ).,>- (2+82)%62820@ +*8*0,*-2.

7,*$*9 A,2D )6#1+*-D*(.(,(%9: T) A()*0+*D'C.0+'9, M) D$*-.O(*0,(%9. T) 7%D*8(>8' 82D2$*0+*D'F 0 66.).('.- 3 '8' 4 ,$*2+2$*6. G$' $.6'E'' I$FP(*9 D*8*0,' 6%>68>8' 2,$.E'$*62((%9 *,).8 ,*80,*9 +'P+'. G$>-#F +'P+# -*I'8'E*628' 0E2)', 82,.$28@(* ' E2,.- 0D.$.)'. ;*I'8'E2/'F D$*6*)'8' )* 6%).8.('> 06'K2, +*,*$%9 D$*P'628' ' D.$.0.+28'. M) 42C'(28' 0 ').(,'B'+2/'' (2$#O(*&* 0B'(+,.$2, '0D*8@E#> -.,*) A8.+,$*-'*&$2B''. R*O# $200.+28' D* 0$.)(.9 8'('' (2 6-8 --. W2,.- C.$.E D.$6'C(%9 ,*((.8@ 0* 0,*$*(% D$*-.O(*0,' 66*)'8' 10--'88'-.,$*6%9 ,$*2+2$. R'P+# 6%6*)'8' C.$.E ,$*2+2$ (2 D$*-.O(*0,@ ' B'+0'$*628' .. + +*O.. H8',.8@(*0,@ *D.$2/'' 0*0,26'82 *, 120 )* 180 -'(. < 60.1 D2/'.(,*6 6 D*08.*D.$2/'*((*- D.$'*). *,-.C280> O'6*9 0'--.,$'C(%9 2(28@(%9 $.B8.+0, $2((>> 2+,'6'E2/'>, *,0#,0,6'. 6%$2O.((*&* I*8.6*&* 0'()$*-2, 0,#8 D* 0,*-. D*>68>80> 6 D.$6%. 0#,+'. ! 14 D*08.*D.$2/'*((%1 0#,*+ D$*6*)'8*0@ I#O'$*62('. (.*2(#02. H.,' 6%D'02(% )*-*9 (2 7-10 0#,+' D*08. *D.$2/''. 3 A,2D – E2+$%,'. +*8*0,*-%. 7%D*8(>80> 6 0$.)(.- C.$.E 6 -.0>/.6. 42 0.&*)(>P('9 ).(@ # 21 $.I.(+2 $.E#8@,2, 8.C.('> -*O(* 0C',2,@ 1*$*P'-: ).,' C#60,6#F, D*E%6 (2 ).B.+2/'F, #).$O'62F, +28*6%. -200%. 7 7 08#C2>1 $.E#8@,2, 8.C.('> #)*68.,6*$',.8@(%9: 0*1$2(.( D*E%6 (2 ).B.+2/'F, *,-.C2F,0> D.$'*)'C.0+'. E2D*$% '8' (.).$O2('. +282. < 4 D2/'.(,*6 $.E#8@,2, (.#)*68.,6*$',.8@(%9: # )6#1 I*8@(%1 6*E('+ 0,.(*E 2(#02, 6 )6#1 08#C2>1 *,-.C28*0@ 6%D2).('. 08'E'0,*9 D$>-*9 +'P+'.

EXPERIENCE OF LAPAROSCOPIC TREATMENTS OF HIGH FORMS ATRESIA RECTUM IN CHILDREN O.S.Danilenko, E.V.Vasileva, K.A.Struyanskiy professor A.N.Smirnov Russian State Medical University by N.I.Pirogov, Moscow, Russian Fediration 32 cases are included in research laparoscopic the interventions, executed to children with the high form of an atresia of a rectum. At all patients in the postoperative period the live symmetric anal reflex, early activization, absence of the expressed painful syndrome, a chair on stoma was marked appeared in the first days. Children are written out home for 7-10 days after operation. For today at 21 children it is possible to consider result of treatment good: children feel a desire on defecation, keep weights. In 7 cases result of treatment the satisfactory: the desire on defecation is kept, periodic locks or an incontience are marked. At 4 patients result unsatisfactory: two patients had an anus stenosis, in two cases loss of a mucous rectum was marked

!"#$%&' ()*+, 2011, ,-.-/%"%&" ' 0."1&2/3%-45 67.5#'5 No1

!

06. !"#$%& «'"(%#)-*%)+),%-".#%" /0)*+"12» Medical and Biological Problems

30"(."(45"+6 ."#$%%: (.1.7., /0)8"..)0 9.:. ;4+&#%7

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– 22 :,9+6<, 9@,&'6< 8! – 14 :,9+6#', 4)E$&61#%&>6 !C – 21 :,9+6;, :-,#$&@)$9GH); 61#%&@ – 3 :,9+6< ) A#$')+%& '=<',#%%=; .!C – 27 :,9+6#' ()%'6@)'%=# 4&$>= 61#%&-6$B)%&>=). (&@$6:2 E&,D%=* 21 1& 79 ,#2. !62#$)6, )@9+6,:< A$) A&>&H) :'#2&'&; ) 2$6%:>)::)&%%&; I,#-2$&%%&; >)-$&:-&A)).

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

FEATURES OF MORPHOLOGICAL CHARACTERISTICS OF CELL MICROENVIRONMENT, EXTRACELLULAR MATRIX AND MICROCIRCULATORY CHANNEL IN BREAST CANCER AND FIBROADENOMA (COMPARATIVE MORPHOLOGICAL STUDY) M.M.Ternov, M.V.Mnikhovich Professor, Corresponding Member of Russian Academy of Medical Sciences L.V.Kaktursky Research Institute of Human Morphology of the Russian Academy of Medical Sciences, Moscow, Russia Studied mammary glands removed at surgery for breast cancer dishormonal diseases, fibroadenomas (FA) - 87 cases. The distribution and nature of the material: diffuse cystic mastopathy (CM) - 22 cases, nodular CM - 14 cases, fibroadenoma breast - 21 cases, sclerosing adenosis - 3 cases and revealed the primary breast cancer - 27 cases (invasive forms of adenocarcinoma).

Vascular link ICR in breast cancer tumors presented with vessels, including on the structural and functional characteristics can distinguish the type protokapillyarov vessels, capillaries, sinusoids and venulopodobnyh microvessels and the absence of pericytes. Cellular composition of

fibroadenomas presented varying degrees of differentiation of fibroblasts, monocytes, lymphocytes and macrophages, fibroblasts formed with macrophages and lymphocytes contacts in the form of dense slab. The study clearly confirms the uneven nature of the differentiation of structural and functional units of benign and malignant breast tumors. !

06-284 ;$&!."'.16'4 +'8!8!+'"101)';1 < "!"&1<$ .!(8+$."%!,! <1.6'%%!,!

8)$81)1&1 ;+4 8)!*'+1.&'.' .!.+7>1 !...06@)$&', /.(.O&119E)-&' -.>.% /.(.O&119E)-&' 069+%&-3::,#1&'62#,D:-); 3%:2)292 (6-B)% ) M='&$&2&- )>.

3.3.!#+%)-&'6 ./!0, !&:-'6, .&::)< ( 033(M )>. 3.3.!#+%)-&'6 ./!0 $6@$6E&26%6 &$)5)%6,D%6< E#:-,#2&+%6< '6-B)%6, A$#1:26',<GH6< :&E&; A$)$&1%=; 6%2)5#%%=; -&>A,#-:. 8&>A,#-: A$&2#-2)'%=* 6%2)5#%&' B.pertussis E=, )@9+#% ' )>>9%&I,#-2$&4&$#@# 1& ) A&:,# 1#2&-:)-6B)) %65$#'6%)#> ) 4&$>6,)%&>. ( -6+#:2'# ):2&+%)-6 6%2)2#, ):A&,D@&'6,) -&>>#$+#:-9G A&,)'6,#%2%9G 6%2):='&$&2-9 ) A&,9+#%%9G %6>) -$&,)+DG 6%2):='&$&2-9 - 7OM B.pertussis. .#@9,D262= )::,#1&'6%)< :')1#2#,D:2'9G2 &E )@>#%#%)<*, A$&):*&1<H)* ' 6%2)5#%%&; :2$9-29$# A$#A6$626. "6-, %6E,G16,) ):+#@%&'#%)# )/),) :>#H#%)# A&,&: A$#B)A)26B)) )@ &E,6:2) I,#-2$&%#;2$6,D%=* 6%2)5#%&'.

O$&):*&1<He# >&?%& &EP<:%)2D -&>A,#-:&&E$6@&'6%)#>- *)>)+#:-&; :L)'-&; ) )@>#%#%)<>) ' 6%2)5#%%&; :2$9-29$# ' $#@9,D262# '&@1#;:2')< 4&$>6,)%6. /-2)'%&:2D A$#A6$626 ' 7/7- 2#:2#, A&:,# 1#2&-:)-6B)) :%)?6,6:D %6 83%. ( A&,D@9 >#*6%)@>6 1#2&-:)-6B)) 7OM ' $#@9,D262# -&>A,#-:&&E$6@&'6%)< :')1#2#,D:2'9G2 $#@9,D262=, A&,9+#%%=# A$) '&:A$&)@'#1#%)) 9:,&'); 1#2&-:)-6B)) 1,< A$#A6$62&' -&>A,#-:6 A$&2#-2)'%=* 6%2)5#%&' ) A6$6,,#,D%&; 1#2&-:)-6B)) A$#A6$626 7OM B.pertussis. O$) )::,#1&'6%)) ' 7/7 2#:2# 9-6@6%%=* A$#A6$62&' ) -&%2$&,#; :%)?#%)< 6-2)'%&:2) %6E,G16,) 2&,D-& 1,< -&>A,#-:%&5& A$#A6$626 6%2)5#%&', 2&516 -66-2)'%&:2D A$#A6$626 7OM %# )@>#%<,6:D. "&-:)+#:-)# :'&;:2'6 7OM B.pertussis E=,) )@9+#%= A$) &A$#1#,#%)) ,#26,D%&5& I44#-26 7OM %6 %#)%E$#1%=* >=L6*, &E$6E&26%%=* 6-2)%&>)B)%&> Q. O&,9+#%%=# $#@9,D262= :')1#2#,D:2'9G2 & :%)?#%)) 2&-:)+%&:2) '6-B)%%&5& A$#A6$626 ' $#@9,D262# 1#2&-:)-6B)) A& LD50 ' 22,5 $6@6. "&-:)+%&:2D A& LD50 A&,9+#%%=* A$#A6$62&' 7OM B.pertussis E=,6 %)?# 2&-:)+%&:2) A$#A6$62&' E.coli ' 1464 $6@6 1,< A$#A6$626 7OM L2.475 ) ' 8097 $6@ 1,< 7OM L2.162. "6-)> &E$6@&>, A&,9+#%%=# $#@9,D262= :')1#2#,D:2'9G2: & '&@>&?%&:2) 1#2&-:)-6B)) 7OM ' :&:26'# -&>A,#-:%&5& '6-B)%%&5& A$#A6$626 4&$>6,)%&>, &A$#1#,#%%&; %6>) 2$#>< $6@,)+%=>) :A&:&E6>) (7/7- 2#:2, )>>9%&I,#-2$&4&$#@, E)&A$&E6 : 6-2)%&>)B)%&> Q).

DETOXICATION OF LIPOPOLYSACCHARIDE AS A PART OF THE COMPLEX VACCINE PREPARATION FOR PREVENTION OF WHOOPING COUGH M.R.Nazirov, A.V.Poddubikov Cand.Sci.(Med.) A.V.Poddubikov Mechnikov Research Institute for Vaccines and Sera of RAMS, Moscow, Russia The original acellular pertussis vaccine representing a natural antigenic complex is developed in Mechnikov Research Institute for Vaccines and Sera, RAMS. The complex of protective antigens B.pertussis has been studied in an immunoelectrophoresis before and after detoxication by warming and formalin. The commercial polyvalent antisera and the rabbit antisera that we received to LPS B.pertussis were used as a source of antibodies. Results of research indicated the changes occurring in antigenic structure of a preparation. So, disappearance and/or shift of strips of a precipitation from area of electroneutral antigens were observed. One can explain the occurring process as a complex formation - chemical lacing and changes in antigenic structure as a result of formalin influence. Activity of a preparation in LAL test after detoxication decreased on 83 %. In favor of the mechanism of detoxication LPS indicated a result of a complex

"#! !

!"#$%& «'"(%#)-*%)+),%-".#%" /0)*+"12»

! formation of the results received at reproduction of conditions of detoxication for preparations of a complex of protective antigens and parallel detoxication of preparation LPS B.pertussis. During research in LAL test of the specified preparations and control of activity depression observed only for a complex preparation of antigens whereas activity of preparation LPS didn't change. Toxic properties of LPS B.pertussis have been studied at definition of lethal effect of LPS on non- inbred mice injected by Actinomycinum D. The received results indicated depression of toxicity of a vaccine preparation as a result of detoxication on LD50 in 22,5 times. Toxicity on LD50 received preparations LPS B.pertussis was below toxicity of preparations E.coli in 1464 times for preparation LPS strain 475 and in 8097 times for LPS strain162. Thus, the received results indicated possibility of detoxication by formalin LPS as a part of a complex vaccine preparation, that we defined in three various ways (LAL test, an immunoelectrophoresis, a biological test with Actinomycinum D).

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“3dMax”.

0#J& 7*K:#+; @%INJ2%+;2 /*J8M5@2%+;2 %2/*+7@%./B&& +*7*$*, 82%2G*%*:/&, G#,J*%*$;N 8#K.N, L26.:*-/*$ G*6*$+*G* J*KG# -26*$2/# 7*G6#7+* ./#K#++*J. $;P2 #6G*%&@J..

A2@*: /*J8M5@2%+*, 3-D %2/*+7@%./B&& 4&*6*G&-27/&N *4H2/@*$ K#76.L&$#2@ $+&J#+&F J*%9*6*G*$, F$6F2@7F $;7*/*&+9*%J#@&$+;J & 82%782/@&$+;J *@+*7&@26M+* :#6M+2,P2G* .-#7@&F 7J*:26&%*$#++;N @%INJ2%+;N 4&*6*G&-27/&N *4H2/@*$ $ J*%9*J2@%&-27/*J, 7@2%2*6*G&-27/*J & :%.G&N #+#6&K#N. USING 3-D RECONSTRUCTION IN MORPHOLOGY L.P.Lavriv, A.V.Korniychuk, N.V.Bernik, N.V.Tabachniuk, V.V.Kolesnik Professor I.Yu.Oliynyk Bukovinian State Medical University, Chernivtsi, Ukraine To obtain a reliable three-dimensional image of an early prenatal ontogenesis use techniques of graphic and plastic reconstruction of biological objects using the series of histological sections. Without denying the role of these methods in addressing a three-dimensional imaging of biological objects, we believe that the method of computing the 3-D reconstruction has every right to exist and the application of the morphology. He is reliable, clear, accessible, relatively cheap, that meet current international standards.

The aim of our work was to evaluate the possibility of using a computer 3-D reconstruction of embryological studies.

The objects of study were anatomical structures in the prenatal human ontogenesis. Fixation and wiring of the material produced in accordance with standard procedures. To create additional reference axes of computer 3-D reconstruction close to the material under study to fill stacked 3.4 dyed yarns. Produced a series of histological sections (60 to 250). After staining sections were photographed with a digital camera, and digital images were treated using a computer program "3-d Max".

We have created three-dimensional computer reconstruction of the nasal septum, maxillary sinus, the ventricles of the human brain according to the above algorithm.

The method of computing the 3-D reconstruction of biological objects worthy of attention of morphologists, and is a highly promising for the

"#! !

further involvement of the simulated three-dimensional biological objects in the morphometric, stereological and other assays. !

06-220 /)"-($/!,5+ 3)0-$/5, (5/)6)-5()+,5+ #+/!"!*1"$!.)%&*5,!

0%+-0),! #+7+*!, "#$"$6"-(18- .!33+/+*2!/$(0+ ,+'+*9!,*59 "-($%$(59 0%+-$0 0$"-*$4$ ,$'4) 0/5"5 ( 4+#)-$2!-5 IN VITRO '.).T#9&G.66&+#, '.'.3%*+:&+, A.U.)#6&G&+, <.A.?#K&K*$, E.<.'+:%22$# :.4.+. '.'.V&K$#+*$, :*B2+@, /.J.+. '.'.?.J2%*$#, '.".)&F7*$ )#K#+7/&, ?*7.:#%7@$2++;, A2:&B&+7/&, C+&$2%7&@2@, )#K#+M, V*77&F ( %F:2 +#.-+;N &7762:*$#+&, 4;6# .7@#+*$62+# $*KJ*L+*7@M G28#@*B&@#%+*, :&992%2+B&%*$/& J2K2+N&J+;N 7@$*6*$;N /62@*/ (AU)) $ /.6M@.%2 8%& 8*762:*$#@26M+*J :*4#$62+&& 9#/@*%*$ %*7@# 9&4%*46#7@*$ (FGF4), 9#/@*%# %*7@# G28#@*B&@*$ (HGF), &+7.6&+@%#+792%%&+ 7262+&@# +#@%&F (ITS) & :2/7#J2@#K*+# (Dex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ex (2 G%.88#). <KJ2+2+&F 92+*@&8# /62@*/ *B2+&$#6& J2@*:*J &JJ.+*B&@*N&J&-27/*G* #+#6&K#. V2K.6M@#@; & $;$*:;: %2K.6M@#@; &7762:*$#+&F 8*/#K#6&, -@* $ *4*&N 76.-#FN /.6M@&$&%*$#+&2 AU) 8%&$*:&@ / &N :&992%2+B&%*$/2 $ G28#@*46#7@;, * -2J 7$&:2@26M7@$*$#6* 8*F$62+&2 $ +&N J#%/2%*$ G28#@*46#7@*$ B&@*/2%#@&+*$ 18 & 19, W-S". A#%/2% K%26;N G28#@*B&@*$ HepatocyteSpecificAntigen (HSA), 4;6 *4+#%.L2+ @*6M/* 8%& /.6M@&$&%*$#+&& AU) $ 7%2:2 ")". 3#/&J *4%#K*J, 7%2:# ")" $;K;$#2@ :&992%2+B&%*$/. AU) +2 @*6M/* $ G28#@*46#7@;, +* & $ G28#@*B&@;, & O@# :&992%2+B&%*$/# */#K#6#7M 4*622 .7@*,-&$*,, -2J $ G%.882 2. "*6.-2++;2 %2K.6M@#@; 8*:@$2%L:#5@, -@* %#7@$*%&J;2 9#/@*%;, $;%#4#@;$#2J;2 ")" $ 7%2:., +2*4N*:&J; :6F :&992%2+B&%*$/& AU) $ G28#@*B&@#%+*J +#8%#$62+&& & F$6F5@7F $#L+;J 9#/@*%*J J&/%**/%.L2+&F :6F 7@$*6*$;N/8%*G2+&@*%+;N /62@*/.

EXPOSURE OF SOLUBLE GROWTH FACTORS PRODUCED BY HEPATIC PERISINUSOIDAL CELLS LEADS TOBONE MARROW DERIVED MESENCHYMAL STEM CELLS DIFFERENTIATION INTO HEPATOCYTES IN VITRO A.K.Shafigullina, A.A.Trondin, M.S.Kaligin, I.M.Gazizov, D.I.Andreeva Dr.Sci.(Bio) A.A.Rizvanov, Assoc.Prof., Cand.Sci.(Med) A.A.Gumerova, A.P.Kiasssov Kazan State Medical University, Kazan, Russia In some articles it was published that mesenchymal stem cells (MSC) are able to differentiate into hepatocytes under sequential exposure of Fibroblast Growth Factor 4 (FGF4), Hepatocyte Growth Factor (HGF), ITS and dexamethasone (Dex). It is known fact that hepatic perisinusoidal cells (HPC) are the source of FGF4 and HGF in the liver, so we can suppose that these cells participate in creation of microenvironment for hepatic progenitor cells and direct their differentiation into hepatocytes. The aim of our project was to study whether it is possible to differentiate MSC into hepatocytes under cultivation them in HPC conditioned media. Materials and methods: HPC were derived from rat`s liver, stromal MSC - from rat`s Bone Marrow. Further MSC were cultivated in HPC conditioned media (group 1) and in media with sequential exposure of growth factors FGF4, HGF, ITS, Dex (group2). Changes in phenotype were detected by immunocytochemistry assays. Results and discussion: in both groups MSC differentiated into hepatoblasts that was confirmed by the appearance of cytokeratin – 18 and19, W-fetoprotein markers. In the second group these markers were detected earlier then in the first group, but the intensity of their expression in group 1 gradually decreased. Hepatocyte Specific Antigen (HSA) – marker of mature hepatocytes was revealed only in group 1. Thus, cultivation of MSC in HPC conditioned media (group 1) leads to differentiation into hepatoblasts and hepatocytes, and this differentiation was more steady then under exposure of exogenous growth factors (group 2). Our results confirm that soluble growth factors produced by HPC are essential for progenitor cells and MSC microenvironment and for their differentiation into hepatocytes.

06-142 !'17+*!+ (!.$($4$ "$"-)() 6)0-+/!: #$/;.0)

!"#$%&' ()*+, 2011, ,-.-/%"%&" ' 0."1&2/3%-45 67.5#'5 No1

!

BACTEROIDALES ! "#$%&'#"% ( )*+,+!-. /0*%1 2 3,#4%'%'#%4 4+/%"(/5,'+-6%'%7#&%2"#.

4%7+*+! #22/%*+!8'#5 !.".#$%&'()& *.+.)., ,-./011.- 2.3.!/(+.4, 5.+.)., 1.).1. 3.6.75.,.-.4 8.11(915(9 :.1$*&-1;40))<9 =0*(>()15(9 ?)(40-1(;0;, =.154&, 8.11(@ 2&5;0-(( ,.-@*5& Bacteroidales @4%@A;1@ .*)(+( (B *.+()(-$AC(D +(5-..-'&)(B+.4 4 5(E0F)(50 F0%.405&. G)( ,-()(+&A; $F&1;(0 4 -&1C0,%0)(( $'%04.*.4, +.*$%(-$A; )& +01;)<9 (++$).%(F015(9 .;40; ( ,-0,@;1;4$A; 5.%.)(B&>(( 5(E0F)(5& ,&;.'0))<+( +(5-..-'&)(B+&+(.

H0%I (11%0*.4&)(@: (B$F(;I ( 1-&4)(;I 5&F01;40))<9 ( 5.%(F01;40))<9 1.1;&4 *.+()(-$AC(D ,-0*1;&4(;0%09 ,.-@*5& Bacteroidales 4 5(E0F)(50 $ %A*09 -&B%(F).'. 4.B-&1;&. =&;0-(&%< ( +0;.*<: (11%0*.4&)(0 J<%. ,-.40*0). 4 '-$,,0 30 B*.-.4<D %A*09 -&B%(F).'. 4.B-&1;&, 5.;.-<0 J<%( -&B*0%0)< )& ;-( ,.*'-$,,< (10 *0;09 .; 4 +01@>04 *. 5 %0;, 15 *0;09 6-14 %0; ( 5 4B-.1%<D 18 -24 %0;). 7;&++< J&5;0-.(*.4 4<*0%@%( ,$;0+ ,.104& 10-(9)<D -&B40*0)(9 /05&%(9 )& 10%05;(4)$A ,(;&;0%I)$A 1-0*$.

K*0);(/(5&>(A F(1;<D 5$%I;$- J&5;0-(9 ,-.4.*(%( ,-( ,.+.C( +0;.*.4 ARDRA (-01;-(5>(.))<9 &)&%(B &+,%(/(>(-.4&)).9 -(J.1.+&%I).9 L6#) ( 10540)(-.4&)(@ /-&'+0);.4 '0).4 16S -86#.

80B$%I;&;<: "10'. J<%. 4<*0%0). 148 E;&++.4 J&5;0-(9 ,.-@*5& Bacteroidales. 2.%IE()1;4. 4<*0%0))<D (B.%@;.4 4. 410D '-$,,&D ,-()&*%0M&%( 4(*&+ B.xylanisolvens, B.vulgatus ( B.uniformis. N&5M0 4 4<1.5.9 5.)>0);-&>(( J<%( .J)&-$M0)< ,-0*1;&4(;0%( -.*.4 Alistipes, Parabacteroides, Odoribacter, Barnesiella ( Prevotella. "(*.4.0 -&B)..J-&B(0 J&5;0-(9 ,.-@*5& Bacteroidales $40%(F(4&%.1I $ *0;09 1;&-E0'. 4.B-&1;& ,. 1-&4)0)(A 1 *0;I+( -&))0'. 4.B-&1;&. "<4.*<: " D.*0 (11%0*.4&)(@ J<%. 4<@1)0)., F;. 1-0*( J&5;0-(9 ,.-@*5& Bacteroidales 4 5(E0F)(50 *.+()(-$A; ,-0*1;&4(;0%( -.*& Bacteroides, .*)&5. 4 +(5-./%.-0 B)&F(;0%I).9 F&1;( %A*09 ;&5M0 ,-(1$;1;4$A; J&5;0-(( *-$'(D -.*.4 ,.-@*5& Bacteroidales, ;&5(D 5&5 Alistipes, Parabacteroides ( Barnesiella. #-.+0 ;.'., 4<@4%0)., F;.

4(*.4.0 -&B)..J-&B(0 5(E0F)<D J&5;0-(9 ,.-@*5& Bacteroidales 1 4.B-&1;.+ $40%(F(4&0;1@.

STUDY OF BACTEROIDALES-ORDER SPECIES COMPOSITION IN FECES OF HEALTHY PEOPLE USING MOLECULAR TECHNIQUES E.V.Kulagina Dr.Sci (Med.), professor B.A.Efimov, Cand. Sci (Med.) A.N.Shkoporov Russian State Medical University, Moscow, Russia Bacteroidales order bacteria constitute a significant part of human intestinal microflora. These bacteria maintain benefical mutualistic relationships with the host, taking part in carbohydrate utilization, local immunity modulation and inhibition of gut colonization by pathogens.

Aim of research: to study and to compare qualitative and quantitative composition of cultivable numerically predominant Bacteroidales order bacteria in the feces of healthy people of different age.

Materials and methods: The research was conducted in a group of 30 healthy people of different age, which were divided into three sub-groups (10 children aged 4 month - 5 years, 15 children aged 6-14 years, and 5 adults aged 18-24 years). Bacteroidales strains were isolated from feces by plating serially diluted homogenates onto selective media. Species identification of pure cultures was accomplished by application of original ARDRA protocol and partial 16S rDNA sequencing.

Results: Totally 148 strains of Bacteroidales order bacteria were isolated. It was found that the majority of Bacteroides-like isolates in all groups belonged to species B.xylanisolvens, B.vulgatus and B.uniformis. Also, members of other genera, such as Alistipes, Parabacteroides, Odoribacter, Barnesiella and Prevotella were detected. Species diversity increased in elder children in comparison with infants.

Conclusion: It was found that Bacteroides genus members prevail among Bacteroidales order bacteria in human gut, but significant proportion of individuals also carry strains of other Bacteroidales order genera such as Alistipes, Parabacteroides and Barnesiella. In addition, it was found that species diversity of intestinal Bacteroidales order bacteria increases with age.

06-135 +2+9%''+27# *%57%/:'+27# 4#7+.+'*,#1 2%,*;8 ( ",-2 2 6%'%7#&%2"# *%7%,4#'#,+!8''+1 8,7%,#8/:'+1 6#3%,7%')#%1 6.3.L.-./004& F%0) 5.-. 636?, ,-./., *.+.). ".O.P&'&F K)1;(;$; /(B(.%.'(( (+. 3.3. 2.'.+.%I>& 636 ?5-&()<, #(04, ?5-&()& " )&1;.@C00 4-0+@ &-;0-(&%I)&@ '(,0-;0)B(@ @4%@0;1@ )&(J.%00

-&1,-.1;-&)0))<+ B&J.%04&)(0+. 601+.;-@ )& )&%(F(0 J.%IE.'.

5.%(F01;4& '(,0-;0)B(4)<D 1-0*1;4 ( ,-.4.*(+<0 +0-.,-(@;(@ )0 $*&0;1@ 1)(B(;I -.1; Q;.9 ,&;.%.'((. R.Q;.+$ &5;$&%I).9 +0*(5.J(.%.'(F015.9 B&*&F09 @4%@0;1@ 4<@4%0)(0 +0D&)(B+.4 4.B)(5).40)(@ ( -&B4(;(@ &-;0-(&%I).9 '(,0-;0)B((.

P >0%IA (B$F0)(@ .1.J0)).1;09 /$)5>(.)(-.4&)(@ +(;.D.)*-(9 10-*>& $ 5-<1 1 '0)0;(F015( *0;0-+()(-.4&)).9 &-;0-(&%I).9 '(,0-;0)B(09, ,-.40*0)< Q51,0-(+0);&%I)<0 (11%0*.4&)(@ )& 18 1,.);&)). '(,0-;0)B(4)<D 5-<1&D-1&+>&D +&11.9 250-300' ( 18 5-<1&D 5.);-.%I).9 '-$,,< %()(( "(1;&-. KB+0-0)(@ +0+J-&)).'. ,.;0)>(&%& ( 15.-.1;( ,.;-0J%0)(@ 5(1%.-.*& 4 1$1,0)B(( +(;.D.)*-(9 10-*>& .1$C01;4%@%( ,. +0;.*$, .,(1&)).+$ =. Brand (1995). R-.>011< +(;.D.)*-(&%I).'. *<D&)(@ ( .5(1%(;0%I).'. /.1/.-(%(-.4&)(@ (11%0*.4&%( 1 ,.+.CIA ,-(J.-& G51('-&/ (Hansatech, England). "<@4%0)., F;. $ 5-<1 1 '0)0;(F015( *0;0-+()(-.4&)).9 &-;0-(&%I).9 '(,0-;0)B(09 +0+J-&))<9 ,.;0)>(&% +(;.D.)*-(9 10-*>& 1.1;&4%@% -113,76±3,65 +". 3 $ 5.);-.%I)<D M(4.;)<D - 152,85±13,52 +" (p<0,01). " ;. 4-0+@ 5&5 15.-.1;I ,.;-0J%0)(@ 5(1%.-.*& 4 1$1,0)B(( +(;.D.)*-(9 10-*>& 1,.);&)). '(,0-;0)B(4)<D 5-<1 J<%& ,.F;( 4 2 -&B& 4<E0, F0+ 4 5.);-.%I).9 '-$,,0 (p<0,05). L.1;.40-). $40%(F0)< $ 1,.);&)). '(,0-;0)B(4)<D 5-<1 J<%( ,.5&B&;0%( 15.-.1;( ,.;-0J%0)(@ 5(1%.-.*& 4 1.1;.@)(( V2 ( 15.-.1;I /.1/.-(%(-.4&)(@ V/ (p<0,001). R-( .*).4-0+0)).+ 1)(M0)(( )& 22,3% *<D&;0%I).'.

5.);-.%@, .;-&M&AC0'. 1;0,0)I 1.,-@M0)(@ ,-.>011.4 *<D&)(@ ( /.1/.-(%(-.4&)(@. N&5(+ .J-&B.+, $ 5-<1 1 '0)0;(F015( *0;0-+()(-.4&)).9 &-;0-(&%I).9 '(,0-;0)B(09 +0+J-&))<9 ,.;0)>(&% +(;.D.)*-(9 10-*>& J<% 1)(M0), 15.-.1;I ,.;-0J%0)(@ 5(1%.-.*& $40%(F0)&, ,-( 1)(M0)(( 1;0,0)( 1.,-@M0)(@ ,-.>011.4 *<D&)(@ ( /.1/.-(%(-.4&)(@. S;( .1.J0)).1;( /$)5>(.)(-.4&)(@ +(;.D.)*-(9 .;%(F&%( (D .; 5-<1 5.);-.%I).9 '-$,,< ( .5&B<4&%( 4%(@)(0 )& *0@;0%I).1;I 10-*>&.

FEATURES OF FUNCTIONING OF HEART MITOCHONDRIA IN RATS WITH GENETICALLY DETERMINED HYPERTENSION N.A.Dorofeyeva Correspondent of Member of Ukrainian National Academy of Sciences,Dr.Sci (Med.),Prof V.F.Sagach National Academy of Sciences of Ukraine A. A. Bogomolets Institute of Physiology, Kiev, Ukraine The purpose of this study was to investigate some features of functioning of cardiac mitochondria in rats with genetically determined arterial hypertension. We compared cardiac mitochondria of 6-month-old spontaneously hypertensive rats and Wistar controls rats-males.The mitochondrial membrane potential and speed of consumption of oxygen in myocardium mitochondria were measured using the method, described M. Brand (1995). Processes of respiration and oxidative phosphorylation in myocardium mitochondria were measured using Oxygraph (Hansatech instruments, Norfolk, England). It has been found that the mitochondrial membrane potential of heart mitochondria was lower in rats with genetically determined arterial hypertension (-113,76 ±3,65 mV) compared to Wistar rats (TUm = -152,85±13,52 +", p<0,01).In spontaneously hypertensive rats the respiration rate in state V2 by Chance and rate of phosphorylation were increase compared to Wistar rats (p<0,001). The respiration control by Chance was depressed 22,3% in rats with genetically determined arterial hypertension relative to Wistar rats.Our data demonstrate that rats with genetically determined arterial hypertension had some features of functioning cardiac mitochondria which distinguished them from control animals. !

06-116 (&827#% 9%/"8 7%3/+!+6+ $+"8 HSP70 ! 8"7#!8;## 3,+7#!++3(.+/%!+6+ #44(''+6+ +7!%78 '8 4+*%/# #'7,8",8'#8/:'+1 +3(.+/# ( ",-2 =.3.704>.4 V&4. %&J.-&;.-(09, *.J.) 2.3.=&-'$%(1 K)1;(;$; >(;.%.'(( 836, P&)5;-R0;0-J$-', 8.11(@ 20%.5 ;0,%.4.'. E.5& Hsp70 ,.+(+. $F&1;(@ 4 -@*0 4&M)09E(D 4)$;-(5%0;.F)<D /$)5>(9, ('-&0; 4&M)$A -.%I 4 /.-+(-.4&)(( ,-.;(4..,$D.%04.'. (++$)).'. .;40;& .-'&)(B+&.

R. ,-0*4&-(;0%I)<+ *&))<+ Hsp70, 4)01W))<9 4 5%0;.F)$A 5$%I;$-$ 1,.1.J0) Q//05;(4). 1;(+$%(-.4&;I ,-.;(4..,$D.%04$A &5;(4).1;I NK-5%0;.5 )&,-&4%0))$A ,-.;(4 5%0;.5 '%(.+< 5-<1< P6, +0%&).+< +<E( "16 ( Q-(;-.J%&1;.4 F0%.405& #562. N&5 ()5$J&>(@ 1 Hsp70 ,-(4.*(%& 5 ,.4<E0)(A >(;.;.51(F015.'. Q//05;& 5(%%0-)<D 5%0;.5 )& 35-40% 4 B&4(1(+.1;( .; ;(,& 5%0;.5 ( 5.)>0);-&>(( J0%5&. P >0%IA .>0)5( (++$).+.*$%(-$AC09 &5;(4).1;( invivo +< (1,.%IB.4&%( +.*0%I ();-&5-&)(&%I).9 .,$D.%( $ 5-<1. X(4.;)<+ ,-.(B4.*(%&1I (+,%&);&>(@ 1$1,0)B(( 5%0;.5 '%(.+< P6 4 .J%&1;I 1;-(&;$+& 1 ,.1%0*$AC(+ 440*0)(0+ Hsp70 4 .,$D.%04<9 $B0% )& 14 1$;5(. Y0-0B )0*0%A .; +.+0);& ()Z05>(( J0%5& ,-.(B4.*(%1@ B&J.-

"#! !

!"#$%& «'"(%#)-*%)+),%-".#%" /0)*+"12»

! !"#"$%"!" &"'!( )#* +&&,%"!+-."/+&+01-2"!" +--#1)"$(%+*.

341%+$(#(-5 +%6+#5.7(4+* "8,/"#1$"9 .2(%+ #+&6"4+.(&+ CD3+, CD4+ + CD8+. :7+ ")%"27(.%"& $$1)1%++ Hsp70 ".&10(#(-5 '%(0+.1#5%(* +%6+#5.7(4+* #+&6"4+.(&+ CD3+, CD4+, CD8+ '"%; +%<124+"%%"!" 2(%(#( + -(&"9 "8,/"#+. :7+ 87+&1%1%++ =;051!"

-;$"7"."0%"!" (#5=,&+%( (BSA) $&1-." Hsp70 8")"=%,> +%6+#5.7(4+> %1 %(=#>)(#+, 8"?."&, )(%%;9 ?6612. &; -$*';$(1& $$1)1%+1& @(817"%(. :"#,01%%;1 71',#5.(.; -$+)1.1#5-.$,>. " 87".+$""8,/"#1$"& +&&,%"&"),#+7,>A1& ?6612.1 ?2'"!1%%"!"

Hsp70 2(2 %( -+-.1&, $7"B)1%%"!", .(2 + %( -+-.1&, 87+"=71.1%%"!" +&&,%+.1.(, 0." )(C. $"'&"B%"-.5 +-8"#5'"$(.5 8718(7(.; "0+A1%%"!" Hsp70 $ 2(01-.$1 ()5>$(%.( $ .17(8++ 7(2(.

INFLUENCE OF HEAT SHOCK PROTEIN HSP70 ON ACTIVATION OF ANTITUMOR IMMUNITY IN THE MODEL OF INTRACRANIAL TUMOR IN RODENTS M.A.Shevtsov Head of the Laboratory, Dr. Sci (Bio.) B.A.Margulis Institute of Cytology RAS, St. Petersburg, Russia Despite recent advances in therapy of malignant glioma survival of patients does not succeed 8-12 months. Among the new treatments currently being tested, immunotherapy appears to be efficient because it offers the potential for high tumor-specific cytotoxicity. Heat shock protein Hsp70 plays very important roles in intracellular functions and also takes part in antitumor immunity. Using different types of cell lines (rat glioma C6, B16 melanoma, K562 human erythroid leukemia cell line) we showed that the preparation of pure Hsp70 introduced in cell culture can effectively stimulate the antitumor response of NK-cells. Incubation with Hsp70 increases a cytotoxic effect of NK-cells up to 35-40% depending on the cell type and protein concentration. For evaluation of immunomodulatory role of Hsp70 in vivo we used a rodent model of intracranial tumor. Hsp70 was injected into the C6 tumor 14 days after the latter implantation. One week later animals were killed and brains were taken for immunohistochemical analysis. An infiltration of tumor tissue with CD3+, CD4+ and CD8+ cells was evaluated. After a single injection of Hsp70 a massive infiltration by lymphocytes DD3+, CD4+, CD8+ in the zone of injection canal and in tumor was observed. Bovine serum albumin (BSA) used as a control protein did not cause infiltration with lymphocytes, thus we propose that this effect is due to an injection of chaperone. The present results reveal a stimulatory effect of exogenous chaperone Hsp70 on the systems of innate and adaptive immune response, that gives a possibility of using Hsp70 preparation as the adjuvant in cancer therapy. !

06-263 PRESENCE OF THE OSTEOCLASTS IN MANDIBLE OF THE HUMAN EMBRYO FROM NINTH TO TWELFTH WEEK OF GESTATION M.Janjic, D.Pancic Professor I.Nikolic Institute for histology and embryology Development of the mandible begins at sixth week of gestation. Mandible is formed mostly through endesmal ossification.

The goal of our study was to examine presence of the osteoclasts and their morphological characteristics in mandible of the human embryo.

Material included eight embryos, both male and female, from ninth to twelfth week of gestation. Tissue samples were stained by using classical HE method. They were used to examine morphological characteristics and topographic localization of osteoclasts, while presence of osteoclasts was determined by using morphometrical method (number of cells per area unit of developed osteal tissue).

The results of our study shows that the osteoclasts are localized mostly near the margine of the primordium of the mandible. They are big, multinuclear and at some places they form groups. In the region of the body of the mandible number of osteoclasts is 662,96 and SD is 259,28. In places where enchondral ossification occurs, in angulus and in the region of the ramus of the mandible, rare solitary osteoclasts can be seen. Obtained result lead to conclusion that remodelation of the osteal tissue of the mandible is most expressed in part of its primordium which is formed through endesmal ossification.

Keywords: Osteoclasts, mandible, human embryo 06-255 KERATOCONJUNCTIVITIS SICCA RHEUMATOID ARTHRITIS M.Jevtic, M.Jovanovic, K.Sokolovic full-time professor G.Zlatanovic School of medicine, University of Nis

IN

PATIENTS

WITH

The study included 166 women and 12 men aged 19 to 65 years (mean 42 years) withrheumatoid artritis. All patients had classic or definite rheumatoid arthritis, as defined by the criteria of theAmerican Rheumatism

"#! !

Association (ARA). We diagnosed keratoconjunctivitis sicca with the aid of theSchirmer test, tear film breakup time, rose bengal and fluorescein corneal staining. In 45% patients withrheumatoid arthritis we found positive the Schirmer test and tear film breakup time. In 25% patients with rheumatoid arthritis we found moderate or severe ocular burning, foreign body sensation, pain and positiverose bengal corneal staining.Key words: Keratoconjunctivitis sicca, rheumatoid arthritis 06-234 CHRONIC HEPATITIS C VIRUS INFECTION-OUR RESULTS K.Sokolovic, M.Jevtic, M.Jovanovic full-time professor L.Konstantinovic School of medicine, University of Nis Introduction: Chronic hepatis C remains a formidable treat to world health.

More than 170.000.000 people world wide are infected by this virus.

Progression of chronic hepatitis C is associated with significant morbidity: cirrhosis,hepatic failure and hepatocelular carcinoma. Combinated Chronic hepatitis C virus infection-our results therapy with pegilated interferons and ribavarin has increased the sustained virologic response (SVR) in the much higher percentage than with previous treatments,such as interferons only.

Materials and methods: Patients with genotypes 1 and 4were given a 48week therapy of peginterferon alfa-2a and ribavarin. Patients with genotypes 2 and 3received same doses of both drugs,but during 24 weeks.

All patients were sheduled for follow-up visit 24 weeks after the end of treatment. Standard PCR tests were used for qualitative and quantitative detection of viral RNAas well as for determinaton of patients genotypes.

Results and discussion: A total of 110 patients were enrolled in the study.

The most common mode of infection was trought i.v. drug use 42.73%, medical interventions 10.00%, sex 4.55%, blood transfusion 7.27%,heamodialisis 13.64%, other 2.73% and unknown mode 19.09%. The frequency of genotypes is for genotype 1-62.73%, for genotype 2-1.82%, for genotype 3-22.73%, for genotype 4-2.73%,for mixed genotypes 7.27%,and there were 3 patients that had no genotype detected (2.73%). Not all patients completed their treatmant, some premature terminated therapy or dropped out (3.64%). For the ones that completed therapy, positive on viral RNA were 24.55% of patients,and negative 67.27%. Finally,5 patients are still waiting for results (4.55%).

Conclusion: Combined therapy is safe and well tolerated,with sustained virologic response (SVR) achived in 67.27% of patients.

Key words: Hepatitis C, chronic and drug therapy, combination 06-146 MORPHOLOGICAL AND HISTOPATHOLOGY CHANGES ON RAT HIPOTHALAMIC NUCLEUS ARCUATUS (ARCN), ADRENAL GLAND AND THIMUS WHICH WAS TREATED BY MONOSODIUM GLUTAMATE N.Stojkovic, N.Ristic, M.Jovanovic past-time professor S.Cekic School Of Medicine, University Of Nis The aim of this paper was to investigate the impact of neurotoxic monosodium glutamate (MSG) on rat hipothalamic nucleus arcuatus (ARCN), adrenal gland and thimus. In newborn animals subcutaneus MSG injections induce lesions at the hypotalamic ARCN level and induce hypothalamic-hypophyseal-adrenal-thymus (HHAT) axis disturbances.

Experimental and control group of animals included 10 Wister rats each. Experimental group animals were treted with MSG (4 mgMSG/g BW) on their 2,4,6,8 and 10 day of postnatal life. From each, experimental and control group five animals were sacrificed 7 days after MSG treatment, the aim was to investigate histopathologic changes in thymus. Rest of the animals were sacrificed 6 months after MSG treatment, for analisis of histopathologic changes in ARCN and adrenal gland. Paraffin sections of the hypothalamic tissue, adrenal gland and thymus were hematoxilin-eosin (HE) and PAS stained.

Macroscopiclly, the treated animals demonstrate skeletal development arest and Cushingoid type of obesity („buffalo type“).

Histopathologic analysis of ARCN in experimental animals demonstrate significantly reduced number of neurons. Other cells express degenerative changes in the form of pycnotic nuclei. Adrenal glands demonstrate hyperplasion of the cortex, with significantly enlarged fascicular and reticular zone, while adrenal medulla exibit haemorogic necrosis. On thymus level of the experimental animals we can find depletion of thymocites in cortex, while in medulla exists haemoragia with destruction of normal tissue. These findings suggest the impaired HHAT axis function in newborn rats treated with monosodium glutamate.

Key words: monosodium glutamate, nucleus arcuatus, adrenal gland, thymus 06-145 EFFICIENCY OF ANTIVIRAL THERAPY IN PERSONS WITH HEMOPHYLIA AND HEPSTITIS C VIRAL INFECTION

!"#$%&' ()*+, 2011, ,-.-/%"%&" ' 0."1&2/3%-45 67.5#'5 No1

!

N.Ristic, M.Jovanovic, D.Zdravkovic, N.Stojkovic full-time professor V.Kostic School of medicine University In Nis Introduction: HCV infection was common cause of morbidity and mortality in patients with hemophilia before 1986.

The Aim: We wanted to investigate the effect of treatment with combination therapy in HCV positive patients with hemophilia.

Materials and Methods: The research included totally 13 persons afflicted with hemophilia and HCV infection out of 21 tested. Parallel with this subcategory the other one was put into comparison, consisiting of 12 patients afflicted with chronic C hepatitis, marked as non-hemophilics. The both subcategories were treated with combination antiviral therapy (peginterferon !-2a and ribavirin) during 48 weeks for genotype 1 and 4, in reference to 24 weeks for genotype 2 and 3. Within the treatment, clinical and laboratory side-effects were noticed, which did not require therapy interruption. A more frequent hemorrhage during the therapy was found within the hemophilics, rather than before initiliazing it.

Results: After the statistical processing of the results (Students t-test), statistically significant difference among these two subcategories was noticed as values for ALT ("""p<0,0001) after 24 weeks of therapy, red blood cells ("p<0,05), haemoglobin and haematocrite ("""p<0,0001) 24 weeks after therapy completing. By PCR examination of the patients, 6 months after the end of treatment, a sustained viral response (SVR) of the same percentage was registrated within both categories.

Conclusion: HCV positive patients patients with hemophilia could be successfully treated with combination therapy of peginterferon alfa-2a and ribavirin.

Key words: Hepatitis C, Hemophilia A; Polymerase Chain Reaction; Antiviral Agents.

06-185 DETERMINATION OF PB AND CD CONTENTS IN INFUSION SOLUTIONS AND SOLUTIONS FOR HEMODIALYSIS K.Milincic, B.Zivkovic, M.Jovanovic Assistant D.Velimirovic, professor Kalicanin Biljana Medical Faculty For treatment of severe clinical disease and the condition in medical practice, there are often used parenteral solutions for hemodialysis, solutions for correcting the imbalance of electrical and fluid replacement.

These solutions can be directly or indirectly reach to the circulation of the blood by injection or after application through the body cavities. Therefore, it is necessary to be sterile, isotonic and non-toxic. The aim of the study was the investigation of consistency of toxic hard metals (Pb and Cd) in infusion solutions and solutions for hemodialysis. Contents of hard metals were determined by a highly sensitive technique, by potentiometric stripping analysis (PSA). Contents of Pb in infusion solutions (NaCl, hetasorb 6 %) ranged from 2.89 to 6.05 #g/L, whereas in solutions for hemodialysis contents of Pb and Cd were 27 #g/L and 4.17 #g/L, respectively. With regard to fact that these solutions enter the circulation of the blood directly, or indirectly in contact with blood and other corporeally fluids of patients, it is necessary to constantly investigate and determinate the contents of hard metals, considering their toxicic and cumulative effect. This is particularlyimportant in cases where these solutions and systems are used for longer period of time (Hemodialysis) when toxic effects of the tested elements more pronounced and effects on clinical condition of patients.

Key words: infusion solutions, solutions for hemodialysis, Pb, Cd, potentiometric stripping analysis. !

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

N*/=. O77/*25+(3= +/,G1,* @*/*0507,4( 1( 7,73*B8 (13,507,2(1315> F(P,3A I;, (2;*1(/,15+A> GF+* H*/820( + I*)*1, 0;A7. $(3*;,(/A , B*352A. O77/*25+(1,G I;5+52,/,7= 1( 0;A7(' B(775> 180-220 6. Q,+531A* 4A/, ;(F2*/*1A 1( 3;, 6;8IIA: R - 15 ,13(031A' 0;A7, II - 20 0;A7 7 (2;*1(/,15+5> GF+5> H*/820(, +AF+(11(G ++*2*1,*B (2;*1(/,1( 10 B6/06 B(77A +183;,4;LJ115, III - 15 H,+531A' 7 M35> H* I(35/56,*>, 0535;A' /*),/, ++*2*1,*B @*/*0507,4( + 25F* 10 B6/06.

E03,+1573= 78I*;507,22,7B83(FA (-9C) 5I;*2*/G/, I5 B*3528 S*+(;, -. (1991), (03,+1573= 0(3(/(FA (TEU) - I5 B*3528 T5;5/L0( (1988), 752*;H(1,* +5773(15+/*11565 6/83(3,51( (DV) - I5 B*3528 ElmanE. (1992), (03,+1573= 6/83(3,51;*2803(FA (DW) - I5 B*3528 X78I5+( <. Y. (1988), 6/83(3,51I*;507,2(FA (D:) - I5 B*3528 :*;*7/*6,15> O. E. (1989). :5/8)*11A* ;*F8/=3(3A 73(3,73,)*70, 54;(453(1A 7 I5B5P=L t-0;,3*;,G -3=L2*13(.

W*F8/=3(3A. ?(4/L2(/, 8+*/,)*1,* (03,+1573, -9C + 1,5 ;(F(, I;, /*)*1,, @*/*0507,45B M353 I50(F(3*/= 71,H(/7G + 1,1 ;(F( , (03,+1573= TEU + 2,5 ;(F(, I;, /*)*1,, (03,+1573= TEU 71,F,/(7= + 5,9 ;(F(. ?(4/L2(/57= 71,H*1,* 8;5+1G DV +5 II 6;8II* + 2,6 ;(F(, I;, /*)*1,, 752*;H(1,* DV I;,4/,H(/57= 0 15;B* , I5+AJ*1,* (03,+1573, D: +5 II 6;8II* + 1,9 ;(F(, I;, /*)*1,, (03,+1573= K*;B*13( 7553+*37+5+(/( 0513;5/L. E03,+1573= DW 1(,45/** +5F;57/( +5 II 6;8II* (+ 1,5 ;(F(), I;, /*)*1,, 51( I;,4/,H(/(7= 0 15;B*.

VA+52A. :5/8)*11A* ;*F8/=3(3A 7+,2*3*/=73+8L3 5 35B, )35 /*)*1,* @*/*0507,45B +AFA+(*3 I5/5H,3*/=15* +/,G1,* 1( 7,73*B8 (13,507,2(1315> F(P,3A I83*B 4/50,;5+(1,G -9.-2.

CELECOXIB INFLUENCE ON THE ANTIOXIDATIVE DEFENCE SYSTEM IN LIVER OF RATS WITH EXPERIMENTAL GASTRIC ULCERS M.Ya.Ukhachevych, S.Khalak Cand.Sci.(Bio), assistant proffesor O.P.Khavrona Danylo Halytsky Lviv National medical university, Lviv, Ukraine Actuality. One of mechanisms of gastric ulcer is increasing neutrophils and monocytes infiltration of mucosa membrane. Neutrophils and monocytes secrete inflammatory cytokines and oxygen radicals after their activation, that resulting in increased expression of NO-synthase (NOS), COX-2 and lipid peroxidation processes intensification.

Goal. To study the celecoxib influence on the antioxidative defence (AOD) systemin case of adrenaline gastric ulcer in rats liver.

Materials and methods. Ten white male rats with the weight of 180-220g have been studied. Animals were divided into three groups: I - 15 intact rats; II - 20 rats with adrenaline gastric ulcer, that was provoked by intraperitoneal adrenaline injecting at the ratio of 10 mg/kg;III - 15 rats with the same pathology that were treated by celecoxib injecting at the ratio of 10 mg/kg. For the catalase (CAT) activity determination the Koroluk M. method (1988)has been used, for the estimating the superoxidedismutase (SOD) activity – the Chevari S. method (1991), reduced glutathione (GSH) content – by Elman E. method (1992), glutathione reductase (GR) activity – Jusupov L.B. method (1988), glutathione peroxidase (GP) activity – Pereslegina I.A. method (1989).

Results. Increasing SOD activity by 1.5 times and decreasing CAT activity by 2,5 times was observed. In case of celecoxib treatment SOD activity decreased by 1,1 times, CAT activity decreased by 5,9 times.

ThedecreaseofGSH level in II group by 2,6 times has been observed. In the case of treatment GSH content decreased by 0,2 times. GP activity growth by 1,9 times in II group, but during the treatment enzyme activity was approximate to normal.

GR activity increased most in IIgroup by 1,5 times, during the treatment enzyme activity was approximate to normal.

Conclusion. The research results show a positive effect of celecoxib treatment on AOD system. Effect occurs throughCOX-2inhibition. !

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

N*/= ,77/*25+(1,G - +AG+,3= +5F;(731A* ,FB*1*1,G ),7/*11573, ?TU 8 /,@ 7 7('(;1AB 2,(4*35B II 3,I( (-CII). :;, M35B F(45/*+(1,,, I;53*0(LP*B 8 /,@ 73(;J* 60 /*3 1( K51* 05B5;4,21573,, 78P*73+*118L ;5/= ,6;(L3 +57I(/,3*/=1A* I;5@*77A. ?TU 5I;*2*/G/, B*3525B I;535)15> @,35K/85;5B*3;,, 1( I;,45;* FACSCalibur 7 ,7I5/=F5+(1,*B 73(12(;315> 05B4,1(@,, B5150/51(/=1A' (13,3*/ 7 2+5>15> K/85;5';5B15> B*305> CD3FITC/CD56/CD16PE (K,;B( BectonDickinson). O77/*25+(/, 54;(F@A 0;5+, I(@,*135+ 7 -CII K,/,(/( WD$& «?TN

"#! !

!"#$%& «'"(%#)-*%)+),%-".#%" /0)*+"12»

! !"#$%&$'$!((».)#*+%(+*'( ,$-*.*&"'( / ,*0("%&$+ + +$.#*1&" 60-69'"& (9 2"'$+"-, !#/,,* 1) ( 70-79 '"&(10 2"'$+"-, !#/,,* 2). 3*%%4" ,#"51&*+'"%4 ,$ 1#"5%(6 *#(76"&(2"1-(6 ( ,$ 2*1&$&" +1&#"2*"6$1&( ,#(.%*-* (%). )#"5%(8 ,#$0"%& 1$5"#9*%(: ;<= + -#$+( 1$1&*+(' + !#/,," 1 4,3+2%, + !#/,," 2 – 11,1+3,2. > $?"(@ !#/,,*@ ,$+4A"%%48 ,$-*.*&"'B ;<= +1&#"2*'1: 1 $5(%*-$+$8 2*1&$&$8 (/ &#"&( $?1'"5$+*%%4@) =*-(6 $?#*.$6, / ?$'B%4@ c )3 II 1 +$.#*1&$6 /+"'(2(+*"&1: ,#$0"%& ;<=. C&( (.6"%"%(: 6$!/& ?4&B 1+:.*%4 %" &$'B-$ 1 +$.#*1&$6, %$ ( 5'(&"'B%$1&BD ( &:9"1&BD .*?$'"+*%(:, 2&$ 1&*+(& +$,#$1 $ ,#$5$'9"%(( (11'"5$+*%(8 %* ?$'BA"6 -$'(2"1&+" ,*0("%&$+ ( 1#*+%"%(( #"./'B&*&$+ 1 !#/,,$8 -$%&#$':.

THE QUANTITATIVE CHARACTERISTIC NATURAL KILLER TCELLS AT PATIENTS WITH A DIABETES OF II TYPE E.G.Galkina, E.Sorokina Professor L.V.Gankovskaya Russian State Medical University, Moscow, Russia Natural killer T-cells (NKT) concern cells of system of congenital immunity and play are important role in development chronic inflammatory processes.

Contribution NKTcells to immune processes is bound to early development of interferon by them scale and other cytokines, and also with cytotoxicity implication. In norm their percentage in a peripheric blood shouldn't exceed 5 %. Norm excess bind to long chronic inflammatory processes.

Research objective - to tap age changes of number NKT at persons with a diabetes of II type . At this disease proceeding at persons is more senior 60 years the essential role is played by inflammatory processes.

NKT defined a method flowing cytofluorometry on device FACSCalibur with use of a standard combination of monoclonal antibodies with double fluorochrome label CD3FITC/CD56/CD16PE (firm Becton Dickinson).

Samples of a blood of patients witha diabetes of II type branch RGMU «NII gerontologies». Comparedindicators at patients aged 60-69'"& (9 persons, group 1) and 70-79 years (10 persons, group 2). The data is presented on averages arithmetic and on frequency of occurrence of a sign (%).

The average percent of maintenance NKTin a blood has made in group 1 4,3+2 %, in group 2 – 11,1+3,2. In both groups the raised indicator ;<= met identical frequency (at third surveyed) Thus, at patients with a diabetes of II typepercent ;<= with the years is enlarged. These changes can be bound not only with the years, but also duration and gravity of disease that brings an attention to the question on continuation of researches on larger quantity of patients and comparison of results with group of screening.

06-305 !"#$%&'$()*!+ ,+*$-!#!.$()*!/ 0%/ 0$1)')-+%&"-() 2!,.)3!!

4-)22$( STAPHYLOCOCCUS AUREUS 2+506 7!$-$#)2! $.,)*!'2) 6 0+-+8 " )-$#!9+"1!2 0+.2)-!-$2 E.>.F*,'(% 5.6.%., ,#$7"11$# G.E.H7(6$+, -.6.%., 1. %. 1. E.;.I-$,$#$+ J$11(81-(8 K$1/5*#1&+"%%48 L"5(0(%1-(8 M%(+"#1(&"&, L$1-+*, J$11(: <$'$%(.*0(: -$9( ?*-&"#(:6( +(5* Staphylococcusaureus + %*1&$:N"" +#"6: 12(&*"&1: $5%(6 (. %*(?$'"" +*9%4@ 7*-&$#$+ ,*&$!"%".* *&$,(2"1-$!$ 5"#6*&(&*. ;(.-(8 O77"-& *%&(?*-&"#(*'B%$8 &"#*,(( $?P:1%:"&1: +41$-$8 1-$#$1&BD #"-$'$%(.*0(( -$9(. )2(&*"&1:, 2&$ ,$'$1&B %$1* 6$9"& +41&/,*&B -*- #"."#+/*# S. aureus, $?"1,"2(+*: #"-$'$%(.*0(D. > 5*%%$8 #*?$&" +45+(%/&$ ,#"5,$'$9"%(" $ #$'( -(A"2%(-* -*- #"."#+/*#*. >45"'"%(" (5"%&(2%4@ A&*66$+ (. -$9( ( ,$'$1&( %$1*, ('( (. -$9( ( -(A"2%(-* 6$9"& 1'/9(&B 5$-*.*&"'B1&+$6 +$.6$9%$1&( 6(!#*0(( A&*66$+ 6"95/ O&(6( ?($&$,*6(. Q. !#/,,4 19 5"&"8 1 *&$,(2"1-(6 5"#6*&(&$6, / +1"@ (.

-$&$#4@ -$9* -$'$%(.(#$+*%* S. aureus, / 18 1#*+%(+*'(1B A&*664 (.

164+$+ 1 -$9( ( 164+$+ (. ,$'$1&( %$1*, ( / 18 – (. A&*664 (.

164+$+ 1 -$9( ( (. 7"-*'(8. >45"'"%%4" A&*664 1&*7('$-$--$+ -/'B&(+(#$+*'(1B %* 1"'"-&(+%$8 ,(&*&"'B%$8 1#"5", (5"%&(7(0(#$+*'(1B 1 ,#(6"%"%("6 -*&*'*.%$!$ &"1&*, -$*!/'*.%$!$ &"1&*, * &*-9" ?($@(6(2"1-$8 (5"%&(7(-*0(( 1 ,$6$NBD API 20 Staph. I&*664 S. aureus 1#*+%(+*'(1B *%*'(.$6 &"6,"#*&/# ,'*+'"%(: #"!($%* X !"%* 1&*7('$-$--$+$!$ ?"'-* E ( *%*'(.$6 5'(% /2*1&-$+ 6"95/ !"%*6( 16s #J;< ( 23s #J;<. S. aureus ?4' +45"'"% (. 164+$+ (. ,$'$1&( %$1* / 94,4% (17/18) ,*0("%&$+, 1$+,*5"%(" 1 -$9%46( A&*66*6( $&6"2*'$1B / 77,8% (14/18) ,*0("%&$+, (. 7"-*'(8 – / 88,9% (16/18) ( 50% (9/18) 1$$&+"&1&+"%%$. >"#$:&%$1&( 1$+,*5"%(8, ,#"51-*.4+*"64" &"$#"&(2"1-$8 6$5"'BD %".*+(1(6$8 -$'$%(.*0(( 13,7% 5': ,$'$1&( %$1* ( 8,8% 5': -(A"2%(-*. C-1,"#(6"%&*'B%4" 5*%%4" ,#$&(+$#"2*& !(,$&"." %".*+(1(6$8 -$'$%(.*0(( ( /-*.4+*D& %* +$.6$9%$1&B 6(!#*0(( A&*66$+ 6"95/ -$9"8, ,$'$1&BD %$1* ( -(A"2%(-$6.

"#! !

USING GENOTYPING TO PROVE A MIGRATION OF STAPHYLOCOCCUS AUREUS STRAINS BETWEEN BIOTOPES OF THE ORGANISM IN INFANTS WITH ATOPIC DERMATITIS A.V.Chaplin Professor B.A.Efimov, Cand.Sci.(Med.), Senior researcher A.N.Shkoporov Russian State Medical University, Moscow, Russia Today the colonization of skin by Staphylococcus aureus is known as one of the most important factors of the pathogenisis of atopic dermatitis. A low effect of antibacterial therapy is explained by a high speed of skin recolonization. It is considered that the nasal cavity may act as a reservoir of S. aureus and provide this recolonization. In this work the supposition about the reservoir role of the intestine is made. An isolation of the identical strains from the skin and the nasal cavity, or from the skin and the intestine may be an evidence of a possibility of strain migration between these biotopes. From the group of 19 infants with atopic dermatitis, all of whom harboured S. aureus on their skin, strains from skin swabs and nasal swabs had been compared in 18 infants, strains from skin swabs and feces had been compared in 18 infants.Staphylococcal strains had been cultured on the selective media, and identified by the catalase test, coagulase test and biochemical identification using API 20 Staph. The strains of S. aureus had been compared by the analysis of melting temperatures of the X region of staphylococcal protein A gene and by the analysis of the lengths of spacers between 16s rRNA and 23s rRNA genes. S. aureus had been was isolated from the nasal swabs in 94,4% (17/18) patients,coincidence with the skin strain had been registered in 77,8% (14/18) patients, from the feces - 88,9% (16/18) and 50% (9/18) respectively. The probabilities of coincidence predicted by a theoretical model of independent colonization are 13,7% for nasal cavity and 8,8% for intestine. The experimental data run contrary to the model of independent colonization and testify the possibility of strain migration between skin, nasal cavity and intestine.

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

U?P"-&$6 (11'"5$+*%(: 1'/9('( '"8-$0(&4, ,$'/2"%%4" (. -#$+( .5$#$+4@ 5$%$#$+ (n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±10 ,-!/6', TGFW1 - 5830±710 ,-!/6'. <$%0"%&#*0(: HNP 1-3 1$1&*+('* 1,8±0,8 %!/6'.

S$'/2"%%4" #"./'B&*&4 ,$.+$':D& 15"'*&B +4+$5, 2&$ 5': O77"-&(+%$!$ ,#(6"%"%(: (%5(+(5/*'B%$!$ -$6,'"-1* (66/%$,",&(5$+ 1 '"2"?%$8 0"'BD 0"'"1$$?#*.%$ $,#"5"':&B O-1,#"11(D 0(&$-(%$+ ( ,#$&(+$6(-#$?%4@ ,",&(5$+ -*- %* /#$+%" !"%$+, &*- ( %* /#$+%" ?"'-$+4@ 6$'"-/'. 3*%%*: #*?$&* ,#$+$5(&1: #*6-*@ S;J2 "S"#1$%*'(.(#$+*%%*: 6"5(0(%*" STUDY OF CYTOKINES AND ANTIMICROBIAL PEPTIDES GENE EXPRESSION DYNAMICS IN WHITE BLOOD CELL CULTURE FROM HEALTHY DONORS; A PERSONALIZED APPROACH Yu.V.Aitova

!"#$%&' ()*+, 2011, ,-.-/%"%&" ' 0."1&2/3%-45 67.5#'5 No1

!

Professor L.V.Gankovskaya Russian State Medical University, Moscow, Russia Currently lots of attention is paid to an individual approach to patient treatment. One of the important functional indicators of his immune system is the level of immunopeptides in peripheral blood. A new method of personalized immunotherapy was developed at the Department of Immunology, RSMU, and its basic principle comprises the local application of the natural composition of cytokines and antimicrobial peptides secreted by patient‘s autologous white blood cells. Local injection of immunopeptides has anti-inflammatory, antimicrobial and immunostimulative effects. The purpose of this work was to study cytokines and antimicrobial peptides gene expression dynamics in white blood cell culture from healthy donors to support a personalized approach to immunotherapy.

The object of the study were white blood cells obtained from blood of healthy donors (n = 15). White blood cells were grown for 3, 24 and 48 hours and the expression level of cytokine genes and HNP-1 was studied with RT-PCR. At the same time immunopeptides concentration in cell cultures was determined using enzyme immunoassay. The study shows that the level of proinflammatory cytokines (IL-1!, IL-6, TNF", etc) gene expression reaches its maximum in 3 hours of growth and decreases in 24 hours. The level of anti-inflammatory cytokines (IL-10, TGF) gene expression remains high during almost 48 hours. Gene expression of IFN" decreases in 3 hours and regains in 24 hours of growth. The cytokine concentration in the supernatant of 24 hour white blood cell cultures was as follows: TNF 20 ± 10 pg/ml, TGF!1 - 5830 ± 710 pg/ml. The concentration of HNP 1-3 was 1.8 ± 0.8 ng/ml.

The results obtained suggest that it is advisable to determine the expression of cytokines and antimicrobial peptides both at level of genes and protein molecules at first for efficient use of individual complex of immunopeptides for therapeutic purposes.

06-270 !"#$%&'()*%#+ ,-(%.# /00(.'&$%,!'& "#1)&2%34 5(',6,$ )(2(%&+ 7,)*%34 ,!'",8 6&1(%'("&(8 #.$.%&'()*+,++-. /,01+220,/&0340, 5+&'6'723'8 7.93 :.;.%85+&0:.*+24.723.< =029&.,24-+77.< 5+&'6'723.< .3.&+5'<, >.8.?3.(., ;022'< @'*+((+AB A.7'5.C4 29D+24-+770+ 5+240 - E4'0(0*'?+230F 24,9349,+ 024,B8 3'G+?7B8 '71+36'F -0 -2+5 5',+. H+()C 7.G+*0 '22(+&0-.7'< <-'(02) 'A9?+7'+ E11+34'-7024' 70-0*0 04+?+24-+770*0 '5597050&9(',9CD+*0 /,+/.,.4.

29/+,('51, 0I(.&.CD+*0 /,04'-05'3,0I7B5 ' /,04'-0-02/.('4+()7B5 &+F24-'+5 - (+?+7'' I0()7B8 J:. $0& 7.I(C&+7'+5 7.80&'('2) 138 I0()7B8 J:, 3040,B+ 5+40&05 2(9?.F70F -BI0,3' IB(' ,.A&+(+7B 7. 2 *,9//B, ,.-706+77B+ /0 /0(9, -0A,.249, 4<K+24' 4+?+7'< ' E4'0(0*'' A.I0(+-.7'<. I *,9//. – 70 I0()7B8 /0(9?.(' 4,.&'6'0779C 4+,./'C, -3(C?.CD9C E4'04,0/70+, /.40*+7+4'?+230+ ' 2'5/405.4'?+230+ (+?+7'+, II *,9//. – 68 I0()7B8 /0(9?.(' - 305/(+32+ 2 4,.&'6'077B5 (+?+7'+5 29/+,('51. L I0()7B8 II *,9//B 203,.D.(.2) &('4+()7024) ('80,.&3', 3040,.< 2024.-(<(. 2,5±0,11 &7<, 40*&. 3.3 - I *,9//+ 3,4±0,29 &7< (;<0,05). M,+&7<< /,0&0(K'4+()7024) &'219736'' 3'G+?7'3. -0 II *,9//+ 2024.-(<(.

3,4±0,12 &7<, ?40 IB(0 &0240-+,70 7'K+, ?+5 - I *,9//+ (;<0,05). N0(' - K'-04+, 2/.A5 2'*50-'&70F 3'G3', 0ID.< 2(.I024) /,080&'(' ,.7)G+ 9 I0()7B8 II *,9//B. %7.405'?+230+ -BA&0,0-(+7'+ 9 I0()7B8 II *,9//B 7.249/.(0 7. 1,3 &7< ,.7)G+, ?+5 9 I0()7B8 I *,9//B (;<0,05). $,0-0&'5.< 4+,./'< 03.AB-.(. -('<7'+ 7. 2,03' 0?'D+7'< 0,*.7'A5. 04 -0AI9&'4+(< ' /,+IB-.7'+ - 24.6'07.,+. $0(70+ I.34+,'0(0*'?+230+ 0?'D+7'+ 0,*.7'A5. 7.249/.(0 ,.7)G+ 9 I0()7B8 II *,9//B (;<0,05). M,+&7'F 30F30-&+7) 9 I0()7B8 I *,9//B 2024.-(<( 8,2±0,36, ?40 7. 1,1 &+7) &0()G+, ?+5 9 I0()7B8 II *,9//B, *&+ E404 /03.A.4+() 2024.-(<( 7,1±0,23 (;<0,05). O.3'5 0I,.A05, 2,.-7'4+()7.< 06+73. E11+34'-7024' ,.A('?7B8 5+40&0- (+?+7'< I0()7B8 J: -B<-'(. /,+'59D+24-. 305/(+3270F 4+,./'' 2 -3(C?+7'+5 70-0*0 04+?+24-+770*0 '559704,0/70*0 /,+/.,.4.

29/+,('51, 0I(.&.CD+*0 /,04'-05'3,0I7B5 ' /,04'-0-02/.('4+()7B5 &+F24-'+5.

THE COMPARATIVE VALUATION OF THE EFFICIENCY OF DIFFERENT METHODS OF FRAGMENT OF THE PATIENTS WITH ACUTE DYSENTERY E.P.Adilgereeva Professor/Dr.Sci.(Med.) D.R.Akhmedov Dagestan State Medical Academy, Makhachkala, Russia Shigellosis ranks high among the etiologic structure of the acute intestinal infections all oves the world. In spite of the achieved success in the treatment of acute dysentery (AD) the efficiency of many antibacterial

preparations reduces owing to increasing spreading of polyresistant shigella strains. The main object our investigation was the study of the efficiency of the new home produced immunomodulatory preparation Super lymph, with antimicrobial and anti-inflammatory action in the treatment of the patients with AD. We supervised 138 patients with AD, which were freely divided into two groups’ equivalent in sex age, severity and ethyology of the disease. The first group - 70 patients were instituted the traditional therapy, including ethiotropical, pathodenetic and symptomatic treatment. The second group 68 patients got super lymph in addition to the traditional therapy. The fevers duration in the second group was 2,5±0,11 days lees, than in the first group 3,4±0,29 (P<0,05). The average duration of intestinal dysfunction in the second group was 3,4±0,12 days, that was for certain lower, that in the first group (P<0,05). Abdominal pains, sigmoid colon spasm, general weakness passed larlies with the second group. Anatomical recovery ensured in the second group 1,3 day larlies than in the first group (P<0,05). The instituted therapy influenced on both the term of clean sing from causative agent and hospital stay. Full bacterial cleansing of the organism ensured earlier in the second group (P<0,05). The average length of hospital stay in the first group was 8,2±0,36 day, which was1,1 day longer, that with the patients in the second group, where it was 7,1±0,23 (P<0,05). Thus the comparative valuation of the efficiency of different methods of treatment of the patients with AD, gained the advantages of combined treatment with the new home – produced immunomodulatory preparation. Super lymph with antimicrobial and anti-inflammatory action.

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– 'A9?'4) -0A50K7024) 24'59(<6'' ,+*+7+,.6'' 5BG+?70F 43.7' A.&7'8 307+?7024+F 3,B2 7. 50&+(' S%T /94U5 4,.72/(.74.6'' MQ$Q ?+(0-+3.. ;.I04. -B/0(7+7. 7. m. gastrocnemius 3,B2 2 97'(.4+,.()70F 'G+5'+F A.&7+F 307+?7024', -BA-.770F /+,+2+?+7'+5 I+&,+77B8 .,4+,'' ' -+7B. V+,+A &-+ 7+&+(' /02(+ 0/+,.6'' 20 3,B2.5 /,0'A-0&'(' -794,'5BG+?79C 4,.72/(.74.6'C 28106 5070793(+.,0- $Q ?+(0-+3.

- 0I+ A.&7'+ 307+?7024', /<4' 3074,0()7B5 3,B2.5 --0&'(' 1'A'0(0*'?+23'F ,.24-0,. W.I0, 0,*.70- /,0'A-0&'(' ?+,+A 2, 5, 7, 14, 28 &7+F /02(+ 4,.72/(.74.6''. $.,.1'70-B+ 2,+AB 5BG+?70F 43.7' 03,.G'-.(' '55970*'2408'5'?+23' 2 -'&02/+6'1'?7B5' .74'4+(.5' 3 HLA-ABC (&(< -B<-(+7'< 3(+403 ?+(0-+3.), CD34 ' 1.340,9 107 P'((+I,.7&4. (5.,3U,.5 E7&04+('06'40-) ' 5'0*+7'79 (5.,3U,9 .34'-',0-.77B8 5'02.4+(('40-). >0,10(0*'?+23'F .7.('A /03.A.(, ?40 MQ$Q ?+(0-+3. 208,.7<C42< &0 14-*0 &7< /02(+ --+&+7'<. $,' E405 /,0'280&'4 '8 &'11+,+76',0-3. E7&04+('F 3./'((<,0- (2-+ 2943') ' 2029&0- (14 29403), . 4.3K+ 07' 9?.24-9C4 - 5BG+?70F ,+*+7+,.6'' /94+5 &'11+,+76',0-3' .34'-',0-.77B+ 5'02.4+(('4B (7 2943'). $,' --+&+7'' - A&0,0-9C 307+?7024) ?+(0-+?+23'+ MQ 0I7.,9K'-.C42< - 4+?+7'+ 2-8 29403.

MQ$Q ?+(0-+3. 9?.24-9C4 - ,+*+7+,.6'' 5BG+?70F 43.7' 3,B2 2 S%T 7'K7'8 307+?7024+F, &'11+,+76',9<2) - E7&04+('F 3./'((<,0' 2029&0- ' .34'-',0-.77B+ 5'02.4+(('4B. IMMUNOHISTOCHEMICAL ANALYSIS OF RAT SKELETAL MUSCLES AFTER UMBILICAL CORD BLOOD MONONUCLEAR CELLS TRANSPLANTATION IN MODEL OF PERIPHERAL ARTERIAL DISEASE M.O.Mavlikeev, A.V.Tabanakova, A.A.Trondin, M.S.Kaligin, I.M.Gazizov, A.A.Gumerova Prof. A.P.Kiassov Kazan State Medical University, Kazan, Russia Peripheral arterial diseases (PAD) occupy important position in structure of cardiovascular diseases. Recent studies showed high efficiency of stem cells (SC) therapy for PAD. One of the most perspective sources of SC is umbilical cord blood (UCD). For clinical application of new method further investigations revealing molecular mechanisms of cell interactions are needed. The aim of investigation was to study the possibility to stimulate

"#! !

!"#$%& «'"(%#)-*%)+),%-".#%" /0)*+"12»

! skeletal muscles regeneration of rats with PAD using human UCB SC transplantation.

The study was performed on m.gastrocnemius of rats with unilateral hind limb ischemia induced by dissection of femoral artery and vein. Two weeks after operation both hind limbs of 20 rats were injected intramuscularly with 2!106 human UCB mononuclears, 5 rats were injected with saline. Animals were sacrified and organs were obtained 2, 5, 7, 14, 28 days after transplantation. Paraffin-embedded slices of muscles were stained with antibodies against HLA-ABC (human cells marker), CD34 and von Willebrand factor (endothelial marker), myogenin (marker of activated myosatellites); antibodies used in study have no cross-reactions with corresponding rat antigens.

Morphological analysis of skeletal muscles showed persisting human UCB mononuclears up to 14th day after transplantation. They differentiate into endothelium of capillaries (2nd day after transplantation) and medium vessels (14th day after transplantation), also they take part in muscular regeneration through the differentiation into functionally active myosatellites (7th day after transplantation). In intact limb mononuclears are revealed 2 days after transplantation.

Thereby human UCB mononuclear cells take part in skeletal muscles regeneration of rats with hind limb ischemia by differentiation into endothelium of capillaries and vessels and activated myosatellites.

06-227 !"!#$% &'()*+(($$ $ ,-"'.$/"!#0"/1 !'2$3"/(2$ TOLL- )/4/5"67 *+.+)2/*/3 "!

8/"/"-'#+!*"67 '#+2'!7 - 5/#0"67 (/(2*68 )!"'*+!2$2/8 ".".#$%$&'($, ).).*%+,+&-' .'/+&0 -$1+.%2 3445&'6'733 8.).9'%+($ *:; )<: =*8; ='>?.%$($ ) @'>6+.&3+ 7'.2 $-03(&' 3?5,$+0>A $-03($/3A Toll-like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a ( '0(+0 &$ 637$&.2 TLR2 3 TLR4 –<* 3 63@'@'63>$!$%3. N<O, >''0(+0>0(+&&'. O'.+%D$&3+ LM:a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aranova, V.V.Grechenko Assoc. Prof. M.V.Khoreva Russian State Medical University In this time, role of TLR is studing actively. Toll-like receptors are activated by means exogenous ligands, but also endogenous ligands, such as DAMP (damage- associated molecular patterns). Extensive disease are following massive tissue damage and release of large quantity endogenous ligands.

High levels of endogenous ligands can lead to excessive activation of immune system, increase production of proinflammatory cytokines, development of systemic inflammatory disease and aftereffects of illness.

The purpose of the given research. To study expression andfunctional activity TLR on MNC peripheral blood of patients with acute destructive pancreatitis. Materials and methods. Basal TLR2 and TLR4 expression on OD14+ peripheral blood monocytes was estimated at dynamics (1,3,7,14 days) by flow cytometry. Functional activity TLR on MNC assessed on

"#! !

development of pro-inflammatory cytokine- TNFS. For an induction of development TNFS used ligands of TLR2 and TLR4 –PG and LPS, respectively. In supernatants MNC defined maintenance TNFS a method of immune-enzyme analysis. . The control group includedhealthy donors of the same age category. At patients with acute destructive pancreatitis we revealed raised stimulating activity of ligands of TLR2 and TLR4onproduction of TNFS in first day. This research demonstrates increased functional activity of these receptors.At 7 day stimulating influence was lowering, but it was preserve increased at patientswith severe disease. We didn’t revealed significant changes of expression TLR2 and TLR4in comparison with healthy donors. Conclusion.At patients with acute destructive pancreatitis we revealed increased offunctional activity TLR2 and TLR4at 1-3 days.We observed decrease of functional activity at finish of first week atpatientswith severe clinical course of disease.

06-194 !"!#$% !((/.$!.$$ !##+#0"/9/ )/#$8/*,$%8!

9+"!

IL7RA ( )*+4*!()/#/:+""/(20; ' *!((+<""/8- ('#+*/%).).#$Q3&>-$A -.C.&. :.*.P56$-'($, $>@3%$&0 ".T.G$%U($ ='>>3K>-3K *'>5.$%>0(+&&2K 8+.3/3&>-3K ;&3(+%>30+0, 8'>-($, ='>>3A =$>>+A&&2K >-6+%'? (=O) – .+43+63&3?3%5ER++ ?$C'6+($&3+ /+&0%$6F&'K &+%(&'K >3>0+42 @'637+&&'K @%3%'.2, %$?(303+ -'0'%'7' '@%+.+6A+0>A &+C'6FQ34 (-6$.'4 @'634'%1&2! ($%3$&0'( %A.$ 7+&'(. ) 3>>6+.'($&3A! @'>6+.&3! 6+0, ( 0'4 ,3>6+ @%3 @'6&'7+&'4&'4 @'3>-+ $>>'/3$/3K, (2A(6+&$ $>>'/3$/3A 7+&$ IL7RA, -'.3%5ER+7' S-/+@F %+/+@0'%$ 3&0+%6+K-3&$-7, > @%+.%$>@'6'D+&&'>0FE - =O. ) 0' D+ (%+4A B0$ $>>'/3$/3A 'C&$%5D+&$ &+ (' (>+! B0&3,+>-3! 7%5@@$!.

G+6FE &$Q+7' 3>>6+.'($&3A C26 $&$63? $>>'/3$/33 @'634'%13?4$ 7+&$ IL7RA > %$?(303+4 =O ( %5>>-'K B0&3,+>-'K 7%5@@+.

V&$63?3%5+4$A 7%5@@$ (-6E,$6$ 506 %5>>-3! C'6F&2! =O, -'&0%'6F&5E 7%5@@5 >'>0$(363 149 ?.'%'(2! %5>>-3! 3&.3(3.'(. *+&'4&$A IMP C26$ (2.+6+&$ 3? -%'(3 4+0'.'4 1+&'6-!6'%'1'%4&'K B->0%$-/33. V&$63? @'634'%13?4$ O/T ( 6 B-?'&+ 7+&$ IL7RA (SNPrs6897932) @%'('.363 4+0'.'4 $66+6+>@+/313,+>-'K @'634+%$?&'K /+@&'K %+$-/33. :0-6'&+&3+ &$C6E.$+42! ,$>0'0 7+&'03@'( '0 %$(&'(+>3A 9$%.3-)$K&C+%7$ @%'(+%A63 @' -%30+%3E >'76$>3A <3%>'&$. V&$63? $>>'/3$/33 @%'('.363 @' 0',&'45 -%30+%3E L3Q+%$, 3>@'6F?5A @%'7%$44&'+ 'C+>@+,+&3+ GraphPadInStat. )@+%(2+ '@%+.+6+&2 ,$>0'02 $66+6+K 3 ,$>0'02 &'>30+6F>0($ $66+6+K 3 7+&'03@'( 7+&$ IL7RA ( %5>>-'K B0&3,+>-'K 7%5@@+. I6A ,$>0'0 $66+6+K 3 7+&'03@'( ( 7%5@@$! ?.'%'(2! 3&.3(3.'( 3 C'6F&2! =O >'C6E.$+0>A %$(&'(+>3+ 9$%.3-)$K&C+%7$. W$>0'02 $66+6+K 3 7+&'03@'( IL7RA ?.'%'(2! %5>>-3! 3&.3(3.'( >''0(+0>0(5E0 ,$>0'0$4 $66+6+K 3 7+&'03@'( B0&'>'( X$@$.&'K "(%'@2 3 #$6-$&, &+-'0'%2! B0&'>'( V?33 3 '063,$E0>A '0 .$&&2!, @'65,+&&2! .6A $1%'$4+%3-$&>-'K 3 &37+%3K>-'K B0&3,+>-3! 7%5@@. O%$(&+&3+ ,$>0'0 $66+6+K, ,$>0'0 &'>30+6F>0($ $66+6+K 3 7+&'03@'( SNPrs6897932 7+&$ IL7RA ( 7%5@@$! C'6F&2! =O 3 ?.'%'(2! %5>>-3! 3&.3(3.'( &+ (2A(36' ?&$,342! $>>'/3$/3K @'634'%1&2! ($%3$&0'( B0'7' 7+&$ > %$?(303+4 =O ( %5>>-'K B0&3,+>-'K 7%5@@+.

M$Q3 %+?56F0$02 @'?('6AE0 @%+.@'6$7$0F, ,0' &$C'%2 7+&'(, ('(6+,+&&2+ ( %$?(303+ =O, 4'750 ($%F3%'($0F ( %$?&2! @'@56A/3A!.

ASSOCIATION ANALYSIS OF IL7RA GENE ALLELIC POLYMORPHISM WITH SUSCEPTIBILITY TO MULTIPLE SCLEROSIS V.V.Bashinskaya Cand. Sci. (Bio), Assoc. Prof. O.G.Kulakova, Cand.Sci.(Bio.) Student E.Yu.Tsareva Russian State Medical University, Moscow, Russia Multiple sclerosis (MS) is a polygenic demyelinating disease of the central nervous system. MS development is determined by a modest contribution of polymorphic variants of several genes. Association of IL7RA gene encoding the S-chain of receptor for interleukin-7 with MS susceptibility has been revealed in recent studies, including genome-wide association studies. However, this association is observed not in all ethnic groups.

The aim of our investigation was to study an association of IL7RA gene with MS development in Russian ethnic group.

The experimental group included 506 Russian MS patients, the control group consisted of 149 healthy Russian individuals. Genomic DNA was extracted from whole blood using a standard phenol-chloroform technique.

The analysis of polymorphism C/T in exon 6 of IL7RA gene (rs6897932) was performed by allele-specific polymerase chain reaction. Deviation of the observed genotype frequencies from Hardy-Weinberg equilibrium was estimated with chi-squaretest. Association analysis was carried out using the

!"#$%&' ()*+, 2011, ,-.-/%"%&" ' 0."1&2/3%-45 67.5#'5 No1

!

Fisher exact test calculated using GraphPad InStat software.

Allele frequencies, allele/genotype carriage frequencies were determined for Russian ethnic group for the first time. Allele and genotype frequencies among healthy individuals and MS patients were in Hardy-Weinberg equilibrium. Allele and genotype frequencies of IL7RA gene correspond to those of Western Europe and Balkan ethnicities, some Asian ethnicities and differ from data obtained for African Americans and Nigerians.

Comparison of allele frequencies, allele/genotype carriage frequencies of SNP rs6897932 in IL7RA gene between MS patients group and control group did not reveal any significant association of polymorphic variants of this gene with MS development in Russian ethnic group.

The results of our investigation suggest that gene sets involved in MS development may vary in different populations.

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

K;%@: .?0;1;%&/@ 2.'C;'/0$C&L 7M-1,6,8, N(O-P = I35.

4$/;0&$%+ & A;/.1+. H &--%;1.=$'&; =2%L*;'+ 91.0.=+; 1.'.0+ (15 *;%.=;2), 6.%@'+;, ?0.:.1&=E&; %;*;'&; - ?0&A;';'&;A 2%;/.*'+: /;:'.%.B&, = (77 8" <34( - 1&$B'.9.A "# (15 *;%.=;2) & 8# (5 *;%.=;2), ) =-;: 6+%. ?.%)*;'. &'D.0A&0.=$''.; 1.60.=.%@'.; -.B%$-&;. #.'C;'/0$C&L C&/.2&'.= 7M-1,6,8, N(O-P .?0;1;%>%& = I35 – -+=.0./2;, -.60$''., ?.-%; &'2)6$C&& 20.=& = /;*;'&; 4 *$-.= ?0& +37°5 = ?0&-)/-/=&& ?.%&3: Q & 2.'/0.%@'., -+=.0./2; 20.=& ?.%)*;''., ?.-%; &'2)6$C&& 20.=& = /;*;'&; 45 A&')/ ?0& 2.A'$/'., /;A?;0$/)0; (~20°5). <;9)%@/$/+ & .6-)F1;'&;. 5.1;0F$'&; 7M-8, 7M-6, N(O-P, 7M-1 = I35 )=;%&*;'. ?. -0$=';'&L -. -/$'1$0/'., -+=.0./2., 1.

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

PROINFLAMMATORY CYTOKINES IL-1,6,8, FNO - 1 AS A PART OF CELL PREPARATIONS FOR REGENERATION OF DAMAGED CORNEAL ENDOTELIUM. D.B.Kalinina Research assistant A.M.Subbot Scientific Research Institute of Eye Diseases Russian Academy of Medical Science, Moscow, Russia Cell therapy based on using activated leucocytes of a peripheric blood is successfully used for the treatment of damaged corneal endothelium - early postoperative bullous keratopathy (BK), severe herpetic keratitis (HK). Cell preparation consist ofleucocytes and Processed Autologous Serum (PAS)which is fed up with cytokines. Studyingrole of them inregeneration of damaged cornea is an actual problem.

The purpose: to define concentration IL-1,6,8, the TNF - P in the PAS. Materials and methods. Healthy donors (15 persons), patients passing treatment with cell therapy with diagnosis BK (15 persons) and HK (5 persons) in Scientific Research Institute of Eye Diseases Russian Academy of Medical Science are included in research, at all have been received the informed voluntary consent. Concentration of cytokines IL-1,6,8, TNF-P defined in the PAS – serum collected after an incubation of a blood within 4 hours at +37°5 at presence polyA:U and control blood serum - the serum received after an incubation of blood within 45 minutes at room temperature (~20°5).

Results and discussion. Maintenance IL-1,6,8,TNF-P in the PAS is enlarged in comparison with standard serum to the value corresponding to concentration of these cytokines in aqueous humour of the forward chamber of an eye at an inflammation (by data from references). It is known that

inhibition of mitotic activity of an endothelium occurs at the expense of contact interactions. In the literature it is described that high concentration IL-1,8,6, TNF-P breaksintercellular contacts in corneal endothelium. We assume that improvement of a functional condition of a cornea, observed in clinical researches, is mediated through putting off of contact inhibition of a mitosis in an endothelium in the presence of proinflammatory cytokines.

Thus, introduction IL-1,8,6, TNF-P in the forward chamber of an eye as a part of a cellular preparation is not dangerously, and, on the contrary, mediates therapeutic effect. !

06-178 $'(5,(* 6(%)#,#!#4#:,#6# HU :*'/& ACHOLEPLASMA LAIDLAWII,& 900*/)($,#%)+ )"&,%0*/.(( /'*)#/ '(,(( HEK-293 !'&;<(4,#8 4,/ I.3.".60.=-2&, -/$0E&, '$)*'+, -./0)1'&2 5.3.M;=&C2&, (77 N&9&2.-S&A&*;-2., 4;1&C&'+ N4"3 <.--&&, 4.-2=$, <.--&> I0&A;';'&; ?%$9A&1'+: =;2/.0.= = B;''.-2%;/.*'., /;0$?&& – .1&' &9 '$&6.%;; 6;9.?$-'+: A;/.1.= 1%> 2.A?;'-$C&& D)'2C&, B;'.=. <;E$LJ&A )-%.=&;A )-?;E'., B;'./;0$?&& >=%>;/-> .6;-?;*;'&; GDD;2/&='., /0$'9&;'/'., G2-?0;--&& 0;2.A6&'$'/'+: B;'.=. K;%@L ?0.=;1;''.B. &--%;1.=$'&> >=&%.-@ &9)*;'&; =%&>'&> 2.'1;'-&0)LJ&: 0;$B;'/.= '$ GDD;2/&='.-/@ %&?.D;2C&& !(#.

O1'&A &9 -?.-.6.= 2.'1;'-$C&& !(# >=%>;/-> ;; -=>9+=$'&; B&-/.'.?.1.6'+A 6;%2.A 6$2/;0&,. H :.1; 0$6./+ 6+% 2%.'&0.=$' B;' Hu 6;%2$ A.laidlawii = -.-/$=; G2-?0;--&.''.B. =;2/.0$, ?.%)*;' E/$AA-?0.1)C;'/ (E.coli) 0;2.A6&'$'/'.B. 6;%2$. <$90$6./$'$ .0&B&'$%@'$> -:;A$ ;B. .*&-/2&. !%> .C;'2& =%&>'&> B&-/.'.?.1.6'+: 6;%2.= 6+%. ?0.=;1;'. -0$=';'&; GDD;2/&='.-/& /0$'-D;2C&& 2%;/.2 HEK-293 2.'1;'-&0.=$''+A& & ';2.'1;'-&0.=$''+A& ?%$9A&1'+A& !(#.

TDD;2/&='.-/@ /0$'-D;2C&& .C;'&=$%$-@ - ?.A.J@L 2.'D.2$%@'., D%).0;-C;'/'., A&20.-2.?&& ?. &'/;'-&='.-/& D%).0;-C;'C&& A$02;0'.B. 6;%2$ GFP = 2%;/2$: HEK-293. I.2$9$'., */. ?0;1=$0&/;%@'$> 2.'1;'-$C&> ?%$9A&1'., !(# 0;2.A6&'$'/'+A B&-/.'.?.1.6'+A 6;%2.A -)J;-/=;''. (= 2-4 0$9$) )=;%&*&=$;/ GDD;2/&='.-/@ /0$'-D;2C&& G)2$0&./&*;-2&: 2%;/.2. <$90$6./$''+, ?.1:.1 A.F;/ 6+/@ &-?.%@9.=$' 1%> ?0.=;1;'&> B;''.-/;0$?;=/&*;-2&: ?0.C;1)0 invitro.

INFLUENCE OF HISTONELIKE HU PROTEIN OF ACHOLEPLASMA LAIDLAWII ON EFFECTIVITY OF HEK-293 CELLS. TRANSFECTION BY PLASMID DNA P.A.Bobrovskiy senior researcher S.A.Levitskiy Research Institute for Physico-Chemical Medicine of FMBA of Russia, Moscow, Russia One of the most safe and popular methods of gene’s function compensation in gene therapy is usage of plasmid vectors. The main term of a successful gene therapy is maintenance of effective transient expression of recombinant genes. The aim of the study was investigating the influence of condensing reagents on lipofection efficiency of DNA. One of the methods of condensing DNA is binding it with histonelike proteins of bacteria.

During the study, the gene of Hu protein of A.laidlawii was cloned into plasmid vector, strain-producer (E.coli) of recombinant protein was derived.

Original method of purifying synthesized protein was developed. To estimate the influence of Hu proteins comparison of effectivity of HEK-293 cells transfection by treated and untreated plasmid DNA was done.

Transfection effectivity was evaluated by fluorescent intensity of marker protein GFP.Fluorescent intensity was visualized by confocal fluorescent microscopy.It is shown that preliminary condensation of plasmid DNA by recombinant histonelike protein dramatically (in 2-4 times) increases transfection efficiency of eukaryotic cells. Such method can be used for carrying out of gene therapy procedures in vitro. !

06-160 $'(5,(* <*;*,3(<&'+,-3 %)$#'#$-3 /'*)#/ ,& $#%%)&,#$'*,(* 4$(6&)*'+,-3 ( /#6,()($,-3 0=,/.(8 6#'#$,#6# <#;6& /"-% !#%'* #%)"#8 9/%!*"(<*,)&'+,#8 (>*<(( O.U.V;=*;'2., <.4.<$1+2, 3.#)10>, 3.".,*;'2.

W$=. %$6.0$/.0&> 2%;/.*'.B. & /2$';=.B. 2)%@/&=&0.=$'&> 7(HS &A. H.#. 8)-$2$, 1.2/.0 A;1. '$)2I.?$'1.?)%.3'10;,8;''$1&;=&* 7'-/&/)/ ';./%.F'., & =.--/$'.=&/;%@'., :&0)0B&& &A. H.#. 8)-$2$, !.';C2, Q20$&'$ K;%@ &--%;1.=$'&>. 79)*&/@ =%&>'&; A;9;':&A$%@'+: -/=.%.=+: 2%;/.2 '$ =.--/$'.=%;'&; 1=&B$/;%@'+: & 2.B'&/&='+: D)'2C&, B.%.='.B. A.9B$ 20+- ?.-%; .-/0., G2-?;0&A;'/$%@'., &E;A&&.

4$/;0&$% & A;/.1+. 7--%;1.=$'&; ?0.=;1;'. '$ 45 91.0.=+: 20+-$:-$A2$: &'60;1'., %&'&& H&-/$0-#&./.. H=;1;'&; 2%;/.*'.B.

"#! !

!"#$%& «'"(%#)-*%)+),%-".#%" /0)*+"12»

! !"#$%&"'" ()*+$)#,'-'& , .$/0 !(.$'&%(,"/&- &1$!&&. 2&,(#/3$ 43'& %"5.$'$/3 /" 6 6%*77. 8%*773 9'$#(:/(; #$%"7&& (IIIA & III<) ) &/#%",$/#%&9*'-%/3! & 7"%$/#$%"'0/3! ,,$.$/&$! 9'$#(:/(6( !"#$%&"'". 8%*773 ) &/#%",$/#%&9*'-%/3! & 7"%$/#$%"'0/3! ,,$.$/&$! 0.9 % NaCl (IIA & II<). I 6%*77" - '(=/((7$%&%(,"//3$ =&,(#/3$. IV 6%*77" - &/#"9#/3$ =&,(#/3$. >$5*'0#"#3. ?('&:$)#,( 7$%$)$:$//3@ 9,".%"#(, /" 14-$ )*#9& , 6%*77"@ (X±A): I - 103,5±3,624, IIA - 19±3,254, IIB - 22±2,33, IIIA 98,5±3,684, IIIB - 92±3,107, IV - 103,9±1,078, :&)'( )#($9 /" 14-$ )*#9& , 6%*77"@: I - 6±0,7169, IIA - 1±0,394, IIB - 1±0,419, IIIA - 5±0,450, IIIB - 4,5±0,469, IV - 5±0,192. B%"9#&:$)9& 7('/($ ,())#"/(,'$/&$ 9(6/&#&,/3@ C*/9D&; , 6%*77$ III /" 14 )*#9&, ,( II 6%*77$ /$5/":&#$'0/($ *'*:1$/&$. E4+"- '$#"'0/()#0 =&,(#/3@: I 6%*77" 0, IIA – 40%, IIB – 70%, IIIA – 12,5%, IIIB – 25%, IV - 0. F"!3; ,3)(9&; *%(,$/0 )!$%#/()#& /" 3 )*#9& (71,4%) & 7 )*#9& (21,4%) , 6%*77"@ ) !(.$'&%(,"/&$! ()#%(; &1$!&& 6('(,/(6( !(56". <3,(.3. <())#"/(,'$/&$ 9(6/&#&,/3@ C*/9D&; 7%(&)@(.&# *=$ /" ,#(%*G /$.$'G /"4'G.$/&; , 6%*77"@ 9'$#(:/(; #$%"7&&. H , 6%*77"@ 4$5 ,,$.$/&- 9'$#(9 *'*:1$/&- /$ /")#*7"'(. I"9=$ , 6%*77"@ 9'$#(:/(; #$%"7&& ,3-,'$/( )*+$)#,$//($ )/&=$/&$ 7(9"5"#$'$; )!$%#/()#& =&,(#/3@.

MESENCHYMAL STEM CELLS INFLUENCE ON NEUROLOGICAL FUNCTIONS RECOVERY OF RATS BRAIN AFTER ACUTE EXPERIMENTAL ISCHEMIA O.Ya.Shevchenko, R.M.Radyk, A.Kudrya, A.Boichenko Director of Laboratory of cell and tissue culture IERS by named V.K. Husak, Dr.Sci (Med.)AndreyPopandopulo Institute of Emergency and Reconstructive Surgery named by V.K. Husak, Donetsk, Ukraine Researches aim. Mesenchymal stem cells influence on neurological functions recovery of rats brain after acute experimental ischemia.

Materials and Methods. The research has been performed on 45 healthy female rats of Wistar-Kioto inbreeding line. The delivery of the cell material was made on the day of ischemia modeling. The animals were divided in 6 groups. Cell therapy groups (IIIA and IIIB) with intraventricular and parenteral cell material delivery. Groups with intraventricular and parenteral 0.9 % NaCl delivery (IIA and IIB). The first group – false-operated animals. IV group – intact animals.

Results. Number of the crossed squares for 14 days in groups (X±A): I 103,5±3,624, IIA - 19±3,254, IIB - 22±2,33, IIIA - 98,5±3,684, IIIB 92±3,107, IV - 103,9±1,078, number of racks for 14 days in groups: I 6±0,7169, IIA - 1±0,394, IIB - 1±0,419, IIIA - 5±0,450, IIIB - 4,5±0,469, IV - 5±0,192. Almost completerecovery of cognitive functions in group for 14 days, while in group II a slight improvement at a later date. Overall mortality of animals: I group - 0, IIA – 40%, IIB – 70%, IIIA – 12,5%, IIIB – 25%, IV - 0. The highest death rate is necessary for 3 days (71,4%) and 7 days (21,4%) in groups with the modeling of acute cerebral ischemia.

Conclusions. The recovery of cognitive functions takes place already on the second week of observations in the cell therapy groups. In the groups without cell delivery there was no statistically significant improvement. The considerable reduction of animals rate mortality is also observed in the cell therapy groups. !

06-150 !"#$ %"%&'(%)"*" +,-)"!, . !,/.()(( 012!"'(%)!"+(31%-"*" 4!"51%%, . 41310( ( )"0-"2 -(6-1 0, +"01 0,!&610(7 .,*&%0"2 (001!.,5(( I.J.K"%"/&: 5", 9"C$.%(; 7%(C$))(% I.?.L*4(,">())&;)9&; 8()*."%)#,$//3; M$.&D&/)9&; N/&,$%)&#$#, M()9,", >())&O$'0G %"4(#3 -,&'()0 !(%C(C*/9D&(/"'0/($ &))'$.(,"/&$ PCC$9#" ,"6(#(!&& /" !&9%(6$-!(.&/"!&9* & )()#(-/&$ ,(./(6( (4!$/" , 7$:$/& (B) & #(/9(; 9&19$ (I?). Q9)7$%&!$/-#"'0/(; !(.$'0G )'*=&'" .,*@)#(%(//-- 7(..&"C%"6!"'0/"- ,"6(#(!&- * 9%3). R$%$5 1,7,14,30,60 & 220 )*# 7()'$ (7$%"D&& , *)'(,&-@ ()#%(6( (73#" 7('-%(6%"C&:$)9&! !$#(.(! (7%$.$'-'& /"7%-=$/&$ 9&)'(%(." (%E2) & )9(%()#0 !$)#/(6( 9%(,(#(9" (FM?) , 7"%$/@&!$ B & !31$:/(; (4('(:9$ I?. S" 6&)#('(6&:$)9&@ )%$5"@ &5!$%-'& 7'(+".0 )&/*)(&./3@ 9"7&''-%(, (, B) & .&"!$#% !&9%()()*.(, (, I?) ) 7(!(+0G !(%C(!$#%&:$)9(; #$@/&9&. F(.$%="/&$ (4+$; ,(.3 , (%6"/"@ (7%$.$'-'& ,$)(,3! !$#(.(!. M"6/&#/(-%$'"9)"D&(//3$ @"%"9#$%&)#&9& (,%$!$/" )7&/-%$1$#(:/(; & )7&/-)7&/(,(; %$'"9)"D&& — I1 & I2) %$6&)#%&%(,"'& ) 7(!(+0G !$#(." 7%(#(//(6( !"6/&#/(6( %$5(/"/)". B(9"5"/(, :#( ,"6(#(!&- 7%&,(.&'" 9 *,$'&:$/&G %"5!$%(, !&9%()()*.(,, *!$/01$/&G FM? & %E2 & /"%")#"/&G I1 & I2 , (4(&@ &5*:$//3@ (%6"/"@. L&/"!&9" &))'$.(,"//3@ 7"%"!$#%(, &!$'" (%6"//*G )7$D&C&9*. I"9, &@ /"&4('$$ ,3%"=$//3$ &5!$/$/&- , B ,3-,'-'&)0 :$%$5 7 )*#, , #(

""! !

,%$!- 9"9 , I? —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

THE VASCULAR FACTOR’S ROLE IN EVOLUTION OF NEURODY-STROPHIC PROCESS IN THE LIVER AND THE SMALL INTESTINE UNDER CONDITIONS OF THE VAGAL INNERVATION’S DISTURBANCE T.I.Baranich Head of Department, professor T.K,Dubovaya Russian State Medical Univercity, Moscow, Russia The purpose of work was morphofunctional research of vagotomy’s effect on a microhemodynamics and a state of water metabolism in liver (L) and small intestine (SI). In experiment were used rats with two-sided subdiaphragmatic vagotomy. After 1, 7, 14, 30, 60 and 220 days since operation in conditions of acute experience the oxygen’s tension (%E2) and regional blood flow (RBF) were defined in parenchyma L and a muscular layer of SI by using a polarographic method. In the histological specimens the sinusoids’ area (in L) and microvascular diameter (in SI) were measured by means of morphometric technique. The total water’s maintenance in organs was determined by gravimetric method. Magnetic-relaxation characteristics (time of spin-lattice and spin-spin relaxation – T1 and I2) were registered by the method of proton magnetic resonance. It turned out that vagotomy resulted in increasing of microvessels’ sizes, decreasing of RBF and %E2 and increasing of I1 and I2 in both studied organs. The dynamics of investigated parameters had the organ’s specificity. So its most visible changes in L were registered in 7 days while in SI - in 7 and 30 days.

By the end of the studied period all investigated parameters approached the reference values. The correlation among changing of microvascular size, RBF and %E2 gave the assump-tion that the vagotomy was accompanied by developing of circulatory hypoxia in L and SI. Poor oxygen’s supply of tissues, most likely, resulted in changing of histohematogenous barrier’s penetration for electrolytes and water, disturbing of hydrologic metabolism.

The decreasing extent of water’s structuring and the increasing its molecules’ mobility (increasing I1 and I2) were assisting in it. Thus the vagotomy resulted in disturbing of microblood circulation and oxygen’s supply of tissues of L and SI and the disturbing of hydrologic metabolism which manifested in increasing total water’s maintenance, decreasing extent of its structuring and increasing of its motility. !

06-129 !"#$ HSP90 . 4!"'&-5(( TNF-8, 9-%4!1%%(( TNF-R1 4!( '1-%,:(),/"0-(0'&5(!".,00": ,4"4)"/1 "4&;"#1.<; -#1)"- #(0(( JURKAT M.<.?'&!$/:$/9(, T.H.R$%9")(,", M.<.K$'9&/", H.S.M"%(19&/" .(9#(%"/#/9"/.&."# !$.&D&/)9&@ /"*9 T.<.?";6(%(.(,", 7%(C$))(%, .(9#(% !$.&D&/)9&@ /"*9 H.B.U&!"

F&4&%)9&; 8()*."%)#,$//3; M$.&D&/)9&; N/&,$%)&#$#, I(!)9, >())&O$'0 &))'$.(,"/&- – (D$/&#0 ,'&-/&$ 4$'9" #$7'(,(6( 1(9" 909L" (Hsp90) /" 7%(.*9D&G TNF-V, P9)7%$))&G TNF-R1 , (7*@('$,3@ 9'$#9"@ '&/&& Jurkat 7%& &/.*9D&& "7(7#(5" invitro. M"#$%&"'(! &))'$.(,"/&- -,'-'&)0 (7*@('$,3$ 9'$#9& '&/&& Jurkat (()#%3; T– '&!C(4'")#/3; '$;9(5). ?*'0#&,&%(,"/&$ 7%(,(.&'& , 7('/(; 7&#"#$'0/(; )%$.$ 7%& 37°C , "#!()C$%$ 5% CO2. S" 3 .$/0 7"))"=" 9'$#9& &/9*4&%(,"'& , )%$.$ ) .(4",'$/&$! &/.*9#(%" "7(7#(5" .$9)"!$#"5(/" (10!9M), &/6&4&#(%" Hsp90 (17-AAG, 5!9M) & , &@ )(:$#"/&& , #$:$/&$ 18 :")(, invitro. H7(7#(5 (D$/&,"'& !$#(.(!

C'*(%$)D$/#/(; !&9%()9(7&& ) 7(!(+0G FITC-!$:$//(6( "//$9)&/" V & 7%(7&.&; &(.&.". N%(,$/0 P9)7$%))&& TNF-R1 (7%$.$'-'& 7%(#(:/(; D&#(C'*(%&!$#%&$;. E7%$.$'$/&$ 7%(.*9D&& TNF-V 7%(,(.&'& !$#(.(! &!!*/(C$%!$/#/(6( "/"'&5". F#"#&)#&:$)9*G (4%"4(#9* ()*+$)#,'-'& ) 7(!(+0G 7%(6%"!!3 SPSS 11.5. ED$/9" :&)'" 9'$#(9, ,)#*7&,1&@ , "7(7#(5, 7%& .(4",'$/&& 17-AAG, .$9)"!$#"5(/" & 7%& &@ )(,!$)#/(! .$;)#,&& 7(9"5"'" *,$'&:$/&$ ."//(6( 7"%"!$#%" 7( (#/(1$/&G 9 9(/#%('G (%>0,05). H/"'&5 7%(.*9D&& TNF-V /$ ,3-,&' 5/":&!3@ %"5'&:&; (%>0,05) !$=.* 6%*77"!&. B%& .(4",'$/&& , 9*'0#*%* (7*@('$,3@ 9'$#(9 17-AAG

!"#$%&' ()*+, 2011, ,-.-/%"%&" ' 0."1&2/3%-45 67.5#'5 No1

! !"#$%&"$'() *+,$-.,!-, /0,1,!2"3-- TNF-R1 '2!'(-2,$)!'

-!2"42!56 4$,2'4 - /0- &'#"+$,!-- &,4("7,2"1'!" (p<0,05). 80('+7,(2!'7 &,9(2+-- 17-AAG - &,4("7,2"1'!", !"/0'2-+, !"#$%&"$'() (!-:,!-, &"!!';' /'4"1"2,$< (p<0,05). ="4-7 '#0"1'7, Hsp90 (!-:",2 >4(/0,((-% TNF-R1 !" 7,7#0"!, '/*6'$,+56 4$,2'4 Jurkat - !, +$-<,2 !" /0'&*43-% TNF-?. @!;-#-0'+"!-, &"!!';' #,$4" /0-+'&-2 4 *(-$,!-% "/'/2'2-.,(4';' &,9(2+-< &,4("7,2"1'!" (!-:,!-% /0,1,!2"3-- TNF-R1 '/*6'$,+56 4$,2'4 /0- &,4("7,2"1'!-!&*3-0'+"!!'7 "/'/2'1, invitro.

THE ROLE OF HSP90 IN PRODUCTION OF TNF-!, TNF-R1 EXPRESSION IN DEKSAMITAZON-INDUCED APOPTOSIS OF JURKAT TUMOR CELL LINE M.V.Klimenchenko, E.A.Cherkasova, M.V.Belkina, A.N.Maroshkina Cand. Sci (Med.) E.V.Kaygorodova, Dr.Sci (Med.) A.P.Zima Siberian State Medical University, Tomsk, Russia The purpose of the study is to evaluate the effect of heat shock protein 90kDa (Hsp90) on the production of TNF-?, TNF-R1 expression in Jurkat tumor cell line with the induction of apoptosis in vitro. Material of the study were Jurkat tumor cell line (acute T-lymphoblastic leukemia), derived from the Russian collection of Institute of Cytology RAS (St. Petersburg). Tumor cells were cultured in complete medium at 37 °C in an atmosphere of 5% CO2. On day 3 passage cells were incubated in medium supplemented with a classical inducer of apoptosis ! dexamethasone (10 mkM), an inhibitor of Hsp90 (17-AAG in concentration of 5 mkM) and the combination of 5 mkM 17-AAG and 10 mkM dexamethasone for 18 hours in vitro. Apoptosis was evaluated by fluorescent microscopy using FITC-labeled annexin V and propidium iodide. To determine the expression level of the receptor for TNF-? (TNF-R1) was used the method of flow cytometry. Determination of TNF-? production was done by enzyme-linked immunosorbent assay.

Statistical processing of the data was performed using SPSS 11.5.

Estimation of the number of tumor cells that have entered into apoptosis in the cultures by adding 17-AAG, dexamethasone and their joint action presents (p> 0,05) showed significant increase in this parameter relative to control. Analysis of TNF-? production did not show significant differences (p> 0,05) between the study groups. It is shown that when inhibitor 17AAG being added to the culture of tumor cells, an increase in presentation with respect to TNF-R1 in intact cells and with the addition of dexamethasone (p <0,05) has been observed. By the joint action of 17-AAG and dexamethasone, on the contrary, there was a decrease of this index (p <0,05). Thus, Hsp90 reduces the TNF-R1expression on the membrane of Jurkat tumor cells and it does not affect the production of TNF-?. Inhibition of this protein leads to an increased apoptotic action of dexamethasone and decrease of TNF-R1 presentation of tumor cells in dexamethasone-induced apoptosis in vitro. !

06-123 "#$%&$' ()*'&$% &+ ,-(+.+/'#$ ,$(-"-0 1(-*-1/$ "23-4+, ,+5%/$ $ "&$5+&$% A.B.B'+'4C"!'+", D.8.E"$)3,+" &.7.!., /0'F,(('0 G.H.E,$)!-4'+" I-2-!(4"< J'(*&"0(2+,!!"< E,&-3-!(4"< D4"&,7-<, I-2", K'((-< D42*"$)!'(2) 0"#'25 '#*($'+$,!" ( '&!'9 (2'0'!5 - 7"(('+57 0"(/0'(20"!,!-,7 4*0,!-<, '('#,!!' (0,&- 7'$'&,:- - :,!L-!, - ( &0*;'9 - /0'2-+'0,.-+'(2)% -!F'07"3-- ' +$-<!-- 4*0,!-< !"

-!2,$$,42*"$)!5, (/'('#!'(2- - /'4"1"2,$- &56"2,$)!'9 (-(2,75.

M,$): @1*.-2) -17,!,!-, /'4"1"2,$,9 /"7<2- - +!-7"!-< * :,!L-! ( 0"1!57 (2":,7 4*0,!-< ( -(/'$)1'+"!-,7 7,2'&'+ "!4,2-0'+"!-< 2,(2-0'+"!-<, " 2"4:, '/0,&,$-2) /'4"1"2,$- /-4'+'9 (4'0'(2+5&'6" &$< '3,!4- !"$-.-9 !"0*C,!-< &56"2,$)!'9 F*!43-- * >2-6 :,!L-!.

E"2,0-"$5 - 7,2'&5: N5$' /0'"!4,2-0'+"!' 100 :,!L-! + +'10"(2, '2 17 &' 39 $,2. O +(,6 + 0"1!5, F"15 AEM /0'+,&,!" /-4F$*'7,20-< (10-11 0"1). A/0,&,$,!5 /'4"1"2,$- /"7<2- - +!-7"!-< * +(,6 :,!L-! ( /'7'L)% '#L,/0-!<256 2,(2'+ (B,7'+ K.G., 2001;). 8'$*.,!!59 7"2,0-"$ '#0"#'2"! (2"2-(2-.,(4- ( -(/'$)1'+"!-,7 /"0"7,20-.,(4-6 - !,/"0"7,20-.,(4-6 7,2'&'+.

K,1*$)2"25: A4"1"$'(), .2' '4'$' 57% '/0'C,!!56 :,!L-! 4*0-2, /0- >2'7 (2": 4*0,!-< ('(2"+-$ '2 1 ;'&" &' 22 $,2. 8' &"!!57 /-4F$*'7,20-- + ;0*//, 4*0<L-6 :,!L-! /-4'+"< (4'0'(2) +5&'6" + (0,&!,7 !" 100 7$/(,4 7,!)C,, .,7 + ;0*//, !,4*0<L-6 (tC2 = 4,7, p<0,001). G$,&*,2 '27,2-2), .2' /0- (2":, 4*0,!-< &' 2-6 $,2 /'4"1"2,$- /-4F$*'7,20-- !, '2$-."%2(< + (0"+!-+",756 ;0*//"6.

80- *+,$-.,!-- (2":" 4*0,!-< /'4"1"2,$) /-4'+'9 (4'0'(2- +5&'6" /0';0,((-+!' *7,!)C",2(< !" 25 %.

8'4"1"2,$- -!2,$$,42" 2"4:, 0"1$-."%2(< * 4*0<L-6 - !,4*0<L-6 :,!L-!. B" 10% (!-:,!5 /'4"1"2,$- /"7<2- !" 3-F05, 4"4 + /0<7'9, 2"4 - '#0"2!'9 /'($,&'+"2,$)!'(2-, &'$;'(0'.!'9 /"7<2- !" ($'+" - !"

19 %. P0'7, 2';', * 4*0<L-6 :,!L-! -17,!<%2(< 6"0"42,0-(2-4+!-7"!-<. Q;' 4'!3,!20"3-< (!-:",2(< !" 16%, (4'0'(2) /,0,4$%.,!-< - !" 20%, " *(2'9.-+'(2) !" 33 %.

R5+'&5: 1. 8'$*.,!!5, !"7- 0,1*$)2"25 (+-&,2,$)(2+*%2, ' 2'7, .2' F"42'0 4*0,!-< * :,!L-! '4"15+",2 +$-<!-, !, 2'$)4' !" ('(2'<!-, &56"2,$)!'9 (-(2,75, !' - /'4"1"2,$- -!2,$$,42", 2"4-, 4"4 /"7<2) +!-7"!-,. 2. G2": 4*0,!-< 2,(!' 4'00,$-0*,2 ( /0'-(6'&<L-7-17,!,!-<7-.

SMOKING INFLUENCE UPON READINGS OF PEAK SPEED OF EXPIRATION MEMORY AND ATTENTION O.N.Novokshanova, A.P.Maltceva Dr.Sci (Med.), professor S.L.Melnikova Chita State Medical Academy, Chita, Russia The Aim:is concerned with studying of the transformation in the memory estimation and the attention estimation in the women with the varied smoking span with the help of the questionnaire method and the test method, as well as with determining of the readings, of the peak speed of expiration for the assessment of the presence of the disturbance of the respiratory function in these women. The Material and Methods:100 (one hundred) women aged from 17 (seventeen) to 39 (thirty nine) were set to the questionnaire. In all of them in different phases of the Ovulation Menstrual Cycle (OMC) peak-phluometria was held 10-11 (ten-eleven) times. The findings of memory and attention in all women with the help of traditional testing were determined. (P.S. Nemov, 2001). The gained material was studied due to statistical data with the application of parametric and nonparametric methods. The results:57 % (fifty-seven per cent) of interviewed women turned out to smoke their smoking span being from 1 (one) year to 22 (twenty-two) years. Due to the data of peak-phluometria the peak speed of expiration was 100 ml/sec. less on the average in the group of female smokers than in the group of female non-smokers (ts = 4,7 p < 0,001). On the smoking span under 2 years the finding of peak-phluometria were marked to be similar in the compared groups in case of acceleration of the smoking span the index of peak speed of expiration was progressively decreased in 25%. The intellect data were also different in female smokers and in female non-smokers. The readings of memory on figures were decreased both in the direct order and in the indirect order on 10% (ten per cent) the readings of long-lasting memory on words were decreased on 19%. Besides the traits of attention are changed in female smokers.

Attention concentration is decreased in 16 %, it`s speed of switching is fallen in 20 % but it` stability is diminished in 33%. !

06-121 $.)6'&$' "#$%&$% -($1#$/'#7&-8- 1/*'11+ &+ 9(1,*'11$: ;'#(-" /',#-"-8- <-(+ $ +,-,/-. #'0(-=$/-" ,'*$>'*$6'1(-0 (*-"$ ) ;-#7&24 $&>+*(/-5 5$-(+*3+ @.R"(%2-!

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

J0*//* (0"+!,!-< ('(2"+-$- 14 1&'0'+56 &'!'0'+, ('/'(2"+-756 /' +'10"(2* - /'$* ( ;0*//'9 #'$)!56 @E. D!"$-1 "/'/2'1" (F$*'0,(3,!2!59 40"(-2,$) - /0'/-&-9 -'&-&, “SigmaAldrich” GVD) - *0'+!< >4(/0,((-- N=V70 (F$*'0,(3,!2 - 7'!'4$'!"$)!5, "!2-2,$"7- BRM22, “SigmaAldrich” GVD) /0'+'&-$- 7,2'&'7 /0'2'.!'9 3-2'F$*'0-7,20-- (FACScan “BectonDickinson”, GVD).

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

O0'+,!) (/'!2"!!';' "/'/2'1" 7'!'!*4$,"0!56 4$,2'4 + ;0*//, #'$)!56 @E #5$ + (0,&!,7 + 3,7 0"1" +5C,, .,7 + 4'!20'$)!'9

"#! !

!"#$%& «'"(%#)-*%)+),%-".#%" /0)*+"12»

! !"#$$%. &'(%')*+',)(- .$,$(,/., *'0#1*",+.'',!, 2232, (.45% $"%+67.8. 4,'(",8-'69 #",+%'- (+ )"%0'%: + 2,2 "./.). ;.4*: ,<"./,:, + 0.'',9 ".<,(% +6=+8%'6 ,),<%'',)(* >4$"%))** ?;@ 70 * .$,$(,/. 08= "./8*A'6B !"#$$ 8%94,1*(,+, B.".4(%"'6% 08= ,)(",9 C./6 &D. E(, $,/+,8*( + 0.8-'%97%: .'.8*/*",+.(- '.$".+8%'',)(8%A%<'6B +,/0%9)(+*9 * $",!',/*",+.(- *B >CC%4(*+',)(-.

STUDY OF THE OXIDATIVE STRESS'S EFFECT ON THE EXPRESSION OF HEAT SHOCK PROTEINS AND APOPTOSIS OF BLOOD LEUKOCYTES IN PATIENTS WITH MYOCARDIAL STROKE I.Vasutin head of department of experimentl and theoretic phisics, professor N.A.Konstantinova Russian State Medical Univercity, Moscow, Russia Heat shock proteins 70 kDa (HSP70) are major components of most conservative protection cell’s system from different injure factors.

Expression of HSP70 rises a lot when stress is got. The protective property of HSP70 can used in therapeutic practice for treatment myocardial infarct or ischemic heart disease. It is perspective direction in medicine now. The purpose of our research was exploring of HSP70’s expression by blood leucocytes and correlation of this process with unprompted and induction apoptosis’s activity of the cells of patients with myocardial infarct.

Materials and methods. Blood leukocytes of 29 patients with myocardial infarct were researched in the exploring. Group of comparing consists of 14 healthy donors. Apoptosis analysis (fluorescent colorant – propidium iodide, “Sigma Aldrich”, USA) and HSP70’s expression (fluorescents – monoclonal antibodies BRM22, “Sigma Aldrich”, USA) was carried out with flow cytometry (FACScan “Becton Dickinson”, USA). Results.

Researching of HSP70’s expression in blood cells of patient showed increase of HSP70’s expression in lymphocytes and monocytes in comparison with healthy donors. However, HSP70’s expression in granulocytes was reduced. Incubation with H2O2 of healthy donor’s cells led to sharply growing of HSP70’s expression in lymphocytes and monocytes. Incubation with H2O2 of patient’s cells led to growing of HSP70’s expression also, but this growing was little in compareson with stressed cells of healthy donors. HSP70’s expression in granulocytes of patients sharply grew after incubation with H2O2. Unprompted apoptosis of patient’s cells was 3,7 times higher then healthy donors. Induction of apoptosis by H2O2 led to raise on 2,2 times higher then healthy donors. So, in the exploring identified features of HSP70’s expression and apoptosis for different types of leucocytes of myocardial infarct’s patients. !

06-41 !"#$%&'(")# *+,)&)-.$,&),+(&/%01 &2.1&,+3 )&'(+3 " *4$)"1 ()#%+3 &.F.G,:.',+, 3.2.H'(,74*', I.J.?#8.',+ 4.:.'. J.K. L.!"%<*' J,8!,!".0)4*9 M,)#0.")(+%''69 D%0*1*')4*9 N'*+%")*(%(, J,8!,!".0, G,))*= 3$#B,8* 4,)(%9 * :=!4*B (4.'%9 )%:%9)(+. )."4,:6 F*'!. =+8=O()= ,0'*: */ )8,5'%97*B "./0%8,+ $.(,8,!** ) (,A4* /"%'*= )+,%+"%:%'',9 * $".+*8-',9 0*.!',)(*4*. P%8-O ".<,(6 =+*8,)$,8#A%'*% ',+6B 0.''6B ,(',)*(%8-', :,"C,8,!*A%)4,9 * !

"#! !

:,8%4#8="',-!%'%(*A%)4,9 B.".4(%"*)(*4* )."4,:6 F*'!. 08= %% +%"*C*4.1**. D.(%"*.86 * :%(,06. Q",+%0%', :,"C,8,!*A%)4,% *))8%0,+.'*% ,$%".1*,'',!, :.(%"*.8. * <*,$(.(,+ 30 $.1*%'(,+ (1628 8%() ) :,"C,8,!*A%)4* +%"*C*1*",+.''6: 0*.!',/,: )."4,:6 F*'!..

Q,8#A%''6% "%/#8-(.(6. &::#',!*)(,B*:*A%)4,% *))8%0,+.'*% $,4./.8, +6".5%''#O >4)$"%))*O PCNA (40,3±5,7%) * .4(*+',)(- :."4%". Ki-67 '. ,A%'- +6),4,: #",+'% (41,5±6,4%). E(* $,4./.(%8* !,+,"=( , <#"'6B (%:$.B 0%8%'*= 48%(,4. Q"* >(,: ,(:%A%' ,(',)*(%8-', '*/4*9 #",+%'- >4)$"%))** <%84. p53 (14,7±3,9%) * :."4%". bcl-2 (12,9±4,1%), 4,(,"6% + 0.'',: )8#A.% ,(".5.O( ,()#()(+*% $"*)$,),<*(%8-',!, ,(+%(. ,"!.'*/:. + +*0% .$,$(,/.. J 95,4% )8#A.%+ ,$"%0%8=8.)- (".')8,4.1*= EWS/FLI1 type1, + ,)(.8-'6B – (".')8,4.1*= EWS/FLI1 type2. J6+,06.

J6=+8%'*% )$%1*C*A%)4*B (".')8,4.1*9 $"* )."4,:% F*'!. ) $,:,R-O QPG + "%5*:% "%.8-',!, +"%:%'* (Real-timePCR) =+8=%()= '.0S5'6: 0*.!',)(*A%)4*: :%(,0,:.

P*(,!%'%(*A%)4*% * *::#',!*)(,B*:*A%)4*% :%(,06 0*.!',)(*4* $,/+,8=O( 0*CC%"%'1*",+.(- )."4,:# F*'!. ) 0"#!*:* :%84,4"#!8,48%(,A'6:* )."4,:.:* (".<0,:*,)."4,:,9, '%9",<8.)(,:,9, 4"#!8,48%(,A',9 8*$,)."4,:,9, :%/%'B*:.8-',9 B,'0",)."4,:,9 * 0".).

DIAGNOSTICS OF ROUND-CELL TUMORS OF BONES AND SOFT TISSUE I.Yu.Romanov, O.N.Antoshkin, D.V.Bulanov Cand. Sci (Med.) V.L.Zagrebin Volgograd State Medical University, Volgograd, Russia The tumors of bones and soft tissues of Ewing sarcoma family are one of the most complicated pathology from the point of view of in time correct diagnostics. The goal of this research was finding of a new data concerning the morphological and molecule-genetic characteristics of Ewing sarcoma for its verification. Materials and methods. Morphological research of an operational material and biopsy of 30 patients (16-28 years) with morphologically verified diagnosis of a Ewing sarcoma. Results.

Immunohistochemical investigation has shown an expression of PCNA (40,3±5,7%) and activity of Ki-67 at very high level (41,5±6,4%). These indicators reveal a high rates of cell division. Rather low level of p53 expression (14,7±3,9%) and bcl-2 (12,9±4,1%) which in this case sows an absence of an adaptive reaction as apoptosis. Translocation EWS/FLI1 type1 was defined in 95,4% of cases, in the others the translocation of EWS/FLI1 type2 took place. Conclusions. Revealing of specific translocations at Ewing sarcoma by means of Real-time PCR is a reliable diagnostic method. Cytogenetic and immunohistochemical diagnostic methods allow to differentiate a Ewing sarcoma with others malignant round-cell tumors (rabdosarcoma, neuroblastoma, liposarcoma, mesenchymal chondrosarcoma, etc.).